

# BIBLIOGRAPHY

---

## Contents

<b>Chapter 1.</b> Early Days	2
<b>Chapter 2.</b> Working with Patients' Families	10
<b>Chapter 3.</b> Spiritual Care in Palliative Care	15
<b>Chapter 4.</b> Sexuality, Intimacy, and Cancer	20
<b>Chapter 5.</b> Advancing Disease	27
<b>Chapter 6.</b> Assessing the Patient in Pain	29
<b>Chapter 7.</b> Pharmacologic Management of Cancer Pain	35
<b>Chapter 8.</b> Nonpharmacologic Strategies in Palliative Care	61
<b>Chapter 9.</b> Psychological Considerations	71
<b>Chapter 10.</b> Managing Other Distressing Problems	77
<b>Chapter 11.</b> Approaching the End	97
<b>Chapter 12.</b> The Last Days	105
<b>Chapter 13.</b> Bereavement	110

## Chapter 1. Early Days

- Acquaviva KD. 2017. *LGBTQ-Inclusive Hospice and Palliative Care: A Practical Guide to Transforming Professional Practice*. New York: Harrington Park Press.
- Back AL, Arnold RM, Tulsky JA, et al. 2003. Teaching communication skills to medical oncology fellows. *J Clin Oncol* 21:2433–36.
- Back A, Arnold R, Tulsky J, with contributions by Fryer-Edwards K and Baile W. 2009. *Mastering Communication with Seriously Ill Patients: Balancing Honesty and Empathy with Hope*. New York: Cambridge University Press.
- Back AL, Bauer-Wu SM, Rushton CH, et al. 2009. Compassionate silence in the patient-clinician encounter: A contemplative approach. *J Pall Med* 12:1113–17.
- Back AL, Fromme EK, Meier DE. 2019. Training clinicians with communication skills needed to match medical treatments to patient values. *J Am Geriatr Soc* 67:S435–S441.
- Bernacki RE, Block SD. 2014. Communication about serious illness care goals: A review and synthesis of best practices. *JAMA Intern Med* 174:1994–2003.
- Bernacki R, Paladino J, Neville BA, et al. 2019. Effect of the serious illness care program in outpatient oncology: A cluster randomized clinical trial. *JAMA Intern Med* 179:751–59.
- Bridges JFP, Lynch T, Schuster ALR, et al. 2018. A review of paper-based advance care planning aids. *BMC Palliat Care* 17:54.
- Brinkman-Stoppelenburg A, Rietjens JAC, van der Heide A. 2014. The effects of advance care planning on end-of-life care: A systematic review. *Palliat Med* 28:1000–1025.
- Bruckel JT, Wong SL, Chan PS, et al. 2017. Patterns of resuscitation care and survival after in-hospital cardiac arrest in patients with advanced cancer. *J Oncol Pract* 13:e821–e830.
- Bruera E, Palmer JL, Pace E, et al. 2007. A randomized, controlled trial of physician postures when breaking bad news to cancer patients. *Palliat Med* 21:501–5.
- Buckman R. 1992. *How to Break Bad News: A Guide for Health Care Professionals*. Baltimore: Johns Hopkins University Press.
- Callahan D. 1993. *The Troubled Dream of Life*. New York: Simon and Schuster.
- Cassell EJ. 1999. Diagnosing suffering: A perspective. *Ann Intern Med* 131:531–34.
- Cherny NI. 2012. Controversies in oncologist-patient communication: A nuanced approach to autonomy, culture, and paternalism. *Oncology* 26:37–43.

- Detering KM, Hancock AD, Reade MC, et al. 2010. The impact of advance care planning on end of life care in elderly patients: Randomised controlled trial. *BMJ* 340:c1345.
- Diem SJ, Lantos JD, Tulsky JA. 1996. Cardiopulmonary resuscitation on television: Miracles and misinformation. *N Engl J Med* 334:1578–82.
- Downey L, Au DH, Curtis JR, et al. 2013. Life-sustaining treatment preferences: Matches and mismatches between patients’ preferences and clinicians’ perceptions. *J Pain Symptom Manage* 46:9–19.
- Emanuel LL, Danis M, Pearlman RA, et al. 1995. Advance care planning as a process: Structuring the discussions in practice. *J Am Geriatr Soc* 43:440–46.
- Figley CR, ed. 1995. *Compassion Fatigue: Coping with Secondary Traumatic Stress in Those Who Treat the Traumatized*. London: Brunner-Routledge.
- Fine RL. 2010. Keeping the patient at the center of patient- and family-centered care. *J Pain Symptom Manage* 40:621–25.
- Five Wishes. 2020. “Five Wishes Advance Directive.” Accessed April 28, 2020. <https://fivewishes.org/shop/order/product/five-wishes-advance-directive>.
- Fumis RRL, Junqueira Amarante GA, de Fátima Nascimento A, et al. 2017. Moral distress and its contribution to the development of burnout syndrome among critical care providers. *Ann Intensive Care* 7:71.
- Gawande A. 2014. *Being Mortal: Medicine and What Matters in the End*. New York: Picador.
- Gilligan T, Coyle N, Frankel RM, et al. 2017. Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618–32.
- Gilligan T, Bohlke K, Baile WF. 2018. Patient-clinician communication: American Society of Clinical Oncology consensus guideline summary. *J Onc Practice* 14:42–46.
- Greer JA, Jacobs JM, El-Jawahri A, et al. 2018. Role of patient coping strategies in understanding the effects of early palliative care on quality of life and mood. *J Clin Oncol* 36:53–60.
- Gries CJ, Engelberg RA, Kross EK, et al. 2010. Predictors of symptoms of post-traumatic stress disorder and depression in family members after patient death in the ICU. *Chest* 137:280–87.
- Groopman J. 1997. *The Measure of Our Days: New Beginnings at Life’s End*. New York: Viking Penguin.
- Haines L, Rahman OK, Sanders JJ, et al. 2019. Factors that impact family perception of goal-concordant care at the end of life. *J Palliat Med* 22:927–32.

- Institute of Medicine. 2014. *Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life*. Washington, DC: National Academies Press.
- Jia Z, Leiter RE, Yeh IM, et al. 2020. Toward culturally tailored advance care planning for the Chinese diaspora: An integrative systematic review. *J Palliat Med* 23:1662–67.
- Kagawa-Singer M, Kassim-Lakha S. 2003. A strategy to reduce cross-cultural miscommunication and increase the likelihood of improving health outcomes. *Acad Med* 78:577–87.
- Keating NL, Landrum MB, Rogers SO, et al. 2010. Physician factors associated with discussions about end-of-life care. *Cancer* 116:998–1006.
- Kon AA, Davidson JE, Morrison W, et al. 2016. Shared decision making in ICUs: An American College of Critical Care Medicine and American Thoracic Society policy statement. *Crit Care Med* 44:188–201.
- Kottek SS. 2011. Toward becoming an accomplished physician: Maimonides versus Galen. *Rambam Maimonides Med J* 2:e0060.
- Kübler Ross E. 1969. *On Death and Dying*. New York: Macmillan.
- Lamont EB, Siegler M. 2000. Paradoxes in cancer patients' advance care planning. *J Palliat Med* 3:27–35.
- Mack JW, Cronin A, Keating NL, et al. 2012. Associations between end-of-life discussion characteristics and care received near death: A prospective cohort study. *J Clin Oncol* 30:4387–95.
- Mack JW, Cronin A, Taback N, et al. 2012. End-of-life care discussions among patients with advanced cancer: A cohort study. *Ann Intern Med* 156:204–10.
- Mack JW, Weeks JC, Wright AA, et al. 2010. End-of-life discussions, goal attainment and distress at the end of life. *J Clin Oncol* 28:1203–8.
- MacKenzie MA, Smith-Howell E, Bomba PA, et al. 2018. Respecting choices and related models of advance care planning: A systematic review of published evidence. *Am J Hosp Palliat Care* 35:897–907.
- Martina D, Geerse OP, Lin C-P, et al. 2021. Asian patients' perspectives on advance care planning: A mixed-method systematic review and conceptual framework. *Palliat Med* 35:1776–92.
- Meier DE, Beresford L. 2009. POLST offers next stage in honoring patient preferences. *J Palliat Med* 12:291–95.

- Modes ME, Engelberg RA, Downey L, et al. 2019. Toward understanding the relationship between prioritized values and preferences for cardiopulmonary resuscitation among seriously ill adults. *J Pain Symptom Manage* 58:567–77.
- Morrison RS, Morrison EW, Glickman DF. 1994. Physician reluctance to discuss advance directives. *Arch Intern Med* 154:2311–18.
- National Hospice and Palliative Care Organization. 2020. “Downloading Your State’s Advance Directive.” Accessed April 28, 2020. <https://www.nhpco.org/patients-and-caregivers/advance-care-planning/advance-directives/downloading-your-states-advance-directive/>.
- National POLST. 2020. “Names of POLST Programs.” Accessed April 28, 2020. <https://polst.org/programs-in-your-state/#levels>.
- Paladino J, Bernacki R, Neville BA, et al. 2019. Evaluating an intervention to improve communication between oncology clinicians and patients with life-limiting cancer: A cluster randomized clinical trial of the serious illness care program. *JAMA Oncol* 5:801–9.
- Perkins HS. 2007. Controlling death: The false promise of advance directives. *Ann Intern Med* 147:51–57.
- Quill TE, Abernethy AP. 2013. Generalist plus specialist palliative care—creating a more sustainable model. *N Engl J Med* 368:1173–75.
- Quill TE, Brody H. 1996. Physician recommendations and patient autonomy: Finding a balance between physician power and patient choice. *Ann Intern Med* 125:763–69.
- Schneiderman LJ, Kaplan RM, Pearlman RA, et al. 1993. Do physicians’ own preferences for life-sustaining treatment influence their perceptions of patients’ preferences? *J Clin Ethics* 4:28–33.
- Schuster RA, Hong SY, Arnold RM, et al. 2014. Investigating conflict in ICUs—Is the clinicians’ perspective enough? *Crit Care Med* 42:328–35.
- Shanawani H, Wenrich MD, Tonelli MR, et al. 2008. Meeting physicians’ responsibilities in providing end-of-life care. *Chest* 133:775–86.
- Silveira MJ, Kim SYH, Langa KM. 2010. Advance directives and outcomes of surrogate decision-making before death. *N Engl J Med* 262:1211–18.
- Stone D, Patton B, Heen S. 2010. *Difficult Conversations: How to Discuss What Matters Most*. 2nd ed. New York: Penguin.

- Sudore RL, Boscardin J, Feuz MA, et al. 2017. Effect of the PREPARE website vs an easy-to-read advance directive on advance care planning documentation and engagement among veterans: A randomized clinical trial. *JAMA Intern Med* 177:1102–9.
- Sudore RL, Lum HD, You JJ, et al. 2017. Defining advance care planning for adults: A consensus definition from a multidisciplinary Delphi panel. *J Pain Symptom Manage* 53:821–32.
- Sudore RL, Schillinger D, Katen MT, et al. 2018. Engaging diverse English- and Spanish-speaking older adults in advance care planning: The PREPARE randomized clinical trial. *JAMA Intern Med* 178:1616–25.
- Taylor LJ, Nabozny MJ, Steffens NM, et al. 2017. A framework to improve surgeon communication in high-stakes surgical decisions: Best case / worst case. *JAMA Surg* 152:531–38.
- Weissman DE, Quill TE, Arnold RM. 2010a. The family meeting: End-of-life goal setting and future planning #227. *J Palliat Med* 13:462–63.
- Weissman DE, Quill TE, Arnold RM. 2010b. Helping surrogates make decisions #226. *J Palliat Med* 13:461–62.
- Wendler D, Rid A. 2011. Systematic review: The effect on surrogates of making treatment decisions for others. *Ann Intern Med* 154:336–46.
- Widera EW, Rosenfeld KE, Fromme EK, et al. 2011. Approaching patients and family members who hope for a miracle. *J Pain Symptom Manage* 42:119–25.
- Yadav KN, Gabler NB, Cooney E, et al. 2017. Approximately one in three US adults completes any type of advance directive for end-of-life care. *Health Aff* 36:1244–51.

## How Prognosis Affects the Advance Care Plan

- Apatira L, Boyd EA, Malvar G, et al. 2008. Hope, truth, and preparing for death: Perspectives of surrogate decision-makers. *Ann Intern Med* 149:861–68.
- Ariadne Labs. 2020. “Serious Illness Care.” Accessed April 28, 2020. <https://www.ariadnelabs.org/areas-of-work/serious-illness-care/>.
- Bakitas MA, Tosteson TD, Li Z, et al. 2015. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *J Clin Oncol* 33:1428–45.
- Basch E, Deal AM, Kris MG, et al. 2016. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. *J Clin Oncol* 34:557–65.

- Blackhall LJ, Murphy ST, Frank G, et al. 1995. Ethnicity and attitudes toward patient autonomy. *JAMA* 274:820–25.
- Cain CL, Surbone A, Elk R, et al. 2018. Culture and palliative care: Preferences, communication, meaning, and mutual decision making. *J Pain Symptom Manage* 55:1408–19.
- Christakis N. 1999. *Death Foretold: Prophecy and Prognosis in Medical Care*. Chicago: University of Chicago Press.
- Clark MA, Person SD, Gosline A, et al. 2018. Racial and ethnic differences in advance care planning: Results of a statewide population-based survey. *J Palliat Med* 21:1078–85.
- Colclough YY. 2017. Native American death taboo: Implications for health care providers. *Am J Hosp Palliat Care* 34:584–91.
- Connor SR, Pyenson B, Fitch K, et al. 2007. Comparing hospice and non-hospice patient survival among patients who die within a three-year window. *J Pain Symptom Manage* 33:238–46.
- Daugherty CK, Hlubocky FJ. 2008. What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognostic disclosure. *J Clin Oncol* 26:5988–93.
- Derry HM, Carrington Reid M, Prigerson HG. 2019. Advanced cancer patients' understanding of prognostic information: Applying insights from psychological research. *Cancer Med* 8:4081–88.
- Emanuel EJ, Fairclough DL, Wolfe P, et al. 2004. Talking with terminally ill patients and their caregivers about death, dying, and bereavement: Is it stressful? Is it helpful? *Arch Intern Med* 164:1999–2004.
- Enzinger AC, Zhang B, Schrag D, et al. 2015. Outcomes of prognostic disclosure: Associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. *J Clin Oncol* 33:3809–16.
- Ferrell B, Sun V, Hurria A, et al. 2015. Interdisciplinary palliative care for patients with lung cancer. *J Pain Symptom Manage* 50:758–67.
- Gilligan T, Coyle N, Frankel RM, et al. 2017. Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618–32.
- Gramling R, Fiscella K, Xing G, et al. 2016. Determinants of patient-oncologist prognostic discordance in advanced cancer. *JAMA Oncol* 2:1421–26.
- Grudzen CR, Richardson LD, Johnson PN, et al. 2016. Emergency department-initiated palliative care in advanced cancer. *JAMA Oncol* 2:591–98.

- Hobbs GS, Landrum MB, Arora NK, et al. 2015. The role of families in decisions regarding cancer treatments. *Cancer* 121:1079–87.
- Ingersoll LT, Alexander SC, Priest J, et al. 2019. Racial/ethnic differences in prognosis communication during initial inpatient palliative care consultations among people with advanced cancer. *Patient Educ Couns* 102:1098–1103.
- Jackson VA, Jacobsen J, Greer JA, et al. 2013. The cultivation of prognostic awareness through the provision of early palliative care in the ambulatory setting: A communication guide. *J Palliat Med* 16:894–900.
- Jacobsen J, Brenner K, Greer JA, et al. 2018. When a patient is reluctant to talk about it: A dual framework to focus on living well and tolerate the possibility of dying. *J Palliat Med* 21:322–27.
- Levy MM. 1999. Making a personal relationship with death. In *Managing Death in the Intensive Care Unit*, Curtis JR, Rubenfeld GD (eds.). Oxford: Oxford University Press.
- Loh KP, Mohile SG, Lund JL, et al. 2019. Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists. *Oncologist* 24:e292–e302.
- Mack JW, Fasciano KM, Block SD. 2018. Communication about prognosis with adolescent and young adult patients with cancer: Information needs, prognostic awareness, and outcomes of disclosure. *J Clin Oncol* 36:1861–67.
- Mack JW, Smith TJ. 2012. Reasons why physicians do not have discussions about poor prognosis and why it matters. *J Clin Oncol* 30:2715–17.
- Mack JW, Walling A, Dy S, et al. 2015. Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer. *Cancer* 121:1891–97.
- Nipp RD, El-Jawahri A, Fishbein JN, et al. 2016. The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. *Cancer* 122:2110–16.
- Nipp RD, Greer JA, El-Jawahri A, et al. 2017. Coping and prognostic awareness in patients with advanced cancer. *J Clin Oncol* 35:2551–57.
- Obermeyer Z, Makar M, Abujaber S, et al. 2014. Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer. *JAMA* 312:1888–96.
- Palmer BW, Harmell AL. 2016. Assessment of healthcare decision-making capacity. *Arch Clin Neuropsychol* 31:530–40.



- Reisfield GM, Wallace SK, Munsell MF, et al. 2006. Survival in cancer patients undergoing in-hospital cardiopulmonary resuscitation: A meta-analysis. *Resuscitation* 71:152–60.
- Sanders JJ, Robinson MT, Block SD. 2016. Factors impacting advance care planning among African Americans: Results of a systematic integrated review. *J Palliat Med* 19:202–27.
- Schillerstrom JE, Horton MS, Royall DR. 2005. The impact of medical illness on executive function. *Psychosomatics* 46:508–16.
- Shen MJ, Trevino KM, Prigerson HG. 2018. The interactive effect of advanced cancer patient and caregiver prognostic understanding on patients' completion of do not resuscitate orders. *Psychooncology* 27:1765–71.
- Smith AK, McCarthy EP, Paulk E, et al. 2008. Racial and ethnic differences in advance care planning among patients with cancer: Impact of terminal illness acknowledgment, religiousness, and treatment preferences. *J Clin Oncol* 26:4131–37.
- Smith TJ, Dow LA, Virago E, et al. 2010. Giving honest information to patient with advanced cancer maintains hope. *Oncology* 24:521–25.
- Smith TJ, Temin S, Alesi ER, et al. 2012. American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. *J Clin Oncol* 30:880–87.
- Stevens EE, Abrahm JA. 2019. Adding silver to the rainbow: Palliative and end-of-life care for the geriatric LGBTQ patient. *J Palliat Med* 22:602–6.
- Temel JS, Greer JA, Muzikansky A, et al. 2010. Early palliative care for patients with metastatic non-small cell lung cancer. *N Engl J Med* 363:733–42.
- Tulsky JA, Chesny MA, Lo B. 1995. How do medical residents discuss resuscitation with patients? *J Gen Intern Med* 10:436–42.
- von Gunten CF, Ferris F, Emanuel LL. 2000. Ensuring competency in end-of-life skills: Communication and relational skills. *JAMA* 284:3051–57.
- Weeks JC, Catalano PJ, Cronin A, et al. 2012. Patients' expectations about effects of chemotherapy for advanced cancer. *N Engl J Med* 367:1616–25.
- Weeks JC, Cook EF, O'Day SSJ, et al. 1998. Relationship between cancer patients' predictions of prognosis and their treatment preferences [see comments]. *JAMA* 279:1709–14.
- Wendler D, Rid A. 2011. Systematic review: The effect on surrogates of making treatment decisions for others. *Ann Intern Med* 154:336–46.
- Wright AA, Mack JW, Kritek PA, et al. 2010. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. *Cancer* 116:4656–63.

- Wright AA, Zhang B, Ray A, et al. 2008. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. *JAMA* 300:1665–73.
- Yennurajalingam S, Rodrigues LF, Shamieh O, et al. 2018. Perception of curability among advanced cancer patients: An international collaborative study. *Oncologist* 23:501–6.
- Yuen JK, Reid MC, Feters MD. 2011. Hospital do-not-resuscitate orders: Why they have failed and how to fix them. *J Gen Intern Med* 7:791–97.

## Ethics Consultations

- Dubler NN, Liebman CB. 2013. *Bioethics Mediation: A Guide to Shaping Shared Solutions*. Revised and expanded ed. Nashville, TN: Vanderbilt University Press
- Kon AA, Davidson JE, Morrison W, et al. 2016. Shared decision making in ICUs: An American College of Critical Care Medicine and American Thoracic Society policy statement. *Crit Care Med* 44:188–201.
- Jonsen AR, Siegler M, Winslade WW. 2017. *Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine*. 8th ed. New York: McGraw-Hill.

## Chapter 2. Working with Patients' Families

- Acquaviva KD. 2017. *LGBTQ-Inclusive Hospice and Palliative Care: A Practical Guide to Transforming Professional Practice*. New York: Harrington Park Press.
- Back AL, Arnold RM, Baile WF, et al. 2007. Efficacy of communication skills training for giving bad news and discussing transitions to palliative care. *Arch Intern Med* 167:453–60.
- Bushfield S, DeFord B. 2009. *End-of-life Care and Addiction: A Family Systems Approach*. New York: Springer.
- Clayton JM, Butow PN, Tattersall MH. 2005. The needs of terminally ill cancer patients versus those of caregivers for information regarding prognosis and end-of-life issues. *Cancer* 103:1957–1964
- Coolen PR. 2012. Cultural relevance in end-of-life care. *Ethno Med*, May 12, 2012. <https://ethnomed.org/clinical/end-of-life/cultural-relevance-in-end-of-life-care>.
- Davies B, Reimer J, Brown P, et al. 1995. *Fading Away: The Experience of Transition in Families with Terminal Illness*. New York: Baywood Publishing.

- Epstein NB, Bishop D, Ryan C, et al. 1993. The McMaster model view of healthy family functioning. In *Normal Family Processes*, Walsh F (ed.). New York: Guilford.
- Fahlberg B, Foronda C, Baptiste D. 2016. Cultural humility: The key to patient/family partnerships for making difficult decisions. *Nursing* 46:14–16.
- Fisher C. 2003. The invisible dimension: Abuse in palliative care families. *J Palliat Med* 6:257–64.
- Gaudio FD, Zaider TI, Brier M, et al. 2012. Challenges in providing family-centered support to families in palliative care. *Palliat Med* 26:1025–1033.
- Gysels M, Evans N, Meñaca A, et al. 2012. Culture and end of life care: A scoping exercise in seven European countries. *PloS One* 7:e34188.
- Hadziabdic E, Hjelm K. 2013. Working with interpreters: practical advice for use of an interpreter in healthcare. *Int J Evid Based Healthc* 11:69–76.
- Juckett G, Unger K. 2014. Appropriate use of medical interpreters. *Am Fam Physician* 90:476–480.
- Kagawa-Singer M, Blackhall LJ. 2001. Negotiating cross-cultural issues at the end of life: “You got to go where he lives.” *JAMA* 286:2993–3001.
- Kerr ME. 2000. One family’s story: A primer on Bowen theory. The Bowen Center for the Study of the Family. 2000. <http://www.thebowncenter.org>.
- King DA, Quill T. 2006. Working with families in palliative care: One size does not fit all. *J Palliat Med* 9:704–15.
- Kissane D, McKenzie M, Bloch S, et al. 2006. Family focused grief therapy: A randomized, controlled trial in palliative care and bereavement. *Am J Psychiatry* 163:1208–18.
- Kramer BJ, Kavanaugh M, Trentham-Dietz A, et al. 2009. Predictors of family conflict at the end of life: The experience of spouses and adult children of persons with lung cancer. *Gerontologist* 50:215–25.
- Langer SL, Brown JD, Syrjala KL. 2009. Intrapersonal and interpersonal consequences of protective buffering among cancer patients and caregivers. *Cancer* 115(S18):4311–25.
- Lawrence JA, Dodds AE. 2003. Goal-directed activities and life-span development. In *Handbook of Developmental Psychology*, Valsiner J, Connolly K (eds.). London: Sage Publications.
- Lin C-P, Cheng S-Y, Mori M, et al. 2019. 2019 Taipei declaration on advance care planning: A cultural adaptation of end-of-life care discussion. *J Palliat Med* 22:1175–77.

- Liossi C, Hatira P, Mystakidou K. 1997. The use of the genogram in palliative care. *Palliat Med* 11:455–461.
- López SR. 1997. Cultural competence in psychotherapy: a guide for clinicians and their supervisors. In *Handbook of Psychotherapy Supervision*, Watkins CE, Jr (ed.). Hoboken, N.J.: John Wiley & Sons.
- Makoff E. 2020. Racial trauma: A palliative care perspective. *J Palliat Med* 23:577–78.
- McGoldrick M, Gerson R, Petry SS. 2008. *Genograms: Assessment and Intervention*. New York: Norton.
- Meyer F, Block S. 2011. Personality disorders in the oncology setting. *J Support Oncol* 9:44–51.
- Molloy DW, Clarnette RM, Braun EA, et al. 1991. Decision making in the incompetent elderly: “The daughter from California Syndrome.” *J Am Geriatr Soc* 39:396–399.
- Mosher DK, Hook JN, Farrell JE, et al. 2017. Cultural humility. In *Handbook of Humility: Theory, Research, and Applications*, E. L. Worthington, D. E. Davis, and J. N. Hook (eds.) (pp. 91–104). New York: Taylor and Francis.
- Mynatt BS, Mowery RL. 2013. The family, larger systems, and end-of-life decision making. In *Handbook of Thanatology* (pp. 119–128). New York: Routledge.
- National Consensus Project for Quality Palliative Care. 2018. *Clinical Practice Guidelines for Quality Palliative Care*. 4th ed. Richmond, VA: National Coalition for Hospice and Palliative Care.
- Northouse L, Katapodi MC, Song L, et al. 2010. Interventions with family caregivers of cancer patients: Meta-analysis of randomized trials. *CA Cancer J Clin* 60:317–39.
- Olson DH. 2000. Circumplex model of marital and family systems. *J Family Therapy* 22:144–67.
- Olson D. 2011. FACES IV and the circumplex model: Validation study. *J Marital Fam Ther* 37:64–80.
- Olson DH, Gorall DM. 2003. Circumplex model of marital and family systems. In *Normal Family Process*, 3rd ed, Walsh F (ed.). New York: Guilford.
- Olson D, Russell CS, Sprenkle DH. 2014. *Circumplex Model: Systemic Assessment and Treatment of Families*. New York: Routledge.
- Peek ME, Wilson SC, Gorawara-Bhat R, et al. 2009. Barriers and facilitators to shared decision-making among African-Americans with diabetes. *J Gen Intern Med* 24:1135–39.

- Periyakoil VJ. 2020. The need of the hour: Culturally competent care for seriously ill patients. *J Palliat Med* 23:440–41.
- Quinn JR, Schmitt M, Baggs JG, et al. 2012. Family members' informal roles in end-of-life decision making in adult intensive care units. *Am J Crit Care* 21:43–51.
- Radina K. 2018. What role do you play in your family? A Chance for Change Counseling. Accessed September 1, 2018. <http://kathyradina.com/role-play-family/>.
- Schenker Y, Smith A, Arnold R, et al. 2012. “Her husband doesn't speak much English”: Conducting a family meeting with an interpreter, *J Palliat Med*. 15:494–498.
- Schuler TA, Zaider TI, Yuelin L, et al. 2014. Typology of perceived family functioning in an American sample of patients with advanced cancer. *J Pain Symptom Manage* 48:281–88.
- Searight HR, Gafford J. 2005. Cultural diversity at the end of life: issues and guidelines for family physicians. *Am Fam Physician* 71:515–522.
- Speice J, Harkness J, Laneri R, et al. 2000. Involving family members in cancer care: focus group considerations of patients and oncological providers. *Psychooncology* 9:101–112.
- Steele R, Davies B. 2015. Supporting families in palliative care. In *Oxford Textbook of Palliative Nursing. Social Aspects of Care* 6. Oxford: Oxford University Press.
- Steinberg SM. 2011. Cultural and religious aspects of palliative care. *Int J Crit Illn Inj Sci* 1:154–56.
- Tran QNH, Dieu-Hien Ht, King IN, et al. 2019. Providing culturally respectful care for seriously ill Vietnamese Americans. *J Pain Symptom Manage* 58:344–54.
- Wygant CRC, Bruera E, Hui D. 2014. Intimate partner violence in an outpatient palliative care setting. *J Pain Symptom Manage* 47:806–13.
- Zaider T, Kissane D. 2009. The assessment and management of family distress during palliative care. *Curr Opin Support Palliat Care* 3:67–71.
- Zaider TI, Kissane DW, Schofield E, et al. 2020. Cancer-Related Communication During Sessions of Family Therapy at the End of Life. *Psychooncology* 29:373–80.

## Partnering with Medical Interpreters

- Flores G, Milagros A, Pizzo Baron C, et al. (2012). Errors in medical interpretation and their potential clinical consequences: A comparison of professional vs. ad hoc vs. no interpreters. *Ann Emerg Med* 60:545–53.

- Green AR, Chijioke Nze C. 2017. Language-based inequity in health care: Who is the “poor historian”? *AMA J Ethics* 19:263–71.
- Hadziabdic E, Hjelm K. 2013. Working with interpreters: Practical advice for use of an interpreter in healthcare. *Int J Evid Based Healthc* 11:69–76.
- IMIA. 2020. IMIA Guide on Working with Medical Interpreters. Accessed September 8, 2020. [https://www.imiaweb.org/uploads/pages/380\\_5.pdf](https://www.imiaweb.org/uploads/pages/380_5.pdf).
- Johnson KS. 2013. Racial and ethnic disparities in palliative care. *J Palliat Med* 16:1329–34.
- Juckett G, Unger K. 2014. Appropriate use of medical interpreters. *Am Fam Physician* 90:476–80.
- Kirby E, Broom A, Good P, et al. 2016. Experiences of interpreters in supporting the transition from oncology to palliative care: A qualitative study. *Asia-Pacific J Clin Oncol*, July 20. <https://doi.org/10.1111/ajco.12563>.
- Kirby E, Lwin Z, Kenny K, et al. 2018. “It doesn’t exist...”: Negotiating palliative care from a culturally and linguistically diverse patient and caregiver perspective. *BMC Palliat Care* 17:90.
- Scamman K. 2018. Best practices for communication through an interpreter in healthcare. *Telelanguage*, August 27. <https://telelanguage.com/best-practices-communicating-through-an-interpreter-in-healthcare/>.
- Schenker Y, Smith A, Arnold R, et al. 2012. “Her husband doesn’t speak much English”: Conducting a family meeting with an interpreter. *J Palliat Med* 15:494–98.
- Silva MD, Genoff M, Zaballa A, et. al. 2016. Interpreting at the end of life: A systematic review of the impact of interpreters on the delivery of palliative care services to cancer patients with limited English proficiency. *J Pain Symptom Manage* 51:569–80.

## Relevant Legislation and Regulations

- Americans With Disabilities Act of 1990, Pub. L. No. 101–336, 104 Stat. 328 (1990), section 1557 (the non-discrimination clause).
- Civil Rights Act of 1964, Pub. L. 88–352, 78 Stat. 241 (1964)
- Executive Order 13166, “Improving Access to Services for Persons with Limited English Proficiency,” August 11, 2000, <https://www.justice.gov/crt/executive-order-13166>.
- The Joint Commission, <https://www.jointcommission.org>.
- Patient Protection and Affordable Care Act, 42 U.S.C. § 18001 et seq. (2010).

## Resources on Culture

American Psychological Association, “Culturally Diverse Communities and Palliative and End-of-Life Care,” <https://www.apa.org/pi/aging/programs/eol/end-of-life-diversity.pdf>.

American Psychological Association, “End-of-Life Issues and Care,” <https://www.apa.org/pi/aging/programs/eol>.

American Psychological Association, “End-of-Life and Socioeconomic Status Fact Sheet,” <https://www.apa.org/pi/ses/resources/publications/end-life>.

Ethno Med: Phyllis R. Coolen’s overview article, “Cultural Relevance in End-of-Life Care,” <https://ethnomed.org/clinical/end-of-life/cultural-relevance-in-end-of-life-care>, provides an overview of the key areas in which culture can influence end-of-life decision-making.

National Hospice and Palliative Care Organization, “Diversity,” <http://www.nhpco.org/Diversity>.

National Institute of Nursing Research, About the Palliative Care: Conversations Matter Campaign, <https://www.ninr.nih.gov/newsandinformation/conversationsmatter/about-conversations-matter>.

National Resource Center on LGBT Aging, “End of Life Decisions,” <https://www.lgbtagingcenter.org/resources/resources.cfm?s=7>.

University of Washington Patient and Family Education Services, “Culture Clues” and end-of-life tip sheets, <http://depts.washington.edu/pfes/CultureClues.htm>.

## Chapter 3. Spiritual Care in Palliative Care

### General

Cassel EJ. 1982. The nature of suffering and the goals of medicine. *N Engl J Med* 306:639–45.

Cassel EJ. 2014. *The Nature of Clinical Medicine: The Return of the Clinician*. Oxford: Oxford University Press.

Cross FK, Livingstone EA, eds. 1997. *The Oxford Dictionary of the Christian Church*. Oxford: Oxford University Press.

Edwards A, Pang N, Shiu V, et al. 2010. The understanding of spirituality and the potential role of spiritual care in end-of-life and palliative care: A meta-study of qualitative research. *Pall Med* 24:753–70.

- Jeuland J, Fitchett G, Shulman-Green D, et al. 2017. Chaplains working in palliative care: Who they are and what they do. *J Pall Med* 20:502–8.
- Puchalski C, Ferrell B, Virani R, et al. 2009. Improving the quality of spiritual care as a dimension of palliative care: The report of the consensus conference. *J Palliat Med* 12:885–904.
- Rosenberg LB, Goodlev ER, Izen SE, et al. 2020. Top ten tips palliative care clinicians should know about caring for Jewish patients. *J Palliat Med* 23:1658–61.
- Tarumi Y, Taube A, Watanabe S. 2003. Clinical pastoral education: A physician’s experience and reflection on the meaning of spiritual care in palliative care. *J Pastoral Care Counsel* 57:27–31.

## The Spiritual Landscape of Patients with Serious Illness

- Bai J, Brubaker A, Meghani SH, et al. 2018. Spirituality and quality of life in Black patients with cancer pain. *J Pain Symptom Manage* 56:390–98.
- Balboni T, Balboni M. 2018. The spiritual event of serious illness. *J Pain Symptom Manage* 56:816–22.
- Balboni TA, Vanderwerker LC, Block SD, et al. 2007. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. *J Clin Oncol* 25:555–60.
- Ehman J, Ott B, Short TH, et al. 1999. Do patients want physicians to inquire about their religious or spiritual beliefs if they become gravely ill? *Arch Intern Med* 159:1803–6.
- Kestenbaum A, Fitchett G, Galchutt P, et al. 2022. Top ten tips palliative care clinicians should know about spirituality in serious illness. *J Palliat Med* 25:312–18.
- Koenig H. 1998. Religious attitudes and practices of hospitalized medically ill older adults. *Intern J Geri Psych* 13:213–24.
- Pew Research Center. 2014. The Religious Landscape Study. <https://www.pewforum.org/religious-landscape-study/>.
- Phelps A, Lauderdale K, Alcorn S, et al. 2012. Addressing spirituality within the care of patients at the end of life: Perspectives of patients with advanced cancer, oncologists, and oncology nurses. Version 2. *J Clin Oncol* 30:2538–44.



## Positive and Negative Religious Coping

- Maiko SM, Ivy S, Newton Watson B, et al. 2019. Spiritual and religious coping of medical decision makers for hospitalized older adult patients. *J Palliat Med* 22:385–92.
- McClain C, Rosenfeld B, Breitbart W. 2003. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. *Lancet* 361:1603–7.
- Monod S, Rochat E, Martin E, et al. 2007. Spiritual assessment in older patients undergoing post-acute rehabilitation: A pilot study. *Gerontologist* 47:S774.
- Pargament K. 2001. *The Psychology of Religion and Coping*. New York: Guilford.
- Pargament K, Feuille M, Burdzy D. 2011. The brief RCOPE: Current psychometric status of a short measure of religious coping. *Religions* 2:51–76.
- Rodin G, Lo C, Mikulincer M, et al. 2009. Pathways to distress: The multiple determinants of depression, hopelessness, and the desire for hastened death. *Soc Sci Med* 68:562–69.

## Spiritual Needs and Spiritual Distress

- Alcorn S, Balboni M, Prigerson HG, et al. 2010. If God wanted me yesterday, I wouldn't be here today: Religious and spiritual themes in patients' experiences of advanced cancer. *J Palliat Med* 13:581–88.
- Attig T. 2003. In *Dying, Death, and Bereavement: A Challenge for Living*, 2nd ed., Corliss IB, Germino BB, Pittman MA (eds.). New York: Springer.
- Cason C. 1983. Spiritual needs of patients—Are they recognized? *Ca Nurs*. 6:187–92.
- Drews MF. 2017. The evolution of hope in patients with terminal illness. *Nursing* 47:11–12.
- Fitchett G, Canada A. 2010. The role of religion/spirituality in coping with cancer: Evidence, assessment, and intervention. In *Psycho-Oncology*, J Holland et al. (ed.). New York: Oxford University Press.
- Grant E, Murray SA, Kendall M, et al. 2004. Spiritual issues and needs: Perspectives from patients with advanced cancer and nonmalignant disease. A qualitative study. *Palliat Support Care* 2:371–78.
- Highfield MF, Cason C. 1983. Spiritual needs of patients: Are they recognized? *Cancer Nurs* 6:187–92.
- Hills J, Paice JA, Cameron JR, et al. 2005. Spirituality and distress in palliative care consultation. *J Palliat Med* 8:782–88.

Jacobs M. 2008. What are we doing here? Chaplains in contemporary healthcare. *Hastings Center Report* 38:15–18.

Sachs E, Kolva E, Pessin H, et al. 2013. On sinking and swimming: The dialectic of hope, hopelessness, and acceptance in terminal cancer. *Am J Hosp Palliat Care* 30:121–27.

Steinhauser K, Christakis N, Clipp EC, et al. 2000. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 284:2476–82.

## Spiritual Assessment

Anandarajah G, Hight E. 2001. Spirituality and medical practice: Using the HOPE questions as a practical tool for spiritual assessment. *Am Fam Physician* 63:81–89.

Delgado-Guay M, Hui D, Parsons HA, et al. 2011. Spirituality, religiosity, and spiritual pain in advanced cancer patients. *J Pain Symptom Manage* 41:986–94.

Fitchett G, Pierson AL, Hoffmeyer C, et al. 2020. Development of the PC-7, a quantifiable assessment of spiritual concerns of patients receiving palliative care near the end of life. *J Palliat Med* 23:248–53.

Shields M, Kestenbaum A, Dunn L. 2014. Spiritual AIM and the work of the chaplain: A model for assessing spiritual needs and outcomes in a relationship. *Pall Support Care* 13:75–89.

## Clinicians Providing Spiritual Care

Astrow AB, Wexler A, Texeira K, et al. 2007. Is failure to meet spiritual needs associated with cancer patients' perceptions of quality of care and their satisfaction with care? *J Clin Oncol* 25:5753–57.

Balboni T, Balboni M, Paulk ME, et al. 2011. Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. *Cancer* 117:5383–91.

Balboni TA, Balboni M, Enzinger AC, et al. 2013. Provision of spiritual support to patients with advanced cancer by religious communities and associations with medical care at the end of life. *JAMA Intern Med* 173:2538–44.

Balboni A, Paulk ME, Balboni MJ, et al. 2010. Provision of spiritual care to patients with advanced cancer: Associations with medical care and quality of life near death. *J Clin Oncol* 20:445–52.

Balboni MJ, Sullivan A, Enzinger AC, et al. 2014. Nurse and physician barriers to spiritual care provision at the end of life. *J Pain Symptom Manage* 48:400–410.

- Bandini J, Thiel M, Meyer EC, et al. 2019. Interprofessional spiritual care training for geriatric care providers. *J Pall Med* 22:1–7.
- Best M, Butow P, Olver I. 2016a. Creating a safe space: A qualitative inquiry into the way doctors discuss spirituality. *Pall Support Care* 14:519–31.
- Best M, Butow P, Olver I. 2016b. Doctors discussing religion and spirituality: A systematic literature review. *Pall Med* 30:327–37.
- Best M, Butow P, Olver I. 2016c. Why do we find it so hard to discuss spirituality? A qualitative exploration of attitudinal barriers. *J Clin Med* 5:77.
- Borneman T, Ferrell B, Puchalski CM. 2010. Evaluation of the FICA tool for spiritual assessment. *J Pain Symptom Manage* 40:163–73.
- Carpenito-Moyet LJ. 2010. *Nursing Diagnosis: Application to Clinical Practice*. Philadelphia: Lippincott Williams and Wilkins.
- Daudt H, d’Archangelo M, Duquette D. 2018. Spiritual care training in healthcare: Does it really have an impact? *Palliat Support Care* 23:1–9.
- Epstein-Peterson ZD, Sullivan AJ, Ensinger AC. 2015. Examining forms of spiritual care provided in the advanced cancer setting. *Am J Hosp Palliat Care* 32:750–57.
- Griffin JL. 2018. Hope modules: Brief psychotherapeutic interventions to counter demoralization from daily stressors of chronic illness. *Acad Psych* 42:135–45.
- Kao LE, Lokko HN, Gallivan K, et al. 2017. A model of collaborative spiritual and psychiatric care of oncology patients. *Psychosomatics* 58:614–23.
- Mako K. 2006. Spiritual pain among patients with advanced cancer in palliative care. *J Palliat Med* 9:1106–13.
- Marin D, Sharma V, Sosunov E, et al. 2015. Relationship between chaplain visits and patient satisfaction. *J Health Care Chaplain* 21:14–24.
- Penderell A, Brazil K. 2010. The spirit of palliative practice: A qualitative inquiry into the spiritual journey of palliative care physicians. *Pall Support Care* 8:415–20.
- Puchalski C, Romer A. 2000. Taking a spiritual history allows clinicians to understand patients more fully. *J Palliat Med* 3:129–37.
- Robinson M, Thiel M, Meyer C. 2007. On being a spiritual care generalist. *Am J Bioethics* 7:724–26.

- Van de Geer J, Groot M, Andela R, et al. 2017. Training hospital staff on spiritual care in palliative care influences patient-reported outcomes: Results of a quasi-experimental study. *Palliat Med* 31:743–53.
- Yang GM, Tan YY, Cheung YBV, et al. 2017. Effect of a spiritual care training program for staff on patient outcomes. *Palliat Support Care* 15:434–43.
- Zollfrank AA, Trevino KM, Balboni MJ, et al. 2015. Teaching health care providers to provide spiritual care: A pilot study. *J Palliat Med* 18:408–14.

## The Role of Religion in Medical Decision-Making

- Bradley C. 2009. Roman Catholic doctrine guiding end-of-life care: A summary of the recent discourse. *J Pall Med* 12:373–77.
- Chakraborty R, El-Jawahri AR, Litzow MR, et al. 2017. A systematic review of religious beliefs about major end-of-life issues in the five major world religions. *Palliat Support Care* 15:609–22.
- Lahaj M. 2011. “End of life care and the chaplain’s role on the medical team. *J IMA* 43:173–78.
- Leong M, Olnick S, Akmal T, et al. 2016. How Islam influences end-of-life care: Education for palliative care clinicians. *J Pain Symptom Manage* 52:771–74.
- Yachter C. 2007. *Kol Torah*. Vol. 17, Halacha. Teaneck, NJ: Torah Academy.

## “I’m Waiting on a Miracle!”

- Cooper B, Ferguson A, Bodurtha JN, et al. 2014. AMEN in challenging conversations: Bridging the gaps between faith, hope, and medicine. *J Oncol Pract* 10:e191–e195.
- Shinall M, Stahl D, Bibler T. 2018. Addressing a patient’s hope for a miracle. *J Pain Symptom Manage* 55:535–39.

## Chapter 4. Sexuality, Intimacy, and Cancer

- Aaberg V. 2016. The state of sexuality education in baccalaureate nursing programs. *Nurse Educ Today* 44:14–19.
- Acquaviva KD. 2017. *LGBTQ-Inclusive Hospice and Palliative Care: A Practical Guide to Transforming Professional Practice*. New York: Harrington Park Press.

- Adams H. 2017. Confronting cancer health disparities due to sexual orientation and gender identity: ASCO publishes guidance on delivering high-quality care to every patient. ASCO Connection, August 30. <https://connection.asco.org>.
- American Cancer Society (ACS). 2019. Cancer Facts and Figures 2019. Atlanta: American Cancer Society.
- Ananth H, Jones L, King M, et al. 2003. The impact of cancer on sexual function: A controlled study. *Palliat Med* 17:202–5.
- Annon J. 1976. The PLISSIT model: A proposed conceptual scheme for the behavioral treatment of sexual problems. *Journal of Sex Education and Therapy* 2:1–15.
- Ashing-Giwa KT, Padilla G, Tejero J, et al. 2004. Understanding the breast cancer experience of women: A qualitative study of African American, Asian American, Latina and Caucasian cancer survivors. *Psychooncology* 13:408–28.
- Association of Reproductive Health Professionals (ARHP). 2008. What you need to know: Talking to patients about sexuality and sexual health. Updated April 2008. <http://www.arhp.org/uploadDocs/sexandsexfactsheet.pdf>.
- Bauer M, Haesler E, Fetherstonhaugh D. 2016. Let’s talk about sex: Older people’s views on the recognition of sexuality and sexual health in the health-care setting. *Health Expectations* 19:1237–50.
- Bayer CR, Eckstrand KL, Knudson G, et al. 2017. Sexual health competencies for undergraduate medical education in North America. *J Sex Med* 14:535–40.
- Bergmark K, Avall-Lundquist E, Dickman P, et al. 1999. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med* 340:1383–89.
- Bober S, Garber J, Recklitis CJ, et al. 2013. A pilot intervention addressing sexual dysfunction after risk-reducing oophorectomy. *J Clin Oncol* 31(suppl): abstr 9644.
- Bober S, Reese J, Barbera L, et al. 2016. How to ask and what to do: A guide for clinical inquiry and intervention regarding female sexual health after cancer. *Curr Opin Support Palliat Care* 10:44–54.
- Bober S, Varela V. 2012. Sexuality in adult cancer survivors: Challenges and intervention. *J Clin Oncol* 30:3712–19.
- Bourgeois-Law G, Lotocki R. 1999. Sexuality and gynecological cancer: A needs assessment. *Can J Hum Sex* 8:231–40.

- Browner I. 2020. Applications in geriatric oncology: Demographics of cancer and aging. Accessed January 21, 2020. [https://www.hopkinsmedicine.org/gec/series/cancer\\_aging.html](https://www.hopkinsmedicine.org/gec/series/cancer_aging.html).
- Cagle JG, Bolte S. 2009. Sexuality and life-threatening illness: Implications for social work and palliative care. *Health and Social Work* 34:223–33.
- Cagle JG, Osteen P, Sacco P, et al. 2017. Psychosocial assessment by hospice social workers: A content review of instruments from a national sample. *J Pain Symptom Manage* 53:40–48.
- Cahil S, Makadon HJ. 2014. Sexual orientation and gender identity data collection in clinical settings and in electronic health records: A key to ending LGBT health disparities. *LGBT Health* 1:34–41.
- Carr SV. 2007. Talking about sex to oncologists and about cancer to sexologists. *Sexologies* 16:265–66.
- Chevret M, Jaudinot E, Sullivan K, et al. 2004. Quality of sexual life and satisfaction in female partners of men with ED: Psychometric validation of the Index of Sexual Life (ISL) questionnaire. *J Sex Marital Ther* 30:141–55.
- Clifford D. 1998. Psychosexual awareness in everyday nursing. *Nursing Standard* 12:42–45.
- Cort E, Monroe B, Oliviere D. 2004. Couples in palliative care. *Sexual and Relationship Therapy* 19:337–54.
- Coyne K, Mandalia S, McCullough S, et al. 2010. The International Index of Erectile Function: Development of an adapted tool for use in HIV-positive men who have sex with men. *J Sex Med* 7:769–74.
- Crenshaw, Kimberle. 1989. Demarginalizing the intersection of race and sex: A Black feminist critique of antidiscrimination doctrine, feminist theory and antiracist politics. *University of Chicago Legal Forum* 1989: article 8.
- Dattilo J, Brewer M. 2005. Assessing clients' sexual health as a component of holistic nursing practice. *J Holist Nurs* 23:208–19.
- Davis C. 2009. Find time to talk to your patients about sex. *Cancer Nursing Practice* 8:6–7.
- Dicola D, Sparr E. 2016. Intimate partner violence. *Am Fam Physician* 94:646–51.
- Dizon DS, Suzin D, McIlvenna S. 2014. Sexual health as a survivorship issue for female cancer survivors. *Oncologist* 19:202–10.
- Fisher A. 2018. Therapeutic sexual aids frequently not available for cancer survivors who need them. ASCO.org, February 12. <https://www.asco.org/about-asco/press-center/news-releases/therapeutic-sexual-aids-frequently-not-available-cancer>.

- Ganz PA, Schag CF, Lee JJ, et al. 1992. The CARES: A generic measure of health-related quality of life for patients with cancer. *Qual Life Res* 1:19–29.
- Gates G. 2017. In U.S., more adults identifying as LGBT. Gallup, January 11. <https://news.gallup.com/poll/201731/lgbt-identification-rises.aspx>.
- Gianotten WL. 2007. Sexuality in the palliative-terminal phase of cancer. *Sexologies* 16:299–303.
- Graves KD, Jensen RE, Cañar J, et al. 2012. Through the lens of culture: Quality of life among Latina breast cancer survivors. *Breast Cancer Res Treat* 136:603–13.
- Griggs J, Maingi S, Blinder V, et al. 2017. American Society of Clinical Oncology position statement: Strategies for reducing cancer health disparities among sexual and gender minority populations. *J Clin Oncol* 35:2203–8.
- Hawkins Y, Ussher J, Gilbert E, et al. 2009. Changes in sexuality and intimacy after the diagnosis and treatment of cancer. *Cancer Nurs* 32:271–80.
- Hendren SK, O'Connor BI, Liu M, et al. 2005. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. *Ann Surg* 242:212–23.
- Hill-Kayser C, Vachani C, Hampshire M, et al. 2011. Sexual side effects (SSE) reported by adolescent/young adult (AYA) versus older cancer survivors. *J Clin Oncol* 29(suppl): abstr 9120.
- Hordern AJ. 2000. Intimacy and sexuality for the woman with breast cancer. *Cancer Nurs* 23:230–36.
- Hordern AJ. 2008. Intimacy and sexuality after cancer: A critical review of the literature. *Cancer Nurs* 31:E9–E17.
- Hordern AJ, Currow DC. 2003. A patient-centered approach to sexuality in the face of life-limiting illness. *Med J Australia* 179(suppl 1):8–11.
- Hordern AJ, Street AF. 2007. Communicating about patient sexuality and intimacy after cancer: Mismatched expectations and unmet needs. *Med J Australia* 186:224–27.
- Hughes MK. 2000. Sexuality and the cancer survivor. *Cancer Nurs* 23:477–82.
- Katz A. 2005. The sounds of silence: Sexuality information for cancer patients. *J Clin Oncol* 23:238–41.
- Katz A. 2009. Gay and lesbian patients with cancer. *Oncol Nurs Forum* 36:203–7.
- Kellogg Spadt S, Rosenbaum T, Dweck A, et al. 2014. Sexual health and religion: A primer for the sexual health clinician. *J Sex Med* 11:1606–19.

- Kuyper MB, Wester F. 1998. In the shadow: The impact of chronic illness on the patient's partner. *Qual Health Res* 8:237–53.
- Lehmann V, Hagedoorn M, Gerhardt C, et al. 2015. Body issues, sexual satisfaction, and relationship status satisfaction in long-term childhood cancer survivors and healthy controls. *Psychooncology* 25:210–16.
- Lemieux L, Kaiser S, Pereira J, et al. 2004. Sexuality in palliative care: Patient perspectives. *Pall Med* 18:630–37.
- MacElveen P, McCorkle R. 1985. Understanding sexuality in progressive cancer. *Sem Oncol Nurs* 1:56–62.
- March AL. 2018. Sexuality and intimacy in the older adult woman. *Nurs Clin North Am* 53:279–87.
- Mick J, Hughes M, Cohen MZ. 2003. Sexuality and cancer: How oncology nurses can address it BETTER. *Oncol Nurs Forum* 30(suppl 2):152–53. Abstract.
- Mutsch J, Friedrich M, Leuteritz K, et al. 2019. Sexuality and cancer in adolescents and young adults—a comparison between reproductive cancer patients and patients with non-reproductive cancer. *BMC Cancer* 19:828. <https://doi.org/10.1186/s12885-019-6009-2>.
- Namiki S, Carlile RG, Namiki TS, et al. 2011. Racial differences in sexuality profiles among American, Japanese, and Japanese American men with localized prostate cancer. *J Sex Med* 8:2625–31.
- Nápoles AM, Ortiz C, Santoyo-Olsson J, et al. 2015. Nuevo Amanecer: Results of a randomized controlled trial of a community-based, peer-delivered stress management intervention to improve quality of life in Latinas with breast cancer. *Am J Public Health* 105(suppl 3):e55–63.
- National Cancer Institute. 2013. Sexuality and reproductive issues (PDQ): Health professional version. <https://pubmed.ncbi.nlm.nih.gov/26389412/>.
- National Cancer Institute. 2020. “Cancer Disparities.” Last updated November 17, 2020. <https://www.cancer.gov/about-cancer/understanding/disparities>.
- National Coalition for Sexual Health. 2016. Sexual Health and Your Patients: A Provider's Guide. Washington, DC: Altarum Institute. <https://nationalcoalitionforsexualhealth.org/tools/for-healthcare-providers/document/ProviderGuide.pdf>.
- Navon L, Morag A. 2003. Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties. *Qual Health Res* 13:1378–92.



- Olsson M, Steineck G, Enskar K, et al. 2018. Sexual function in adolescent and young adult cancer survivors—a population-based study. *J Cancer Surviv* 12:450–59.
- Park J, Safer J. 2018. Clinical exposure to transgender medicine improves students’ preparedness above levels seen with didactic teaching alone: A key addition to the Boston University model for teaching transgender healthcare. *Transgender Health* 3:10–16.
- Price B. 2010. Sexuality: Raising the issue with patients. *Canc Nurs Practice* 9:29–35.
- Quinn GP, Alpert AB, Sutter M, et al. 2020. What oncologists should know about treating sexual and gender minority patients with cancer. *J Oncol Pract* 16:309–16.
- Quinn GP, Sanchez JA, Sutton SK, et al. 2015. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. *CA Cancer J Clin* 65:384–400.
- Rosen R, Brown C, Heiman J, et al. 2000. The Female Sexual Function Index: A multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 26:191–208.
- Rosen RC, Riley A, Wagner G, et al. 1997. The International Index of Erectile Function: A multidimensional scale for assessment of erectile dysfunction. *Urology* 49:822–30.
- Rubin ES, Rulio J, Tsai P, et al. 2018. Best practices in North American pre-clinical medical education in sexual history. *J Sex Med* 15:1414–25.
- Saunamaki N, Andersson M, Engstrom M. 2010. Discussing sexuality with patients: Nurses’ attitudes and beliefs. *J Adv Nurs* 66:1308–16.
- Schabath MB, Blackburn CA, Sutter ME, et al. 2019. National Survey of Oncologists at National Cancer Institute-designated comprehensive cancer centers: Attitudes, knowledge, and practice behaviors about LGBTQ patients with cancer. *J Clin Oncol* 37:547–58.
- Schover LR. 1999. Counseling cancer patients about changes in sexual function. *Oncology* 13:1585–91.
- Schover LR, Rhodes MM, Baum G, et al. 2011. Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT): A peer counseling program to improve reproductive health among African American breast cancer survivors. *Cancer* 117:4983–92.
- Seaborne LA, Prince RJ, Kushner DM. 2015. Sexual health education in U.S. physician assistant programs. *J Sex Med* 12:1158–64.
- Shell JA. 2007. Including sexuality in your nursing practice. *Nurs Clin N Am* 42:685–96.
- Shell JA, Smith CK. 1994. Sexuality and the older person with cancer. *Oncol Nurs Forum* 21:553–58.

- Shindel AW, Ando AA, Nelson CJ, et al. 2010. Medical student sexuality: How sexual experience and sexuality training impact US and Canadian medical students' comfort in dealing with patients' sexuality in clinical practice. *Academic Med* 85:1321–30.
- Shindel AW, Baazeem A, Eardley I, et al. 2016. Sexual health in undergraduate medical education: Existing and future needs and platforms. *J Sex Med* 13:1013–26.
- Spaulding S. 2006. You tell us: No patient assessment is complete without asking one simple question. *ONS News* 21:6–7.
- Srinivasan S, Glover J, Tampi RR, et al. 2019. Sexuality and the older adult. *Curr Psychiatry Rep* 21:97.
- Stanton A, Handy A, Meston C. 2018. Sexual function in adolescents and young adults diagnosed with cancer: A systematic review. *J Cancer Surviv* 12:47–63.
- Stevens E, Abrahm J. 2019. Adding silver to the rainbow: Palliative and end-of-life care for the geriatric LGBTQ patient. *J Palliat Med* 22:602–6.
- Symonds T, Perelman MA, Althof S, et al. 2007. Development and validation of a premature ejaculation diagnostic tool. *Eur Urol* 52:565–73.
- Taylor B. 2014. Experiences of sexuality and intimacy in terminal illness: A phenomenological study. *Palliat Med* 28:438–47.
- Tracy JK, Junginger J. 2007. Correlates of lesbian sexual functioning. *J Women's Health (Larchmt)* 16:499–509.
- Weijmar Schultz WCM, Van de Wiel HBM. 2003. Sexuality, intimacy, and gynecological cancer. *J Sex and Marital Therapy* 29(suppl):121–28.
- Wiggins D, Wood R, Granai C, et al. 2007. Sex, intimacy, and the gynecologic oncologist. *J Psychosoc Oncol* 25:61–70.
- Wittenberg A, Gerber J. 2009. Curricula in medical schools: Results from a two-arm study collecting data from patients and medical students. *J Sex Med* 6:362–68.
- World Health Organization. 2020. "Sexual Health." Accessed January 2, 2020. [https://www.who.int/health-topics/sexual-health#tab=tab\\_1](https://www.who.int/health-topics/sexual-health#tab=tab_1).
- Zhou ES, Nekhlyudov L, Bober SL. 2015. The primary health care physician and the cancer patient: Tips and strategies for managing sexual health. *Transl Androl Urol* 4:218–31. doi: 10.3978/j.issn.2223-4683.2014.11.07.

## Chapter 5. Advancing Disease

- Amin MB, Edge S, Greene F, et al., eds. 2017. *AJCC Cancer Staging Manual*. 8th ed. New York: Springer.
- Applebaum AJ, Kolva EA, Kulikowski JR, et al. 2014. Conceptualizing prognostic awareness in advanced cancer: A systematic review. *J Health Psychol* 19:1103–19.
- Back AL. 2020. Patient-clinician communication issues in palliative care for patients with advanced cancer. *J Clin Oncol* 38:866–76.
- Childers JW, Back AL, Tulskey JA, et al. 2017. REMAP: A framework for goals of care conversations. *J Oncol Pract* 13: e844–e850.
- Collins ME, Abrahm JL. 2019. Communication challenges at the crossroads of oncology and palliative care: Finding a way forward when clinicians differ on prognosis. *J Palliat Care* 34:241–44.
- D'Aulaire I, D'Aulaire EP. 1962. *D'Aulaires' Book of Greek Myths*. New York: Bantam Doubleday Dell.
- Elk R, Emanuel L, Hauser J, et al. 2020. Developing and testing the feasibility of a culturally based tele-palliative care consult based on the cultural values and preferences of southern, rural African American and white community members: A program by and for the community. *Health Equity* 4:52–83.
- Franklin RW, ed. 1999. *The Poems of Emily Dickinson: Reading Edition*. Cambridge: Harvard University Press, Belknap Press.
- Geerse OP, Lamas DJ, Sanders JJ, et al. 2019. A qualitative study of serious illness conversations in patients with advanced cancer. *J Palliat Med* 22:773–81.
- Gray TF, Temel JS, El-Jawahri A. 2020. Illness and prognostic understanding in patients with hematologic malignancies. *Blood Reviews* 45:100692.  
<https://doi.org/10.1016/j.blre.2020.100692>.
- Hui D. 2015. Prognostication of survival in patients with advanced cancer: Predicting the unpredictable? *Cancer Control* 22:489–97.
- Hui D, Maxwell JP, Paiva CE. 2019. Dealing with prognostic uncertainty: The role of prognostic models and websites for patients with advanced cancer. *Curr Opin Support Palliat Care* 13:360–68.

- Jackson VA, Jacobsen J, Greer JA, et al. 2013. The cultivation of prognostic awareness through the provision of early palliative care in the ambulatory setting: A communication guide. *J Palliat Med* 16:894–900.
- Jacobsen J, Brenner K, Greer JA, et al. 2018. When a patient is reluctant to talk about it: A dual framework to focus on living well and tolerate the possibility of dying. *J Palliat Med* 21:322–27.
- Kübler-Ross E. 1969. *On Death and Dying*. New York: Collier.
- LeBlanc TW, Marron JM, Ganai S, et al. 2019. Prognostication and communication in oncology. *J Oncol Pract* 15:208–15.
- LeBlanc TW, Temel JS, Helft PR. 2018. “How much time do I have?”: Communicating prognosis in the era of exceptional responders. *ASCO Educational Book*, no. 38:787–94.
- Lunney JR, Lynn J, Foley DJ, et al. 2003. Patterns of functional decline at the end of life. *JAMA* 289:2387–92.
- Lunney JR, Lynn J, Hogan C. 2002. Profiles of older Medicare decedents. *J Am Geriatr Soc* 50:1108–12.
- Meier DE. 2014. “I don’t want Jenny to think I’m abandoning her”: Views on overtreatment. *Health Aff* 33:895–98.
- Norton SA, Wittink MN, Duberstein PR, et al. 2019. Family caregiver descriptions of stopping chemotherapy and end-of-life transitions. *Support Care Cancer* 27:669–75.
- Paladino J, Bernacki R, Neville BA, et al. 2019. Evaluating an intervention to improve communication between oncology clinicians and patients with life-limiting cancer: A cluster randomized clinical trial of the Serious Illness Care Program. *JAMA Oncol* 5:801–9.
- Parikh RB, Manz C, Chivers C, et al. 2019. Machine learning approaches to predict 6-month mortality among patients with cancer. *JAMA Netw Open* 2:e1915997.
- Rauch PK, Muriel AC. 2006. *Raising an Emotionally Healthy Child When a Parent Is Sick*. New York: McGraw-Hill.
- Rauch PK, Muriel AC, Cassem NH. 2002. Parents with cancer: Who’s looking after the children? *J Clin Oncol* 20:4399–4402.
- Schou KC, Hewison J. 1999. *Experiencing Cancer: Quality of Life in Cancer Treatment*. Buckingham, UK: Open University Press.
- Sekeres MA, Stone RM, Zahrieh D, et al. 2004. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. *Leukemia* 18:809–16.

- Simmons CPL, McMillan DC, McWilliams K, et al. 2017. Prognostic tools in patients with advanced cancer: A systematic review. *J Pain Symptom Manage* 53:962–70.
- Stuart B, Danaher T, Awdish R, et al. 2019. Finding hope and healing when cure is not possible. *Mayo Clin Proc* 94:677–85.
- Taylor LJ, Nabozny MJ, Steffens NM, et al. 2017. A framework to improve surgeon communication in high-stakes surgical decisions: Best case / worst case. *JAMA Surg* 152:531–38.
- Temel JS, Gainor JF, Sullivan RJ, et al. 2018. Keeping expectations in check with immune checkpoint inhibitors. *J Clin Oncol* 36:1654–57.
- Weissman, DE. 2003. Determining prognosis in advanced cancer #13a. *J Palliat Med* 6:433–34.

## Chapter 6. Assessing the Patient in Pain

### General

- Abdo H, Calvo-Enrique L, Lopez JM, et al. 2019. Specialized cutaneous Schwann cells initiate pain sensation. *Science* 365:695–99.
- Anderson KO, Green CR, Payne R. 2009. Racial and ethnic disparities in pain: Causes and consequences of unequal care. *J Pain* 10:1187–1204.
- Barkwell DP. 1991. Ascribed meaning: A critical factor in coping and pain attenuation in patients with cancer-related pain. *J Palliat Care* 7:5–14.
- Bookbinder M, Kiss M, Coyle N, et al. 1995. Improving pain management practices. In *Cancer Pain Management*, 2nd ed., McGuire DB, Yarbo CH, Ferrell BR (eds.). Sudbury, MA: Jones and Bartlett.
- Byock I. 1997. *Dying Well: Peace and Possibilities at the End of Life*. New York: Riverhead.
- Cassell E. 2004. *The Nature of Suffering and the Goals of Medicine*. 2nd ed. New York: Oxford University Press.
- Chisholm-Burns MA, Spivey CA, Gatwood J, et al. 2017. Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services. *Am J Health Syst Pharm* 74:653–68.
- Claton BA, Rabow MW, Branagan L, et al. 2019. Top ten tips palliative care clinicians should know about telepalliative care. *J Palliat Med* 22:981–85.

- Cobaugh DJ. 2017. Pharmacy access: Why are minorities' options different? *Am J Health Syst Pharm* 74:634–35.
- Daut RL, Cleeland CS, Flanery RC. 1983. The development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain* 17:197–210.
- Doan RA and Monk KR. 2019. Glia in the skin activate pain responses (editorial). *Science* 365:641–42.
- Fallon M, Giusti R, Aielli F, et al., on behalf of the ESMO Guidelines Committee. 2018. Management of cancer pain in adult patients: ESMO clinical practice guidelines. *Ann Oncol* 29(4 suppl) iv166–iv191.
- Ferrell BR, Johnston-Taylor EJ, Sattler GR, et al. 1993. Searching for the meaning of pain: cancer patients', caregivers' and nurses' perspectives. *Cancer Practice* 1:185–94.
- Ferrell BR, Rhiner M. 1991. High-tech comfort: Ethical issues in cancer pain management for the 1990s. *J Clin Ethics* 2:108–12.
- Ferrell BR, Rhiner M, Zichi-Cohen M, et al. 1991. Pain as a metaphor for illness, part I: Impact of cancer pain on family caregivers. *Oncol Nurs Forum* 8:1303–9.
- Fink RS, Gates R. 1995. Cultural diversity and cancer pain. In *Cancer Pain Management*, 2nd ed, McGuire DB, Yarbrough CH, Ferrell BR (eds.). Boston: Jones and Bartlett.
- Fisch MJ, Kee JW, Weiss M, et al. 2012. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. *J Clin Oncol* 30:1980–88.
- Fischer T, Hosie A, Luckett T, et al. 2019. Strategies for pain assessment in adult patients with delirium: A scoping review. *J Pain Symptom Manage* 58:487–502.
- Fishman B, Pasternak S, Wallenstein SL, et al. 1987. The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. *Cancer* 60:1151–58.
- Flanagan AY. 2018. Intersection of Pain and Culture. NetCE document released October 1, 2018. <https://www.netce.com/coursecontent.php?courseid=1691>.
- Galer BS, Jensen MP. 1997. Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale. *Neurology* 48:332–38.
- Green CR, Ndao-Brumblay SK, West B, et al. 2005. Differences in prescription opioid analgesic availability: Comparing minority and white pharmacies across Michigan. *J Pain* 6:689–99.
- Herr K. 2011. Pain assessment strategies in older patients. *J Pain* 12(1 suppl):S3–S13.

- Herr K, Bursch H, Ersek M, et al. 2010. Use of pain-behavioral assessment tools in the nursing home: Expert consensus recommendations for practice. *J Gerontol Nurs* 36:18–29.
- Hollingshead NA, Ashburn-Nardo L, Stewart JC, et al. 2016. The pain experience of Hispanic Americans: A critical literature review and conceptual model. *J Pain* 17:513–28.
- Hollingshead NA, Meints SM, Miller MM, et al. 2016. A comparison of race-related pain stereotypes held by white and Black individuals. *J Appl Soc Psychol* 46:718–23.
- Lawton AJ, Lee K, Cheville AL, et al. 2019. Assessment and management of patients with metastatic spinal cord compression: A multidisciplinary review. *J Clin Oncol* 37:61–71.
- LeBlanc TW, Kamal AH. 2018. Management of cancer pain. In DeVita, Hellman, and Rosenberg's *Cancer: Principles and Practice of Oncology*, 11th ed, DeVita VT, Lawrence TS, Rosenberg SA, et al. (eds.). Philadelphia: Wolters Kluwer Health.
- Liu JYW, Chung JWY, Wong TKS. 2003. The psychometric properties of Chinese pain intensity verbal rating scale. *Acta Anaesthesiol Scand*. 47:1013–19.
- Marvaldi L, Panayotis N, Alber S, et al. 2020. Importin  $\alpha 3$  regulates chronic pain pathways in peripheral sensory neurons. *Science* 369:842–46.
- McCaffery M, Ferrell BR. 1991. How would you respond to these patients in pain? *Nursing* 21:34–37.
- Miaskowski C, Zimmer EF, Barrett KM, et al. 1997. Differences in patients' and family caregivers' perceptions of the pain experience influence patient and caregiver outcomes. *Pain* 72:217–26.
- Minello C, George B, Allano G, et al. 2019. Assessing cancer pain: The first step toward improving patients' quality of life. *Supp Care Cancer* 27:3095–3104.
- Morrison RS, Wallenstein S, Natale DK, et al. 2000. "We don't carry that"—Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. *N Engl J Med* 342:1023–26.
- Narayan MC. 2010. Culture's effects on pain assessment and management. *Am J Nurs* 110:38–49.
- Paice JA, Portenoy R, Lacchetti C, et al. 2016. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Practice Guideline. *J Clin Oncol* 34:3325–45.
- Portenoy RK, Ahmed E. 2018. Cancer pain syndromes. *Hematol Oncol Clin North Am* 32:371–86.

- Portenoy RK, Hagen NA. 1990. Breakthrough pain: Definition, prevalence and characteristics. *Pain* 41:273–82.
- Portnow J, Lim C, Grossman SA. 2003. Assessment of pain caused by invasive procedures in cancer patients. *JNCCN* 3:435–39.
- Rhiner M, Coluzzi PH. 1995. Family issues influencing management of cancer pain. In *Cancer Pain Management*, 2nd ed, McGuire DB, Yarbrow CH, Ferrell BR (eds.). Boston: Jones and Bartlett.
- Robinson-Lane SG, Booker SQ. 2017. Culturally responsive pain management for Black older adults. *J Gerontol Nurs* Mar 2:1–8.
- Swarm RA, Paice JA, Angelescu DL, et al. 2019. Adult cancer pain, version 3. NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 17:977–1007.
- van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. 2016. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. *J Pain Symptom Manage* 51:1070–90.
- Warden V, Hurley AC, Volicer L. 2003. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. *J Am Med Dir Assoc* 4:9–15.
- Yousef MS and Price TJ. 2020. The importins of pain (editorial). *Science* 369:774–75.

## PROs and Clinical Decision Support

- Absolom K, Warrington L, Hudson E, et al. 2021. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. *J Clin Oncol* 39:734–47.
- Anderson KO, Palos GR, Mendoza TR, et al. 2015. Automated pain intervention for underserved minorities with breast cancer. *Cancer* 121:1882–90.
- Back A, Friedman T, Abraham J. 2020. Palliative care skills and new resources for oncology practices: Meeting the palliative care needs of patients with cancer and their families. *ASCO Oncol Educ Book* 40:1–9.
- Bakitas M, Lyons KD, Hegel MT, et al. 2009. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The Project ENABLE II randomized controlled trial. *JAMA* 302:741–49.
- Balas EA, Boren SA. 2000. Managing clinical knowledge for health care improvement. In *Yearbook of Medical Informatics 2000: Patient-Centered Systems*, Bommel J, McCray AT (eds.). Stuttgart, Germany: Schattauer Verlagsgesellschaft mbH, pp. 65–70.



- Basch E, Barbera L, Kerrigan CL, et al. 2018. Implementation of patient-reported outcomes in routine medical care. *Am Soc Clin Oncol Educ Book* May 23:122–34.
- Basch E, Deal AM, Dueck AC, et al. 2017. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA* 318:197–98.
- Basch EM, Teal R, Dueck AC, et al. 2020. Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial (AFT-39, NCT03249090). *Proc ASCO 2020* 38(15 suppl):7044.
- Basch E, Leahy AB, Dueck AC. 2021. Benefits of digital symptom monitoring with patient-reported outcomes during adjuvant cancer treatment. *J Clin Oncol* 39:701–2.
- Borneman T, Piper BF, Sun VC, et al. 2007. Implementing the fatigue guidelines at one NCCN member institution: Process and outcomes. *J Natl Compr Canc Netw* 5:1092–1101.
- Bright TJ, Wong A, Dhurjati R, et al. 2012. Effect of clinical decision-support systems: A systematic review. *Ann Intern Med* 157:29–43.
- Cooley ME, Lobach DF, Johns E, et al. 2013. Creating computable algorithms for symptom management in an outpatient thoracic oncology setting. *J Pain Symptom Manage* 46:911–24.e911.
- Cooley ME, Nayak MM, Abrahm JL, et al. 2017. Patient and caregiver perspectives on decision support for symptom and quality of life management during cancer treatment: Implications for eHealth. *Psychooncology* 26:1105–12.
- Denis F, Basch E, Septans A-L, et al. 2019. Comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. *JAMA* 321:306–7.
- Hoffman KM, Trawalter S, Axt JR, et al. 2016. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between Blacks and whites. *Proc Natl Acad Sci* 113:4296–4301.
- Kamdar M, Centi AJ, Agboola S, et al. 2018. A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain. *J Clin Oncol* 36(34 suppl):76.
- Kawamoto K, Houlihan CA, Balas EA, et al. 2005. Improving clinical practice using clinical decision support systems: A systematic review of trials to identify features critical to success. *BMJ* 330:765.

- Koleck TA, Dreisbach C, Bourne PE, et al. 2019. Natural language processing of symptoms documented in free-text narratives of electronic health records: A systematic review. *JAMIA* 29:364–79.
- Latoszek-Berendsen A, Tange H, van den Herik HJ, et al. 2010. From clinical practice guidelines to computer-interpretable guidelines: A literature overview. *Methods Inf Med* 49:550–70.
- Lobach DF. 2013. The road to effective clinical decision support: Are we there yet? *BMJ* 346:f1616.
- Lobach DF, Johns EB, Halpenny B, et al. 2016. Increasing complexity in rule-based clinical decision support: The Symptom Assessment and Management Intervention. *JMIR Med Inform* 4:e36.
- Osheroff JA, Pifer EA, Teich JM, et al. 2005. *Improving Outcomes with Clinical Decision Support: An Implementer's Guide*. Chicago: Healthcare Information and Management Systems Society Press.
- Velikova G, Absolom K, Warrington L, et al. 2020. Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-Events: Patient Information and Advice): An eHealth intervention during chemotherapy. *Proc ASCO* 2020 38(15 suppl):7002.
- Wagner LI, Schink J, Bass M, et al. 2015. Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory care. *Cancer* 121:927–34.

## Telehealth

- Back A, Friedman T, Abrahm J. 2020. Palliative care skills and new resources for oncology practices: Meeting the palliative care needs of patients with cancer and their families. *ASCO Oncol Educ Book* 40:1–9.
- Bonsignore L, Bloom N, Steinhauser K, et al. 2018. Evaluating the feasibility and acceptability of a telehealth program in a rural palliative care population: TapCloud for palliative care. *J Pain Symptom Manage* 56:7–14.
- Calton BA, Rabow MW, Branagan L, et al. 2019. Top ten tips palliative care clinicians should know about telepalliative care. *J Palliat Med* 22:981–85.
- Fratkin M. 2019. Telemedicine 3.0: How video technology can support people with serious illness. *Palliative in Practice* (blog), June 12. <https://resolutioncare.com/news/telemedicine-3-0-how-video-technology-can-support-people-with-serious-illness/>.

Shin JY, Kang TI, Noll RB, et al. 2018. Supporting caregivers of patients with cancer: A summary of technology-mediated interventions and future directions. *Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet* 38:838–49.

Worster B, Swartz K. 2017. Telemedicine and palliative care: An increasing role in supportive oncology. *Curr Oncol Rep* 19:37.

## Chapter 7. Pharmacologic Management of Cancer Pain

Brutcher RE, Kurihara C, Bicket MC, et al. 2019. Compounded topical creams to treat localized chronic pain: A randomized controlled trial. *Ann Intern Med* 170:309–18.

Fallon M, Giusti R, Aielli F, et al, on behalf of the ESMO Guidelines Committee. 2018. Management of cancer pain in adults: ESMO Clinical Practice Guidelines. *Ann Oncol* 29 (suppl 4):iv166–iv191.

Fisch MJ, Lee JW, Weiss M, et al. 2012. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. *J Clin Oncol* 30:1980–88.

Henson LA, Maddocks M, Evans C, et al. 2020. Palliative care and the management of common distressing symptoms in advanced cancer: Pain, breathlessness, nausea and vomiting, and fatigue. *J Clin Oncol* 38:90514.

Mercadante S. 1999. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. *Cancer* 85:1849–58.

Mercadante S. 2011. Emerging drugs for cancer-related pain. *Support Care Cancer* 19:1887–93.

National Comprehensive Cancer Network (NCCN). 2020. NCCN Adult Cancer Pain Guideline, version 1. <https://www.nccn.org>.

Paice JA, Ferrell B. 2011. The management of cancer pain. *CA Cancer J Clin* 61:157–82.

Schug SA, Zech D, Dorr U. 1990. Cancer pain management according to WHO analgesic guidelines. *J Pain Symptom Manage* 5:27–32.

van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. 2016. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. *J Pain Symptom Manage* 51:1070–90.

World Health Organization. 2011. Ensuring balance in national policies on controlled substances: Guidance for availability and accessibility of controlled medicines. (Update being planned.) [https://www.who.int/medicines/areas/quality\\_safety/guide\\_on\\_pain/en/](https://www.who.int/medicines/areas/quality_safety/guide_on_pain/en/).

Zech D, Grond S, Lynch J, et al. 1995. Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. *Pain* 63:65–76.

## Drug Use in Hepatic Failure

Wilcock A, Charlesworth A, Prentice W, et al. 2019. Prescribing in chronic severe hepatic impairment. *J Pain Symptom Manage* 58:515–37.

## Drug Use in Renal Failure

Sande TA, Laird BJ, Fallon MT. 2017. The use of opioids in cancer patients with renal impairment: A systematic review. *Support Care Cancer* 25:661–75.

Wilcock A, Charlesworth S, Twycross R, et al. 2017. Prescribing non-opioid drugs in end-stage kidney disease. *J Pain Symptom Manage* 54:776–87.

## NSAIDs

### *General Discussion*

Avril T and Chevet E. 2019. Stress in signaling in pain control (editorial). *Science* 365:224–25.

Chopra S, Giovanelli P, Alvarado-Vazquez PA, et al. 2019. IRE1alpha-XPB1 signaling in leukocytes controls prostaglandin biosynthesis and pain. *Science* 365:248.

Magee DJ, Jhanji S, Poulogiannis G, et al. 2019. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: A systematic review and reappraisal of the evidence. *Br J Anesth* 123:e412–e423.

Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature* 231:232–35.

### *Efficacy*

Buckley MM, Brogden RN. 1990. Ketorolac: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. *Drugs* 39:86–109.

Eisenberg E, Berkey CS, Carr DB, et al. 1994. Efficacy and safety of non-steroidal anti-inflammatory drugs for cancer pain: A meta-analysis. *J Clin Oncol* 12:2756–65.

Reynolds LW, Hoo RK, Brill RJ, et al. 2003. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. *J Pain Symptom Manage* 25:133–41.

Samala RV, Mellar MP. 2012. Palliative care per rectum. *J Palliat Med* 15:1038–39.

Stuart MJ, Murphy SM, Oski FA, et al. 1972. Platelet function in recipients of platelets from donors ingesting aspirin. *N Engl J Med* 287:1105–9.

Warren DE. 1996. Practical use of rectal medications in palliative care. *J Pain Symptom Manage* 11:378–87.

### *Side Effects and Complications*

Chan FFKL, Hung LCT, Suen BY, et al. 2002. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. *N Engl J Med* 347:2104–10.

DeMaria AN, Weir MR. 2003. Coxibs—beyond the GI tract: Renal and cardiovascular issues. *J Pain Symptom Manage* 25(suppl):S41–S49.

Gloth FM. 1996. Concerns with chronic analgesic therapy in elderly patients. *Am J Med* 101 (suppl 1):9S–24S.

Hawkey CJ, Karrasch KA, Szczepanski L, et al. 1998. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. *N Engl J Med* 338:727–34.

Laine L. 2003. Gastrointestinal effects of NSAIDs and coxibs. *J Pain Symptom Manage* 25(suppl):S32–S40.

Samala RV, Mellor MP. 2012. Palliative care per rectum #257. *J Palliat Med* 15:1038–39.

Scheiman JM. 1996. NSAIDs, gastrointestinal injury, and cytoprotection. *Gastroenterol Clin North Am* 25:279–98.

Yeomans ND, Tulassay Z, Juhasz L, et al. 1998. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. *N Engl J Med* 338:719–26.

## **Opioids**

### *Strategies for Minimizing Harm*

Balboni TA, Balboni MJ. 2018. The spiritual event of serious illness. *J Pain and Symptom Manage* 56:816–22.

Bruera E, Del Fabbro E. 2018. Pain management in the era of the opioid crisis. 2018 ASCO Educational Book 38:807–12.

Catechism of the Catholic Church. 1997. 2nd ed. Alexandria, Va.: Pauline, St. Paul Books and Media.

Chi NC, Demiris G. 2017. Family caregivers' pain management in end-of-life care: A systematic review. *Am J Hosp Palliat Care* 34:470–85.

Dowell D, Haegerich TM, Chou R. 2016. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA* 315:1624–45.

Fallon M, Giusti R, Aielli F, et al., on behalf of the ESMO Guidelines Committee. 2018. Management of cancer pain in adults: ESMO Clinical Practice Guidelines. *Ann Oncol* 29 (suppl 4):iv166–iv191.

National Comprehensive Cancer Network (NCCN). 2019. Guidelines for Supportive Care. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#supportive](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive).

Scarborough BM, Smith CB. 2018. Optimal pain management for patients with cancer in the modern era. *CA Cancer J Clin* 68:182–96.

### *Risk Mitigation*

Butler SF, Budman SH, Fernandez KC, et al. 2007. Development and validation of the Current Opioid Misuse Measure. *Pain* 130:144–56.

Dale R, Edwards J, Ballantyne J. 2016. Opioid risk assessment in palliative medicine. *J Commun Support Oncol* 14:94–100.

Koyyalagunta D, Bruera E, Aigner C, et al. 2013. Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. *Pain Med* 14:667–75.

Lee J S-J, Hou HM, Edelman AL, et al. 2017. New persistent opioid use among patients with cancer after curative-intent surgery. *J Clin Oncol* 35:4042–49.

Meltzer EC, Rybin D, Saitz R, et al. 2011. Identifying prescription opioid use disorder in primary care: Diagnostic characteristics of the Current Opioid Misuse Measure. *Pain* 152:397–402.

Paice JA. 2019. Risk assessment and monitoring of patients with cancer receiving opioid therapy. *Oncologist* 24:1–5.

Paice JA, Portenoy R, Lacchetti C, et al. 2016. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 34:3325–45.

Spahn V, Del Vecchio G, Labuz D, et al. 2017. A nontoxic pain killer designed by modeling of pathological receptor conformations. *Science* 355:966–69.

Yasin JT, Leader AE, Petok A, et al. 2019. Validity of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) in patients with cancer. *J Opioid Manage* 15:272–74.

### *General Guidelines*

- Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. 2009. Establishing “best practices” for opioid rotation: Conclusions of an expert panel. *J Pain Symptom Manage* 38:418–25.
- George B, Minello C, Allano G, et al. 2019. Opioids in cancer-related pain: Current situation and outlook. *Support Care Cancer* 27:3105–18.
- Knotkova H, Fine PG, Portenoy RK. 2009. Opioid rotation: The science and the limitations of the equianalgesic dose table. *J Pain Symptom Manage* 38:426–39.
- Morrison RS, Wallenstein S, Natale DK, et al. 2000. “We don’t carry that”—Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. *N Engl J Med* 342:1023–26.
- Moryl N, Coyle N, Foley KM. 2008. Managing an acute pain crisis in a patient with advanced cancer: “This is as much of a crisis as a code.” *JAMA* 299:1457–67.
- Strouse TB. 2009. Pharmacokinetic drug interactions in palliative care: focus on opioids. *J Palliat Med* 12:1043–50.
- Thomas SH, Silen W, Cheema F, et al. 2003. Effects of morphine analgesia on diagnostic accuracy in Emergency Department patients with abdominal pain: A prospective, randomized trial. *J Am Coll Surg* 196:18–31.
- Weinberg BBBA, Inturissi CE, Reidenberg B, et al. 1988. Sublingual absorption of selected opioid analgesics. *Clin Pharmacol Ther* 44:335–42.

### *Oral Route*

#### *CODEINE*

- Desmeules J, Gascon M-P, Dayer P, et al. 1991. Impact of environmental and genetic factors on codeine analgesia. *Eur J Clin Pharmacol* 41:23–26.
- Sindrup SH, Arendt-Nielsen L, Rosen K, et al. 1992. The effect of quinidine on the analgesic effect of codeine. *Eur J Clin Pharmacol* 42:587–91.

#### *FENTANYL (ORAL/NASAL TRANSMUCOSAL)*

- Christie JM, Simmonds M, Patt R, et al. 1998. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. *J Clin Oncol* 16:3238–45.
- Fine PG, Marcus M, Just De Boer A, et al. 1991. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. *Pain* 45:149–53.

- Lyseng-Williamson KA. 2011. Fentanyl pectin nasal spray in breakthrough pain in opioid-tolerant adults with cancer. *CNS Drugs* 25:511–22.
- Nicholson B, Agarwala SS. 2011. Opioid delivery in the treatment of cancer breakthrough pain: A review of routes of administration. *J Opioid Manage* 7:69–79.
- Payne R, Caluzzi P, Hart L, et al. 2001. Long-term safety of oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain. *J Pain Symptom Manage* 22:579–83.
- Twycross R, Prommer EE, Mihalyo M, et al. 2012. Fentanyl (transmucosal). *AHFS* 28:08:08. *J Pain Symptom Manage* 44:131–49.
- Zecca E, Brunelli C, Centurioi F, et al. 2017. Fentanyl sublingual tablets versus subcutaneous morphine for the management of severe cancer pain episodes in patients receiving opioid treatment: A double-blind, randomized, noninferiority trial. *J Clin Oncol* 35:759–65.
- Zhang H, Zhang J, Streisand JB. 2002. Oral mucosal drug delivery: Clinical pharmacokinetic and therapeutic applications. *Clin Pharmacokinet* 41:661–80.
- MEPERIDINE*
- Kaiko RF, Foley KM, Grabinski PY, et al. 1983. Central nervous system excitatory effects of meperidine in cancer patients. *Ann Intern Med* 13:180–85.
- LEVORPHANOL*
- McNulty JP. 2007. Can levorphanol be used like methadone for intractable refractory pain? *J Palliat Med* 10:293–96.
- Pham TC, Fudin J, Raffa RB. 2015. Is levorphanol a better option than methadone? *Pain Med* 16:1673–79.
- BUPRENORPHINE*
- Davis MP. 2012. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. *J Support Oncol* 10:209–19.
- Davis MP, Pasternak G, Behm B. 2018. Treating chronic pain: An overview of clinical studies centered on the buprenorphine option. *Drugs* 78:1211–28.
- Johnson RE, Fudala PJ, Payne R. 2005. Buprenorphine: Considerations for pain management. *J Pain Symptom Manage* 29:297–326.
- McCance-Katz EF, Sullivan L, Nallani S. 2010. Drug interactions of clinical importance among the opioids methadone and buprenorphine, and other frequently prescribed medications: A review. *Am J Addict* 19:4–16.
- Pergolizzi JV, Mercadante S, Echaburu AV, et al. 2009. The role of transdermal buprenorphine in the treatment of cancer pain: An expert panel consensus. *Curr Med Res Opin* 25:1517–28.



Poulain P, Denier W, Douma J, et al. 2008. Efficacy and safety of transdermal buprenorphine: A randomized placebo-controlled trial in 289 patients with severe pain. *J Pain Symptom Manage* 36:117–25.

#### METHADONE

Bach TV, Pan J, Kirstein A, et al. 2016. Use of methadone as an adjuvant medication to low-dose opioids for neuropathic pain in the frail elderly: A case series. *J Palliat Med* 19:1351–55.

Elsass K, Marks S, Malone N. 2018. Nonoral routes of methadone for analgesia in palliative care #358. *J Palliat Med* 21:1357–58.

Foley KM. 2003. Opioids and chronic neuropathic pain. *N Engl J Med* 348:1279–81.

Fürst P, Lundström S, Klepstad P, et al. 2020. The use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at the end of life: A national Swedish survey in specialized palliative care. *J Palliat Med* 23:226–32.

Gourevich M. 2009. First do no harm . . . Reduction. *Ann Intern Med* 150:417–18.

Martyn JAJ, Mao J, Bittner EA. 2019. Opioid tolerance in critical illness. *N Engl J Med* 380:365–78.

Mastroianni A, Ravaglia G. 2017. Serotonin syndrome due to co-administration of linezolid and methadone. *Infez Med* 25:263–66.

McCance-Katz EF, Sullivan L, Nallani S. 2010. Drug interactions of clinical importance among the opioids methadone and buprenorphine, and other frequently prescribed medications: A review. *Am J Addict* 19:4–16.

McPherson ML, Walker KA, Davis MP, et al. 2019. Safe and appropriate use of methadone in hospice and palliative care: Expert consensus white paper. *J Pain Symptom Manage* 57:635–45.

Mulneh B, Richardson DR, Hicks C, et al. 2019. Trials and tribulations of corrected QT interval monitoring in oncology: Rationale for a practice-changing standardized approach. *J Clin Oncol* 37:2719–21.

Reddy S, Hui D, El Osta B, et al. 2010. The effect of oral methadone on the QTc interval in advanced cancer patients: A prospective pilot study. *J Palliat Med* 13:33–38.

Sylvester RK, Schauer C, Thomas J, et al. 2011. Evaluation of methadone absorption after topical administration to hospice patients. *J Pain Symptom Manage* 41:828–35.

#### MORPHINE (SUSTAINED-RELEASE KADIAN [KAPANOL])

Broomhead A, Kerr R, Tester W, et al. 1997. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. *J Pain Symptom Manage* 14:63–73.

Gourlay GK, Cherry DA, Onley MM, et al. 1997. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. *Pain* 69:295–302.

#### OXYCODONE (SUSTAINED-RELEASE)

Bruera E, Belzile M, Pituskin E, et al. 1998. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *J Clin Oncol* 16:3222–29.

Kaiko RF, Benziger DP, Fitzmartin RD, et al. 1996. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. *Clin Pharmacol Ther* 59:52–61.

Kaiko R, Lacouture P, Hopf K, et al. 1996. Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine. *Clin Pharmacol Ther* 59:130.

Kaplan R, Parris WC-V, Citron ML, et al. 1998. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. *J Clin Oncol* 16:3230–37.

#### OXYMORPHONE

Craig DS. 2010. Oxymorphone extended-release tablets (Opana ER) for the management of chronic pain: A practical review for pharmacists. *P&T* 35:324–57.

Sloan PS. 2008. Review of oral oxymorphone in the management of pain. *Ther Cli Risk Manag* 4:777–87.

#### TAPENTADOL

Mercadante S. 2017. The role of tapentadol as a strong opioid in cancer pain management: A systematic and critical review. *Curr Med Res Opin*. 33:1965–69.

Wade WE, Spruill WJ. 2009. Tapentadol hydrochloride: A centrally acting oral analgesic. *Clin Therapeutics* 31:2804–18.

#### TRAMADOL

Barakat A. 2019. Revisiting tramadol: A multi-modal agent for pain management. *CNS Drugs* 33:481–501.

Mahlberg R, Kunz D, Sasse J, et al. 2004. Serotonin syndrome with tramadol and citalopram. *Am J Psychiatry* 161:1129.

### *Topical Opioids*

- Paice JA, Von Roenn JH, Hudgins JC, et al. 2008. Morphine bioavailability from a topical gel formulation in volunteers. *J Pain Symptom Manage* 35:314–20.
- Stein C. 1995. The control of pain in peripheral tissue by opioids. *N Engl J Med* 332:1685–90.
- Zeppetella G, Paul J, Ribeiro MDC. 2003. Analgesic efficacy of morphine applied topically to painful ulcers. *J Pain Symptom Manage* 25:555–58.

### *TRANSDERMAL FENTANYL*

- Ahmedzai S, Brooks D, on behalf of the TTS-Fentanyl Comparative Trial Group. 1997. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. *J Pain Symptom Manage* 13:254–61.
- Donner B, Zena M, Tryba M, et al. 1996. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. *Pain* 64:527–34.
- Kornick CA, Santiago-Palma J, Khojainova N, et al. 2001. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. *Cancer* 92:3056–61.
- Payne R, Mathias SD, Pasta DJ, et al. 1998. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 16:1588–93.
- Portenoy RK, Mehta Z, Ahmed E. 2013. Cancer pain management with opioids: Optimizing analgesia. <https://www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia>.
- Portenoy RK, Southam MA, Gupta SK, et al. 1993. Transdermal fentanyl for cancer pain: Repeated dose pharmacokinetics. *Anesthesiology* 78:36–43.
- Tassinari D, Santori S, Tamburini E, et al. 2008. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: A meta-analysis and systematic review of the literature. *J Palliat Med* 11:492–501.
- Tassinari D, Santori S, Tamburini E, et al. 2009. Transdermal fentanyl as a front-line approach to moderate-severe pain: A meta-analysis of randomized clinical trials. *J Palliat Care* 25:172–80.
- Varvel JR, Shafer SL, Hwang SS, et al. 1989. Absorption characteristics of transdermally administered fentanyl. *Anesthesiology* 70:928–34.

### *Rectal Route*

- Bruera E, Fainsinger R, Spachynski K, et al. 1995. Clinical efficacy and safety of a novel controlled release morphine suppository and subcutaneous morphine in cancer pain: A randomized evaluation. *J Clin Oncol* 13:1520–27.

- Davis MP, Walsh D, LeGrand SB, et al. 2002. Symptom control in cancer patients: The clinical pharmacology and therapeutic role of suppositories and rectal suspensions. *Support Care Cancer* 10:117–38.
- De E, Gomery P, Rosenberg LB. 2017. Palliation of bladder spasms #337. *J Palliat Med* 20:1158–59.
- De Conno F, Ripamonti C, Saiti L, et al. 1995. Role of rectal route in treating cancer pain: A randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naïve cancer patients with pain. *J Clin Oncol* 13:1004–8.
- Leow KP, Cramond T, Smith MT. 1995. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. *Anesth Analg* 80:296–302.
- Samala RV, Davis MP. 2012. Palliative care per rectum #257. *J Palliat Med* 15:1038–39.
- Watanabe S, Belzile M, Kuehn N, et al. 1996. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: Clinical and economic considerations. *Cancer Treat Rev* 22:131–36.

#### *Intravenous Route*

- Citron ML, Kaira J-M, Seltzer VL, et al. 1992. Patient-controlled analgesia for cancer pain: A long-term study of inpatient and outpatient use. *Cancer Invest* 10:335–41.
- Coyle N, Adelhardt J, Foley KM, et al. 1990. Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. *J Pain Symptom Manage* 5:83–93.
- Portenoy RK, Moulin DE, Rogers A, et al. 1986. IV infusion of opioids for cancer pain: Clinical review and guidelines for use. *Cancer Treat Rep* 70:575–81.

#### *Subcutaneous Route*

- Bruera E, Fainsinger R, Moore M, et al. 1991. Local toxicity with subcutaneous methadone: Experience of two centers. *Pain* 45:141–45.
- Coyle N, Cherny NI, Portenoy RK. 1994. Subcutaneous opioid infusions in the home. *Oncology* 8:21–27.
- Fürst P, Lundström S, Klepstad P, et al. 2020. The use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at the end of life: A national Swedish survey in specialized palliative care. *J Palliat Med* 23:226–32.

McPherson ML, Walker KA, Davis MP, et al. 2019. Safe and appropriate use of methadone in hospice and palliative care: Expert consensus white paper. *J Pain Symptom Manage* 57:635–45.

### *Spinal Opioids / Anesthetics*

Careskey H, Narang S. 2018. Interventional anesthetic methods for pain in hematology/oncology patients. *Hematol Oncol Clin North Am* 32:433–45.

Du Pen SL, Kharasch ED, Williams A, et al. 1992. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. *Pain* 49:293–300.

Du Pen S, Williams A. 1994. The clinical dilemma of systemic to epidural morphine conversion: Development of a conversion tool for cancer pain patients. *Pain* 56:113–18.

Eisenach JC, Du Pen S, Dubois M, et al., the Epidural Clonidine Study Group. 1995. Epidural clonidine analgesia for intractable cancer pain. *Pain* 61:391–98.

Johnson SM, Duggan AW. 1981. Evidence that opiate receptors at the substantia gelatinosa contribute to the depression by intravenous morphine of the spinal transmission of impulses in the unmyelinated primary afferents. *Brain Res* 207:223–28.

Kitahata LM, Collins JG. 1981. Spinal action of narcotic analgesics. *Anesthesiology* 54:153–63.

Narang S, Weisheipl A, Ross EL, eds. 2016. *Surgical Pain Management: A Complete Guide to Implantable and Interventional Pain Therapies*. Oxford: Oxford University Press.

Smith TJ, Coyne P, Staats PS, et al. 2003. Implantable drug delivery system (IDDA) provides sustained pain control, less drug toxicity, and better survival compared to medical management (CMM) (abstr #2967). *Proc Am Soc Clin Oncol* 22:738.

Smith TJ, Staats PS, Deer T, et al. 2002. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory pain: Impact on pain, drug related toxicity, and survival. *J Clin Oncol* 20:4040–49.

### *Opioid-Induced Side Effects*

#### *CONSTIPATION*

Becker G, Blum HE. 2009. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. *Lancet* 373:1198–1206.

Blair HA. 2019. Naldemedine: A review in opioid-induced constipation. *Drugs* 79:1241–47.

Bruera E, Suarez-Almazor M, Velasco A, et al. 1994. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective review. *J Pain Symptom Manage* 9:515–19.

- Chamberlain BH, Cross K, Winston JL, et al. 2009. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. *J Pain Symptom Manage* 8:683–90.
- Cleveland MJB, Flavin DP, Ruben RA, et al. 2001. New polyethylene glycol laxative for treatment of constipation in adults: A randomized, double-blind, placebo-controlled study. *South Med J* 94:478–81.
- Currow DC, Coughlan M, Fardell B, et al. 1997. Use of ondansetron in palliative medicine. *J Pain Symptom Manage* 13:302–7.
- Fine PG, Chen Y-W, Wittbrodt E, et al. 2019. Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer patients receiving continuous opioid therapy. *Supp Care Cancer* 27:687–96.
- Ginex PK, Hanson BJ, LeFebvre KB, et al. 2020. Management of opioid-induced and non-opioid-related constipation in patients with cancer: systematic review and meta-analysis. *Oncol Nurs Forum* 47:E211–24.
- Jones R, Prommer E, Backstedt D. 2016. Naloxegol: A novel therapy in the management of opioid-induced constipation. *Am J Hosp Palliat Care* 33:875–80.
- Kosten TR, O'Connor PG. 2003. Management of drug and alcohol withdrawal. *N Engl J Med* 348:1786–95.
- Lee-Robichaud H, Thomas K, Morgan J, et al. 2010. Lactulose versus polyethylene glycol for chronic constipation. *Cochrane Database Syst Rev* 7:CD007570.
- McNicol E, Boyece DB, Schumann R, et al. 2008. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: Systematic review and meta-analysis of randomized controlled trials. *Pain Med* 9:634–59.
- Miner PB, Koltun WD, Weiner GJ, et al. 2017. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. *Am J Gastroenterol* 112:613–21.
- Nelson AD, Camilleri M. 2016. Opioid-induced constipation: advances and clinical guidance. *Ther Adv Chronic Dis* 7:121–34.
- Pasay D, Guirguis M, Shkrobot R, et al. 2017. Association of dissemination of an educational communication tool with docusate administration. *JAMA Intern Med* 177:1433–36.
- Portenoy RK, Thomas J, Moehl Boatwright ML, et al. 2008. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study. *J Pain Symptom Manage* 35:458–68.

Teuri U, Vapaatalo H, Korpela R. 1999. Fructooligosaccharides and lactulose cause more symptoms in lactose maldigesters and subjects with pseudohypolactasia than in control lactulose digesters. *Am J Clin Nutr* 69:973–79.

Walters JB, Montagnini M. 2010. Current concepts in the management of opioid-induced constipation. *J Opioid Manage* 6:435–44.

Webster LR, Brewer RP, Lichtien P, et al. 2018. Efficacy of lubiprostone for the treatment of opioid-induced constipation, analyzed by opioid class. *Pain Med* 19:1195–1205.

#### NAUSEA

Currow DC, Coughlan M, Fardell B, et al. 1997. Use of ondansetron in palliative medicine. *J Pain Symptom Manage* 13:302–7.

Ferris FD, Kerr IG, Sone M, et al. 1991. Transdermal scopolamine use in the control of narcotic-induced nausea. *J Pain Symptom Manage* 6:389–93.

#### SEDATION

Boyer EW. 2012. Management of opioid analgesic overdose. *N Engl J Med* 367:146–55.

Brasure M, Fuchs E, MacDonald R, et al. 2016. Psychological and behavioral interventions for managing insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. *Ann Intern Med* 165:113–24.

Cheng J, Groninger H. 2012. Modafinil #259 (Fast Facts). *J Palliat Med* 15:1388–89.

Kreeger L, Duncan A, Cowap J. 1996. Psychostimulants used for opioid-induced drowsiness. *J Pain Symptom Manage* 11:1–2.

Kurita GP, Sjøgren P, Ekholm O, et al. 2011. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: A multinational study. *J Clin Oncol* 28:1297–1303.

Mailis-Gagnon A, Lakha SF, Furlan A, et al. 2012. Systematic review of the quality and generalizability of studies on the effects of opioid on driving and cognitive/psychomotor performance. *Clin J Pain* 28:542–55.

Pergolizzi JV, Jr., Taylor R, LeQuang JA, et al. 2018. Driving under the influence of opioids: What prescribers should know. *J Opioid Manage* 14:415–27.

Prommer E. 2006. Modafinil: Is it ready for prime time? *J Opioid Manage* 2:130–36.

Rozans M, Dreisbach A, Lertora JJJ, et al. 2002. Palliative uses of methylphenidate in patients with cancer: A review. *J Clin Oncol* 20:335–39.

Ryan SA, Dunne RB. 2018. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: A systematic review. *Pain Manag* 8:231–45.

Sanft T, Tevaarwerk A, Denlinger CS, et al. 2021. Survivorship, version 3. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1466>.

Wilwerding MB, Loprinzi CL, Mailliard JA, et al. 1995. A randomized crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. *Support Care Cancer* 3:135–38.

#### RESPIRATORY DEPRESSION

Boyer EW. 2012. Management of opioid analgesic overdose. *N Engl J Med* 367:146–55.

Legrand SB, Estfan B, Walsh D, et al. 2004. Parenteral opioid dose titration and ventilatory function. *J Clin Oncol* 22(14S):8005.

Ryan SA, Dunne RB. 2018. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: A systematic review. *Pain Manag* 8:231–45.

#### MYOCLONUS

Hagen N, Swanson R. 1997. Strychnine-like multifocal myoclonus and seizures in extremely high dose opioid administration: Treatment strategies. *J Pain Symptom Manage* 14:51–58.

#### PRURITUS

Jannuzzi RG. 2016. Nalbuphine for treatment of opioid-induced pruritus: A systematic review of the literature. *Clin J Pain* 32:87–93.

McNicol E, Horowicz-Mehler N, Fisk RA, et al. 2003. Management of opioid side-effects in cancer-related and chronic noncancer pain: A systematic review. *J Pain* 4:231–56.

Portenoy RK, Mehta Z, Ahmed E. 2019. Cancer pain management with opioids: Optimizing analgesia. <https://www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia>.

Zylicz Z, Smits C, Prajnik M. 1998. Paroxetine for pruritus in advanced cancer. *J Pain Symptom Manage* 16:121.

## Adjuvant Analgesics

### Neuropathic Adjuvants

#### GENERAL DISCUSSIONS

Gilron I, Baron R, Jensen T. 2015. Neuropathic pain: Principles of diagnosis and treatment. *Mayo Clin Proc* 90:532–45.



- Rekand T, Merete Hagen E, Granning M. 2012. Chronic pain following spinal cord injury. *Tidsskr Nor Legeforen* 132:974–79.
- Samala RV, Davis MP. 2012. Palliative care per rectum #257. *J Palliat Med* 15:1038–39.
- Solomon LR. 2016. Functional B12 deficiency in advanced malignancy: Implications for the management of neuropathy and neuropathic pain. *Support Care Cancer* 24:3489–94.
- Warren DE. 1996. Practical use of rectal medications in palliative care. *J Pain Symptom Manage* 11:378–87.

#### ANTIDEPRESSANTS

- Gilron I, Bailey JM, Tu D, et al. 2009. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised crossover trial. *Lancet* 374:1252–61.
- Guan J, Tanaka S, Kawakami K. 2016. Anticonvulsants or antidepressants in combination pharmacotherapy for treatment of neuropathic pain in cancer patients: A systematic review and meta-analysis. *Clin J Pain* 32:719–25.
- Moore RA, Aldington DS, Cole P, et al. 2015. Amitriptyline for neuropathic pain in adults. *Cochrane Database Syst Rev*; CD008242. doi: 10.1002/14651858.CD008242.pub3

#### TREATMENT-INDUCED NEUROPATHY

- Durand JP, Deplanque G, Montheil V, et al. 2012. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double blind, placebo-controlled phase III trial. *Ann Oncol* 23:200–205.
- Emery EC, Wood JN. 2018. Gaining on pain. *N Engl J Med* 379:485–87.
- Fallon MT, Storey DJ, Dirshan A, et al. 2015. Cancer treatment-related neuropathic pain: Proof of concept study with menthol-a TRPM8 agonist. *Support Care Cancer* 23:2769–77.
- Glimelius B, Manojlovic N, Pfeiffer P, et al. 2018. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagafodipir (PledOx): A placebo-controlled randomized phase II study (PLIANT). *Acta Oncol* 57:393–402.
- Greenlee H, Hershman DL, Shi Z, et al. 2017. BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: The Pathways study. *J Natl Cancer Inst* 109:1–8.
- Grisold W, Cavaletti G, Windebank AJ. 2012. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. *Neuro-Onc* 14:iv45–iv54.
- Hanai A, Ishiguro H, Sozu T, et al. 2018. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: Prospective self-controlled trial. *JNCI* 110:141–48.

- Hershman DL, Lacchetti C, Dworkin RH, et al. 2014. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 32:1941–67.
- Hershman DL, Till C, Wright JD, et al. 2016. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. *J Clin Oncol* 34:3014–22.
- Jiang J, Shen Q, Rong X, et al. 2019. Effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer: A randomized controlled trial. *J Clin Oncol* 37:135–43.
- Kleckner I, Kamen CS, Gewandter JS, et al. 2018. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicenter, randomized trial. *Support Care Cancer* 26:1019–28.
- Loprinzi CL, Lacchetti C, Bleeker J, et al. 2020. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *J Clin Oncol* 38:3325–48.
- Loprinzi CL, Le-Rademacher J, Majithia N, et al. 2020. Scrambler therapy for chemotherapy neuropathy: A randomized phase II trial. *Support Care Cancer* 28:1183–97.
- Loprinzi CL, Reeves BN, Dakhil SR, et al. 2011. Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. *J Clin Oncol* 29:1472–78.
- Majithia N, Temkin SM, Ruddy KJ, et al. 2016. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: Outcomes and lessons. *Support Care Cancer* 24:1439–47.
- Reyad RM, Omran AF, Abbas DN, et al. 2019. The possible preventive role of pregabalin in postmastectomy pain syndrome: A double-blinded randomized controlled trial. *J Pain Symptom Manage* 57:1–9.
- Rosenbaek F, Holm HS, Hjelmberg JvB, et al. 2020. Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer. *Support Care Cancer* 28:3763–69.
- Saito Y, Kobayashi M, Yamada T, et al. 2020. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. *Support Care Cancer* 28:221–27.
- Stockstill K, Doyle TM, Yan X, et al. 2018. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. *J Exp Med* 215:1301–13.
- Stout NL. 2017. Expanding the perspective on chemotherapy-induced peripheral neuropathy management. *J Clin Oncol* 35:2593–94.

- Stubblefield MD, Burstein HJ, Burton AW, et al. 2009. NCCN task force report: Management of neuropathy in cancer. *J Natl Compr Canc Netw* 7:S1–S26.
- Sundar R, Bandia A, Tan SSH, et al. 2017. Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: A pilot study. *Front Oncol* 6:274.
- Teoh D, Smith TJ, Song M, et al. 2018. Care after chemotherapy: Peripheral neuropathy, cannabis for symptom control, and mindfulness. 2018 ASCO Educational Book 38:469–79.
- Wang J, Udd KA, Vldisheva A, et al. 2016. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. *Support Care Cancer* 24:3105–10.
- Zimmermann C, Atherton PJ, Pachman D, et al. 2016. MC11C4: A pilot, randomized, placebo-controlled double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. *Support Care Cancer* 24:1071–78.

#### *NK-1 RECEPTOR ANTAGONISTS*

- Dulin JD, Coyne PJ, Bohm NM, et al. 2017. Fosaprepitant for the management of refractory pain in a patient with cancer-related dermatomyositis. *J Palliat Med* 20:1415–19.

#### *CORTICOSTEROIDS*

- Cooley L, Dendle C, Wolf J, et al. 2014. Consensus guidelines for diagnosis, prophylaxis and management of *Pneumocystis jirovecii* pneumonia in patients with haematological and solid malignancies. *Int Med J* 44:1350–63.
- Haywood A, Good P, Khan S, et al. 2015. Corticosteroids for the management of cancer-related pain in adults. *Cochrane Database Syst Rev* 24:CDO010756.
- Paulson O, Aass N, Kaasa S, et al. 2013. Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. *J Pain Symptom Manage* 46:96–105.

#### *SPINAL CORD METASTASES AND COMPRESSION*

- Abrahm JL, Banffy MB, Harris MB. 2008. Spinal cord compression in patients with advanced metastatic cancer: “All I care about is walking and living my life.” *JAMA* 299:937–46.
- Lawton AJ, Lee KA, Cheville AL, et al. 2019. Assessment and management of patients with metastatic spinal cord compression: A multidisciplinary review. *J Clin Oncol* 37:61–71.
- Maranzano E, Latini P, Beneventi S, et al. 1996. Radiotherapy without steroids in selected metastatic spinal cord compression patients: A phase II trial. *J Clin Oncol* 19:179–83.
- Patchell R, Tibbs PA, Regine WF, et al. 2005. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomized trial. *Lancet* 366:643–48.

Rades D, Huttenlocher S, Dunst J, et al. 2010. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. *J Clin Oncol* 28:3597–3604.

Rose PS, Laufer I, Boland PJ, et al. 2009. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. *J Clin Oncol* 27:5075–79.

Sahgal A, Myrehaug SD, Liva S, et al. 2020. CCTG SC.24/TROG 17.06: A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases. *ASTRO Proceedings*, Abstract LBA 2.

#### ACUTE HERPETIC ZOSTER INFECTION AND POST-HERPETIC NEURALGIA

Thakur R, Phillips A. 2012. Treating herpes zoster and post-herpetic neuralgia: An evidence-based approach. *J Fam Pract* 61(suppl):S9–S15.

Thomas B, Farquhar-Smith P. 2011. Extended-release gabapentin in post-herpetic neuralgia. *Expert Opinion on Pharmacotherapy* 12:2565–71.

Whitley RJ, Weiss H, Gnann JW, et al., and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. 1996. Acyclovir with and without prednisone for the treatment of herpes zoster. *Ann Intern Med* 125:376–83.

#### ANTICONVULSANTS

Attal N, Cruccu G, Baron R. 2010. EFNS Guidelines on the pharmacologic treatment of neuropathic pain: 2010 revision. *Eur J Neurology* 17:1113–e88.

Gill D, Derry S, Wiffen PJ, et al. 2011. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev* 10: CD009183. doi: 10.1002/14651858.CD009183.pub2.

Gilron I, Baron R, Jensen T. 2015. Neuropathic pain: Principles of diagnosis and treatment. *Mayo Clin Proc* 90:532–45.

Mersfelder TL, Nichols WH. 2016. Gabapentin: Abuse, dependence, and withdrawal. *Ann Pharmacother* 50:229–33.

#### CANNABINOIDS

Abrams DI, Jay CA, Shade SB, et al. 2007. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* 68:515–21.

Boehnke KF, Clauw D. 2019. Brief commentary: cannabinoid dosing for chronic pain management. *Ann Intern Med* 170:118.

- Ellis RJ, Toperoff W, Vaida F, et al. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology* 34:672–80.
- Hill KP. 2015. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. *JAMA* 313:2474–83.
- Johnson JR, Burnell-Nugent M, Lossignol D, et al. 2010. Multicenter, double-blind, randomized placebo-controlled, parallel-group trial of the efficacy, safety, and tolerability of the THC:CBD extract and THC extract in patient with intractable cancer-related pain. *J Pain Symptom Manage* 39:167–79.
- Jugl S, Keshwani S, Adkins L, et al. 2020. A systematic review of evidence for cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care. *Proc ASCO* 38:12091.
- Lapoint J, Meyer S, Yu CK, et al. 2018. Cannabinoid hyperemesis syndrome: Public health implications and a novel model treatment guideline. *West J Emerg Med* 19:380–86.
- Lynch ME, Cesar-Rittenberg P, Hohmann AG. 2014. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. *J Pain Symptom Manage* 47:166–73.
- Monte AA, Shelton SK, Mills E, et al. 2019. Acute illness associated with cannabis use, by route of exposure: An observational study. *Ann Intern Med* 170:531–37.
- Mücke M, Phillips T, Radbruch L, et al. 2018. Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database Syst Rev* 3:CD012182.
- National Academies of Science, Engineering and Medicine. 2017. *Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: National Academies Press.
- Nugent SM, Morasco BJ, O’Neil ME, et al. 2017. The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review. *Ann Intern Med* 167:319–31.
- Portenoy RK, Ganae-Motan ED, Allende S, et al. 2012. Nabiximols for opioid-treated cancer patients with poorly controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. *J Pain* 13:438–49.
- Steele G, Arneson T, Zylla D. 2019. A comprehensive review of cannabis in patients with cancer: Availability in the USA, general efficacy, and safety. *Curr Oncol Rep* 21:10.
- Strouse T. 2016. Cannabinoids in cancer treatment settings. *J Commun Support Oncol* 14:1–5.

Whiting PF, Wolff RF, Deshpande S, et al. 2015. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA* 313:2456–73.

#### KETAMINE

Bell RF, Eccleston C, Kalso E. 2017. Ketamine as adjuvant to opioids for cancer pain. *Cochrane Database Syst Rev* 6:CD003351.

Loveday BA, Sindt J. 2015. Ketamine protocol for palliative care in cancer patients with refractory pain. *J Adv Pract Oncol* 6:555–61.

Mercadante S, Arouri E, Tirelli W, et al. 2000. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double dose study. *J Pain Symptom Manage* 4:246–51.

Moryl N, Coyle N, Foley KM. 2008. Managing an acute pain crisis in a patient with advanced cancer: “This is as much of a crisis as a code.” *JAMA* 299:1457–67.

Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. 2016. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin Pharmacokinet* 55:1059–77.

Quibell R, Fallon M, Mihalyo M, et al. 2015. Ketamine. *J Pain Symptom Manage* 50:268–78.

Yang C-Y, Wong C-S, Chang J-Y. 1996. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. *Can J Anaesth* 43:379–83.

#### LIDOCAINE INFUSION

Ferrini R. 2000. Parenteral lidocaine for severe intractable pain in six hospice patients continued at home. *J Palliat Med* 3:193–200.

Ferrini R, Paice J. 2004. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. *J Support Oncol* 2:90–94.

Kintzel PE, Knol JD, Roe G. 2019. Intravenous lidocaine administered as twice daily bolus and continuous infusion for intractable cancer pain and wound care pain. *J Palliat Med* 22:343–47.

Mao J, Chen LL. 2000. Systemic lidocaine for neuropathic pain relief. *Pain* 87:7–17.

Sharma S, Rajagopal MR, Palat G, et al. 2009. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. *J Pain Symptom Manage* 37:85–93.

#### DEXMEDETOMIDINE

Hofherr M, Abrahm JL, Rickerson E. 2020. Dexmedetomidine: A novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. *J Palliat Med* 23:1515–17.

Mupamombe CT, Luczkiewicz D, Kerr C. 2019. Dexmedetomidine as an option for opioid refractory pain in the hospice setting. *J Palliat Med* 22:1478–81.

#### *Adjuvants for Bone Pain*

##### BONE-MODIFYING AGENTS (BIPHOSPHONATES AND RANK-LIGAND INHIBITORS)

DeMille DM, Piscitelli M, Ocker A, et al. 2014. Vitamin D deficiency in the oncology setting. *J Commun Support Oncol* 12:13–19.

Fournier PG, Stressing V, Ebetino FH, Clézardin P. 2010. How do bisphosphonates inhibit bone metastases in vivo. *Neoplasia* 12:571–78.

Ripamonti CI, Napoli N. 2020. Are we ready to use teriparatide to treat medication-related osteonecrosis of the jaw in clinical practice? *J Clin Oncol* 38:2949–51.

Sim I-W, Borromeo GL, Tsao C, et al. 2020. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial. *J Clin Oncol* 38:2971–80.

Stark Toller C, Charlesworth S, Mihalyo M, et al. 2019. Bisphosphonates. *J Pain Symptom Manage* 57:1018–30.

Van Poznak CH, Temin S, Yee GC, et al. 2011. American Society of Clinical Oncology Executive Summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. *J Clin Oncol* 29:1221–27.

von Moos R, Skacel T. 2012. Denosumab: First data and ongoing studies of prevention of bone metastases. *Recent Results Cancer Res* 192:187–96.

von Moos R, Body JJ, Egerdie B, et al. 2013. Pain and health-related quality of life in patient with advanced solid tumours and bone metastases: Integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. *Support Care Cancer* 21:3497–3507.

Yarom N, Shapiro CL, Peterson DE, et al. 2019. Medication-related osteonecrosis of the jaw: Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO) / ASCO clinical practice guideline. *J Clin Oncol* 37:2270–90.



#### KYPHOPLASTY/VERTEBROPLASTY

Health Quality Ontario. 2016. Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: A systematic review. *Ont Health Technol Assess Ser* 16:1–202.

Jensen ME, Kallmes DK. 2002. Percutaneous vertebroplasty in the treatment of malignant spinal disease. *Cancer J* 8:194–206.

#### RADIOFREQUENCY ABLATION

Gennaro N, Sconfienza LM, Ambrogio F, et al. 2019. Thermal ablation to relieve pain from metastatic bone disease: A systematic review. *Skeletal Radiol* 48:1161–69.

Goetz MP, Callstrom MR, Charboneau JW, et al. 2004. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: A multicenter study. *J Clin Oncol* 22:300–306.

Rosenthal D, Callstrom MR. 2012. Critical review and state of the art in interventional oncology: Benign and metastatic disease involving bone. *Radiology* 262:765–80.

#### EXTERNAL BEAM RADIATION AND RADIOPHARMACEUTICALS

Cheetham PJ, Petrylak DP. 2012. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: Mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. *Oncology* 26:330–37.

Paes FM, Ernani V, Hosein P, et al. 2011. Radiopharmaceuticals: When and how to use them to treat metastatic bone pain. *J Support Oncol* 9:197–205.

Pal S, Dutta S, Adhikary SS, et al. 2014. Hemi body irradiation: An economical way of palliation of pain in bone metastasis in advanced cancer. *South Asian J Cancer* 3:28–32.

Parker C, Nilsson S, Heinrich D, et al. 2013. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 369:213–23.

Shiloh R, Krishnan M. 2018. Radiation for treatment of painful bone metastases. *Hematol Oncol Clin North Am* 32:459–68.

#### SKELETAL MUSCLE RELAXANTS

Hardek B, Pruskowski J. 2017. Skeletal muscle relaxants #340. *J Palliat Med* 20:1293–94.

### *Anesthetic and Interventional Methods*

#### GENERAL REFERENCES

Aman MM, Mahmoud A, Deer T, et al. 2021. The American Society of Pain and Neuroscience (ASPN) best practices and guidelines for the interventional management of cancer-associated pain. *J Pain Res* 14:2139–64.



Careskey H, Narang S. 2018. Interventional anesthetic methods for pain in hematology/oncology patients. *Hematol Oncol Clin North Am* 32:433–45.

Narang S, Weisheipl A, Ross EL. eds. 2016. *Surgical Pain Management: A Complete Guide to Implantable and Interventional Pain Therapies*. Oxford: Oxford University Press.

Viswanathan A, Vedantam A, Hess KR, et al. 2019. Minimally invasive cordotomy for refractory cancer pain: A randomized controlled trial. *Oncologist* 24:e590–e596.

#### TOPICAL AGENTS

Argoff CE. 2003. Targeted topical peripheral analgesics in the management of pain. *Curr Pain Headache Rep* 7:34–38.

Kumar M, Chawla R, Goyal M. 2015. Topical anesthesia. *J Anaesthesiol Clin Pharmacol* 31:450–56.

#### EMLA

Rice LJ, Cravero J. 1994. Relieving the pain and anxiety of needle injections—Experience with EMLA cream (lidocaine 2.5% and prilocaine 2.5%) dermal anesthetic. *Today's Ther Trends* 11:175–85.

Stow PJ, Glynn CJ, Minor B. 1989. EMLA cream in the treatment of post-herpetic neuralgia: Efficacy and pharmacokinetic profile. *Pain* 39:301–5.

#### LIDOCAINE

Galer BS, Jensen MP, Ma T, et al. 2002. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. *Clin J Pain* 18:297–301.

Katz NP, Gammaitoni AR, Davis MW, et al. 2002. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: An effectiveness trial. *Pain Med* 3:1–10.

Rowbotham MC, Davies PS, Fields HL. 1995. Topical lidocaine gel relieves postherpetic neuralgia. *Ann Neurol* 37:246–53.

#### CAPSAICIN

Ellison N, Loprinzi CL, Kugler J, et al. 1997. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. *J Clin Oncol* 15:2974–80.

Haanpää M, Treede RD. 2012. Capsaicin for neuropathic pain: Linking traditional medicine and molecular biology. *Eur Neurol* 68:264–75.

Watson CPN, Evans RJ, Watt VR. 1988. Postherpetic neuralgia and topical capsaicin. *Pain* 33:333–40.

Watson CPN, Evans RJ, Watt VR. 1989. The post-mastectomy pain syndrome and the effect of topical capsaicin. *Pain* 38:177–86.

Watson CPN, Tyler KL, Bickers DR, et al. 1993. A randomized vehicle-controlled trial of topical capsaicin in the treatment of post-herpetic neuralgia. *Clin Ther* 15:510–26.

#### ORAL ANESTHETICS

Sloan P, Basta M, Stoeck P, et al. 1999. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. *Anesth Analg* 89:760–61.

#### Neural Blockade and Neuroablation

Careskey H, Narang S. 2018. Interventional anesthetic methods for pain in hematology/oncology patients. *Hematol Oncol Clin North Am* 32:433–45.

Correia JS, Silva M, Castro C, et al. 2019. The efficacy of the ganglion impar block in perineal and pelvic cancer pain. *Support Care Cancer* 27:4327–30.

Ferrante FM, Bedder M, Caplan RA, et al. 1996. Practice Guidelines for Cancer Pain Management: a report by the American Society of Anesthesiologists' Task Force on Pain Management, Cancer Pain Section. *Anesthesiology* 84:1243–57.

Mueller K, Karimuddin AA, Metcalf C, et al. 2020. Management of malignant rectal pain and tenesmus: A systematic review. *J Palliat Med* 23:964–71.

Narang S, Weisheipl A, Ross EL, eds. 2016. *Surgical Pain Management: A Complete Guide to Implantable and Interventional Pain Therapies*. Oxford: Oxford University Press.

Slatkin NE, Rhiner M. 2003. Phenol saddle blocks for intractable pain at the end of life: Report of four cases and literature review. *Am J Hospice Palliat Care* 20:62–66.

Turnbull JH, Gebauer SL, Miller BL, et al. 2011. Cutaneous nerve transection for the management of intractable upper extremity pain caused by invasive squamous cell carcinoma. *J Pain Symptom Manage* 42:126–33.

Wyse JM, Carone M, Paquin SC, et al. 2011. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. *J Clin Oncol* 29:3541–46.

#### CINGULOTOMY

Agarwal N, Choi PA, Shin SS, et al. 2016. Anterior cingulotomy for intractable pain. *Interdisc Neurosurg* 6:80–83.

Sharim J, Pouratian N. 2016. Anterior cingulotomy for the treatment of chronic intractable pain: A systematic review. *Pain Physician* 19:537–50.

## Relieving Pain in Older Persons

American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. 2009. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc* 57:1331–46.

Bach TV, Pan J, Kirstein A, et al. 2016. Use of methadone as an adjuvant medication to low-dose opioids for neuropathic pain in the frail elderly: a case series. *J Palliat Med* 19:1351–55.

Bernabei R, Gambassi G, Lapane K, et al., for the SAGE Study Group. 1998. Management of pain in elderly patients with cancer. *JAMA* 279:1877–82.

Gloth FM III. 2011. Pharmacologic management of persistent pain in older persons: Focus on opioids and nonopioids. *J Pain* 12(suppl 1):S14–S20.

Jones MR, Ehrhardt KP, Ripoli JG, et al. 2016. Pain in the elderly. *Curr Pain Headache Rep* 20:23.

Warden V, Hurley AC, Volicer L. 2003. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. *J Am Med Dir Assoc* 4:9–15.

## Relieving Pain in Patients with Substance Use Disorder (see also Risk Mitigation)

Alford DP, Comptom P, Samet JH. 2006. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Ann Intern Med* 144:127–34.

Dale R, Edwards J, Ballantyne J. 2016. Opioid risk assessment in palliative medicine. *J Commun Support Oncol* 14:94–100.

Doverly M, Somogyi AA, White JM, et al. 2001. Methadone maintenance patients are cross-tolerant to the anti-nociceptive effects of morphine. *Pain* 93:155–63.

Dowell D, Haegerich TM, Chou R. 2016. CDC guideline for prescribing opioids for chronic pain—United States. *JAMA* 315:1624–45.

Goodlev ER, Discala S, Darnall BD, et al. 2019. Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorder: A team-based, interdisciplinary approach to cancer survivorship. *J Palliat Med* 22:1308–17.

Paice JA. 2019. Risk assessment and monitoring of patients with cancer receiving opioid therapy. *Oncologist* 24:1–5.

- Peles E, Schreiber S, Gordon J, et al. 2005. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. *Pain* 113:340–46.
- Scarborough BM, Smith CB. 2018. Optimal pain management for patients with cancer in the modern era. *CA Cancer J Clin* 68:182–96.

## Managing Pain in Cancer Survivors

- Bruera E, Del Fabbro E. 2018. Pain management in the era of the opioid crisis. 2018 ASCO Educational Book 38:807–12.
- CDC. 2019. Pocket guide: Tapering opioids for chronic pain. Guideline for prescribing opioids for chronic pain. <https://www.cdc.gov/drugoverdose>.
- Goodlev ER, Discala S, Darnall BD, et al. 2019. Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorder: A team-based, interdisciplinary approach to cancer survivorship. *J Palliat Med* 22:1308–17.
- Loren AW. 2018. Harder to treat than leukemia: Opioid use disorder in survivors of cancer. *N Engl J Med* 379:2485–87.
- Rieder T. 2019. In *Pain: A Bioethicist's Personal Struggle with Opioids*. New York: Harper Collins.
- Salz T, Lavery JA, Lipitz-Snyderman AN, et al. 2019. Trends in opioid use among older survivors of colorectal, lung and breast cancers. *J Clin Oncol* 37:1001–11.
- Wesson DR, Ling W. 2003. The Clinical Opiate Withdrawal Scale (COWS). *J Psychoactive Drugs* 35:253–59.

## Managing Pain in Multiple Myeloma and Hematopoietic Stem Cell Transplant Recipients

- Ma JD, El-awahri AR, LeBlanc TW, et al. 2018. Pain syndromes and management in adult hematopoietic stem cell transplantation. *Hematol Oncol Clin North Am* 32:551–67.
- Samala RV, Valent J, Oche N, et al. 2019. Palliative care in patients with multiple myeloma. *J Pain Symptom Manage* 58:1113–18.

## Common Clinical Situations: Rapidly Relieving Excruciating Pain

- Hofherr M, Abrahm JL, Rickerson E. 2020. Dexmedetomidine: A novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. *J Palliat Med* 23:1515–17.

- Moryl N, Coyle N, Foley KM. 2008. Managing an acute pain crisis in a patient with advanced cancer: “This is as much of a crisis as a code.” *JAMA* 299:1457–67.
- Mupamombe CT, Luczkiewicz D, Kerr C. 2019. Dexmedetomidine as an option for opioid refractory pain in the hospice setting. *J Palliat Med* 22:1478–81.
- Roberts SB, Wozencraft CP, Coyne PJ, et al. 2011. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. *J Palliat Med* 14:371–73.

## Chapter 8. Nonpharmacologic Strategies in Palliative Care

### General Integrative Oncology / Complementary and Alternative Medicine

- Bardia A, Barton DL, Prokop LJ, et al. 2006. Efficacy of complementary and alternative medicine therapies for cancer pain: A systematic review. *J Clin Oncol* 24:5457–64.
- Cassileth BR. 2011. *The Complete Guide to Complementary Therapies in Cancer Care: Essential Information for Patients, Survivors, and Health Professionals*. Singapore: World Scientific.
- Davis EL, Oh B, Butow PN, et al. 2012. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: A systematic review. *Oncologist* 17:1475–81.
- Frenkel M, Cohen L. 2014. Effective communication about the use of complementary and integrative medicine in cancer care. *J Altern Complement Med* 20:12–18.
- Henson LA, Maddocks M, Evans C, et al. 2020. Palliative care and the management of common distressing symptoms in advanced cancer: Pain, breathlessness, nausea and vomiting, and fatigue. *J Clin Oncol* 38:905–14.
- Latte-Naor S, Mao JJ. 2019. Putting integrative oncology into practice: Concepts and approaches. *J Onc Pract* 15:7–14.
- Levy C, Casler N, FitzGerald D. 2018. Battlefield acupuncture: An emerging method for easing pain. *Am J Phys Med Rehabil* 97:e18–e19.
- Lyman GH, Greenlee H, Bohlke K, et al. 2018. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO Clinical Practice Guidelines. *J Clin Oncol* 36:2647–55.
- Maindet C, Brunod A, Minello C, et al. 2019. Strategies of complementary and integrative therapies in cancer-related pain—attaining exhaustive cancer pain management. *Support Care Cancer* 27:3119–32.

- NCCN. 2020a. NCCN Guidelines for adult cancer pain, version 1. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413>.
- NCCN. 2020b. NCCN Guidelines for cancer-related fatigue, version 2. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1424>.
- National Center for Complementary and Integrative Health. 2021. Complementary, alternative, or integrative health: What's in a name? Last updated April 2021. <https://www.nccih.nih.gov/health/integrative-health>.
- National Center for Complementary and Integrative Health. 2017. Mind and body practices. Last updated September 2017. <https://www.nccih.nih.gov/health/mindbody>.
- Paice JA, Portenoy R, Lacchetti C, et al. 2016. Management of chronic pain in survivors of adult cancers: ASCO Clinical Practice Guideline. *J Clin Oncol* 34:3325–45.
- Syrjala KL, Jensen MP, Mendoza E, et al. 2014. Psychological and behavioral approaches to cancer pain management. *J Clin Oncol* 32:1703–11.
- Tenner L, Hlubocky FJ, Blanke CD, et al. 2019. Let's talk about those herbs you are taking: Ethical considerations for communication with patients with cancer about complementary and alternative medicine. *J Onc Practice* 15:44–50.

## Alternative Medical Systems

### *Acupuncture*

- Alimi D, Rubino C, Pichard-Leandri E, et al. 2003. Analgesic effect of auricular acupuncture for cancer pain: A randomized, blinded, controlled trial. *J Clin Oncol* 21:4120–26.
- American Academy of Medical Acupuncture. Home page. Last updated 2020. <https://www.medicalacupuncture.org>.
- Bao T, Patil S, Chen C, et al. 2020. Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: A randomized clinical trial. *JAMA Netw Open* 3:e200681.
- Choi TY, Lee MS, Kim TH, et al. 2012. Acupuncture for the treatment of cancer pain: A systematic review of randomised clinical trials. *Support Care Cancer* 20:1147–58.
- Deng G, Cassileth BR. 2015. Complementary therapies in pain management. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC (eds.). Oxford: Oxford University Press.

- Filshie J, White A, Cummings M, eds. 2016. Medical acupuncture: A Western scientific approach. 2nd ed. Edinburgh: Elsevier.
- Garcia MK, McQuade J, Haddad R, et al. 2013. Systematic review of acupuncture in cancer care: A synthesis of the evidence. *J Clin Oncol* 31:952–60.
- Han X, Wang L, Shi H, et al. 2017. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. *BMC Cancer* 17:40.
- Helms JM. 1999. An overview of medical acupuncture. In *Essentials of Complementary and Alternative Medicine*, Jonas WB, Levin JS (eds.). Baltimore, MD: Lippincott Williams and Wilkins.
- Helms JM. 2020. “An Overview of Medical Acupuncture.” American Academy of Medical Acupuncture. Accessed May 24, 2020. <https://www.medicalacupuncture.org/an-overview-of-medical-acupuncture/>.
- Johnson MI, Filshie J, Thompson JW. 2012. Transcutaneous electrical nerve stimulation and acupuncture. In *Interventional Control in Cancer Pain Management*, Hester J, Sykes N, Peat S (eds.). Oxford: Oxford University Press.
- Levy CE, Casler N, FitzGerald DB. 2018. Battlefield acupuncture: An emerging method for easing pain. *Am J Phys Med Rehabil* 97:e18–19.
- Lu W, Giobbie-Hurder A, Freedman RA, et al. 2020. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: A randomized controlled pilot trial. *Oncologist* 25:310–18.
- Lu W, Rosenthal DS. 2010. Recent advances in oncology acupuncture and safety considerations in practice. *Curr Treat Options Oncol* 11:141–46.
- Lu W, Rosenthal DS. 2018. Oncology acupuncture for chronic pain in cancer survivors: A reflection on the ASCO Chronic Pain Guideline. *Hematol Oncol Clin North Am* 32:519–33.
- Molassiotis A, Bardy J, Finnegan-John J, et al. 2012. Acupuncture for cancer-related fatigue in patients with breast cancer: A pragmatic randomized controlled trial. *J Clin Oncol* 30:4470–76.
- National Institutes of Health. 1998. National Institutes of Health Consensus Conference: acupuncture. *JAMA* 280:1518–24.
- O’Sullivan E, Higginson I. 2010. Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: A systematic review. *Acupunct Med* 28:191–99.

- Paice JA, Lacchetti C, Bruera E. 2016. Management of chronic pain in survivors of adult cancers: ASCO Clinical Practice Guideline summary. *J Oncol Pract* 12:757–62.
- Paley CA, Johnson MI, Tashani OA, et al. 2015. Acupuncture for cancer pain in adults. *Cochrane Database Syst Rev* 2015:CD007753.
- Pfister DG, Cassileth BR, Deng GE, et al. 2010. Acupuncture for pain and dysfunction after neck dissection: Results of a randomized controlled trial. *J Clin Oncol* 28:2565–70.
- Smith ME, Bauer-Wu S. 2012. Traditional Chinese medicine for cancer-related symptoms. *Semin Onc Nurs* 28:64–74.
- von Trott P, Oei SL, Ramsenthaler C. 2020. Acupuncture for breathlessness in advanced diseases: A systematic review and meta-analysis. *J Pain Symptom Manage* 59:327–38.
- Wardley AM, Ryder D, Misra V, et al. 2020. ACUFOCIN: Randomized trial of ACUpuncture plus standard care versus standard care alone for chemotherapy induced peripheral neuropathy (CIPN). *Proc ASCO* 2020 38(15suppl):12003.
- Zhang CS, Yang AW, Zhang AL, et al. 2014. Sham control methods used in ear-acupuncture / ear-acupressure randomized controlled trials: A systematic review. *J Altern Complement Med* 20:147–61.
- Zia FZ, Olaku O, Bao T, et al. 2017. The National Cancer Institute’s conference on acupuncture for symptom management in oncology: State of the science, evidence, and research gaps. *J Natl Cancer Inst Monogr* 2017:68–73.

## Yoga

- Danhauer SC, Addington EL, Sohl SJ, et al. 2017. Review of yoga therapy during cancer treatment. *Support Care Cancer* 25:1357–72.
- International Association of Yoga Therapists. 2020. Find a certified (C-IAYT) yoga therapist. Accessed May 19, 2020. <https://www.iayt.org>.
- Khalsa SK. 1998. *Fly Like a Butterfly: Yoga for Children*. Portland, OR: Rudra Press.
- Lewis JK. 2020. Yoga for cancer-related symptoms. *J Palliat Med* 23:719–20.
- Ott MJ. 2002. Yoga as a clinical intervention. *Adv Nurse Pract* 10:81–83, 90.
- Raub JA. 2002. Psychophysiologic effects of hatha yoga on musculoskeletal and cardio-pulmonary function: A literature review. *J Altern Complement Medicine* 8:797–812.
- Robinson G, Walter T, Godsey J. 2019. Integrating yoga therapy into oncology care. *Association of Community Cancer Centers*, July-August, 26–35. <https://www.accc->



cancer.org/docs/documents/oncology-issues/articles/ja19/ja19-integrating-yoga-therapy-into-oncology-care.pdf.

## Manipulative and Body-Based Methods

- Cheville AL, Smith SR, Basford JR. 2018. Rehabilitation medicine approaches to pain management. *Hematol Oncol Clin North Am* 32:469–82.
- Childs DS, Le-Rademacher J, McMurray R, et al. 2021. Randomized trial of Scrambler therapy for chemotherapy-induced peripheral neuropathy: A crossover analysis. *J Pain Symptom Manage* 61:1247–53.
- Hurlow A, Bennett MI, Robb KA, et al. 2012. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database Syst Rev* 14:CD006276.
- Lee S-H, Kim J-Y, Yeo S, et al. 2015. Meta-analysis of massage therapy on cancer pain. *Integr Cancer Ther* 4:297–304.
- Michel TH. 2003. Physical therapists: Palliative care competencies. In *Dying, Death, and Bereavement: A Challenge for Living*, 2nd ed., Corless IB, Germino BB, Pittman MA (eds.). New York: Springer.
- NCCN. 2020a. NCCN Guidelines for adult cancer pain, version 1. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1413>.
- NCCN. 2020b. NCCN Guidelines for cancer-related fatigue, version 2. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1424>.
- Teoh D, Smith TJ, Song M, et al. 2018. Care after chemotherapy: Peripheral neuropathy, cannabis for symptom control, and mindfulness. *Am Soc Clin Oncol Educ Book* 38:469–79.
- Wilkinson S, Barnes K, Storey L. 2008. Massage for symptom relief in patients with cancer: Systematic review. *J Adv Nurs* 63:430–39.
- Wilkinson SM, Love SB, Westcombe AM, et al. 2007. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: A multicenter randomized controlled trial. *J Clin Oncol* 10:532–39.

## Lymphedema

- McLaughlin SA, Stout NL, Schaverien MV. 2020. Avoiding the swell: Advances in lymphedema prevention, detection, and management. 2020 ASCO Educ Book e17–e26.

### *Qi Gong and Tai Chi*

Zeng Y, Xie X, Cheng ASK. 2019. Qigong or Tai Chi in cancer care: An updated systematic review and meta-analysis. *Curr Oncol Reports* 21:48.

### Speech and Language Therapy

Chahda L, Mathisen BA, Carey LB. 2017. The role of speech-language pathologists in adult palliative care. *Int J Speech Lang Pathol* 19:58-68.

Hansen K, Chenoweth M, Thompson H, et al. (2018). Role of the speech-language pathologist (SLP) in the head and neck cancer team. In *Multidisciplinary Care of the Head and Neck Cancer Patient*, vol. 174 of *Cancer Treatment and Research*, Maghami E., Ho A. (eds.). Cham: Springer.

Jackson P, Robbins M, Frankel S. 1996. Communication impediments in a group of hospice patients. *Palliat Med* 9:1–26.

Luckett T, Reid KLP. 2015. Speech and language therapy in palliative care. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC. (eds.). Oxford: Oxford University Press.

Salt N, Davies S, Wilkinson S. 1999. The contribution of speech and language therapy to palliative care. *Eur J Palliat Care* 6:126–29.

### Mind-Body Interventions

Barkwell DP. 1991. Ascribed meaning: A critical factor in coping and pain attenuation in patients with cancer-related pain. *J Palliat Care* 7:5–14.

Beecher HK. 1946. Pain in men wounded in battle. *Ann Surg* 123:96–105.

Beecher HK. 1956. Relationship of significance of wound to the pain experienced. *JAMA* 161:1609–13.

Benson H, Beary JF, Carol MP. 1974. The relaxation response. *Psychiatry* 37:37–46.

Butler LD, Koopman C, Neri E, et al. 2009. Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. *Health Psychol* 28:579–87.

Egbert LD, Battit GE, Welch CE, et al. 1964. Reduction of postoperative pain by encouragement and instruction of patients. *N Engl J Med* 270:825–27.

Garland EL, Brintz CE, Hanley AW, et al. 2020. Mind-body therapies for opioid-treated pain: A systematic review and meta-analysis. *JAMA Intern Med* 180:91–105.

- Goodlev ER, Discala S, Darnall BD, et al. 2019. Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid-use disorders: A team-based, interdisciplinary approach to cancer survivorship. *J Palliat Med* 22:1308–17.
- Gorin SS, Krebs P, Badr H, et al. 2012. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. *J Clin Oncol* 30:539–47.
- Heinricher MM, Fields HL. 2013. Development of pain pathways and mechanisms. In Wall and Melzack's *Textbook of Pain*, 6th ed., SB McMahon, Koltzenberg M et al. (eds.). Philadelphia, PA: Saunders, Elsevier.
- Indovina P, Barone D, Gallo L, et al. 2018. Virtual reality as a distraction intervention to relieve pain and distress during medical procedures: A comprehensive literature review. *Clin J Pain* 34:858–77.
- Johnson T, Bauler L, Vos D, Hifko A, et al. 2020. Virtual reality use for symptom management in palliative care: A pilot study to assess user perceptions. *J Palliat Med* 23:1233–38.
- Loscalzo M. 1996. Psychological approaches to the management of pain in patients with advanced cancer. *Hematol Oncol Clin North Am* 10:139–55.
- Malloy KM, Milling LS. 2010. The effectiveness of virtual reality distraction for pain reduction: A systematic review. *Clin Psych Rev* 30:1011–18.
- Niki K, Okamoto Y, Maeda I, et al. 2019. A novel palliative care approach using virtual reality for improving various symptoms of terminal cancer patients: A preliminary prospective, multicenter study. *J Palliat Med* 22:702–7.
- Posadzki P, Ernst E. 2011. Guided imagery for musculoskeletal pain: A systematic review of randomized clinical trials. *Clin J Pain* 27:648–53.
- Posadzki P, Lewandowski W, Terry R, et al. 2012. Guided imagery for non-musculoskeletal pain: A systematic review of randomized clinical trials. *J Pain Symptom Manage* 44:95–104.
- Rodin G, Lo C, Rydall A, et al. 2018. Managing cancer and living meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer. *J Clin Oncol* 36:2422–32.
- Scapin S, Echevarria-Guanilo ME, Fuculo PRB Jr, et al. 2018. Virtual reality in the treatment of burn patients: A systematic review. *Burns* 44:1403–16.
- Schneider SM, Hood LE. 2007. Virtual reality: A distraction intervention for chemotherapy. *Oncol Nurs Forum* 34:39–46.

- Syrjala KL, Jensen MP, Mendoza E, et al. 2014. Psychological and behavioral approaches to cancer pain management. *J Clin Oncol* 32:1703–11.
- Talbot JD, Marrett S, Evans AC, et al. 1991. Multiple representations of pain in human cerebral cortex. *Science* 251:1355–58.
- Turk DC. 2003. Cognitive-behavioral approach to the treatment of chronic pain patients. *Reg Anesth Pain Med* 28:573–79.
- Ulrich RS. 1984. View through a window may influence recovery from surgery. *Science* 224:420–21.
- Wolsko PM, Eisenberg DM, Davis RB, et al. 2004. Use of mind-body medical therapies. *J Gen Intern Med* 19:43–50.
- Zeng Y, Zhang J-E, Cheng ASK, et al. 2019. Meta-analysis of the efficacy of virtual-reality-based interventions in cancer-related symptom management. *Integr Cancer Ther* 18:1–8.

### *Mindfulness Meditation*

- Bauer-Wu S, Sullivan AM, Rosenbaum E, et al. 2008. Facing the challenges of hematopoietic stem cell transplantation with mindfulness meditation: A pilot study. *Integr Cancer Ther* 7:62–69.
- Carlson LE. 2010. Meditation and yoga. In *Psycho-Oncology*, 2nd ed., Holland JC, Breitbart WS, Jacobsen PB, et al. (eds.). New York: Oxford University Press.
- Carlson LE, Ursuliak Z, Goodey E, et al. 2001. The effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up. *Support Care Cancer* 9:112–23.
- Center for Mindfulness. 2021. UMass Memorial Health. Last updated 2021. <https://www.ummhealth.org/umass-memorial-medical-center/services-treatments/center-for-mindfulness>.
- Compen F, Bisseling E, Schellekens M, et al. 2018. Face-to-face and internet-based mindfulness-based cognitive therapy compared with treatment as usual in reducing psychological distress in patients with cancer: A multicenter randomized controlled trial. *J Clin Oncol* 36:2413–21.
- Haller H, Winkler MM, Klose P, et al. 2017. Mindfulness-based stress reduction for women with breast cancer: An updated systematic review and meta-analysis. *Acta Oncol* 56:1665–76.
- Hoffman CJ, Ersser SJ, Hopkinson JB, et al. 2012. Effectiveness of mindfulness-based stress reduction in mood-, breast-, and endocrine-related quality of life, and well-being in stage 0–III breast cancer: A randomized, controlled trial. *J Clin Oncol* 30:1335–42.

- Kabat-Zinn J. 1990. *Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness*. New York: Dell.
- Ott MJ, Norris RL, Bauer-Wu SM. 2006. Mindfulness meditation for oncology patients: A discussion and critical review. *Integr Cancer Ther* 5:98–108.
- Shapiro SL, Schwartz GE, Bonner G. 1998. Effects of mindfulness-based stress reduction on medical and pre-medical students. *J Behav Med* 21:581–99.
- Specia M, Carlson LE, Goodey E, et al. 2000. A randomized, wait-list controlled clinical trial: The effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. *Psychosom Med* 62:613–22.
- Stahl B, Goldstein E. 2010. *A Mindfulness-Based Stress Reduction Workbook*. Oakland, CA: New Harbinger.
- Teoh D, Smith TJ, Song M, et al. 2018. Care after chemotherapy: Peripheral neuropathy, cannabis for symptom control, and mindfulness. *Am Soc Clin Oncol Educ Book* 38:469–79.
- Wren AW, Somers TJ, Wright MA, et al. 2012. Self-compassion in patients with persistent musculoskeletal pain: Relationship of self-compassion to adjustment to persistent pain. *J Pain Symptom Manage* 43:759–70.

### *Hypnosis*

- Barber J, ed. 1996. *Hypnosis and Suggestion in the Treatment of Pain: A Clinical Guide*. New York: Norton.
- Esdaile J. (1850) 2012. *Mesmerism in India and Its Practical Application in Surgery and Medicine*. Hartford, England: Silus Andrus and Son. Reprint, London: Classic Reprint Series, Forgotten Books.
- Montgomery GH, Schnur JB, Kravits K. 2013. Hypnosis for cancer care: over 200 years young. *CA Cancer J Clin* 63:31–44.
- Spiegel D, Moore R. 1997. Imagery and hypnosis in the treatment of cancer patients. *Oncology* 11:1179–95.
- Waxman D, ed. 2002. *Hartland's Medical and Dental Hypnosis*. 4th ed. London: Balliere Tindall.

### *Neurofeedback*

- Hetkamp M, Bender J, Rheindorf N, et al. 2019. A systematic review of the effect of neurofeedback in cancer patients. *Integr Cancer Ther* 18:1–13.

### *Music Therapy*

- Bradt J, Dileo C, Magill L, et al. 2016. Music interventions for improving psychological and physical outcomes in cancer patients. *Cochrane Database Syst Rev* 10:CD006911.
- Freeman L, Caserta M, Lund D, et al. 2006. Music thanatology: Prescriptive harp music as palliative care for the dying patient. *Am J Hosp Palliat Care*. 23:100-104.
- Gramaglia C, Gambaro E, Vecchi C, et al. 2019. Outcomes of music therapy interventions in cancer patients—a review of the literature. *Crit Rev Oncol/Hematol* 138:241–54.
- Hanser S. 2006. Music therapy in adult oncology: Research issues. *J Soc Integr Oncol* 4:62–66.
- Hanser S, Mandel SE. 2010. *Manage Your Stress and Pain through Music*. Boston: Berklee Press.
- Horrigan B. 2001. Interview with Therese Schroeder-Sheker: Music thanatology and spiritual care for the dying. *Altern Ther* 7:69–77.
- Magill L. 2001. The use of music therapy to address the suffering in advanced cancer pain. *J Palliat Care* 17:161–66.
- Magill L. 2010. Music therapy. In *Psycho-Oncology*, 2nd ed., Holland JC, Breitbart WS, Jacobsen PB, et al. (eds.). New York: Oxford University Press.
- O’Callaghan C. 2015. Music therapy in palliative care. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC (eds.). Oxford: Oxford University Press.
- Olofsson A, Fossum B. 2009. Perspectives in music therapy in adult cancer care: A hermeneutic study. *Onc Nurs Forum* 36:E223–E231.
- Richard-Lalonde M, Gélinas C, Boitor M, et al. 2020. The effect of music on pain in the adult intensive care unit: A systematic review of randomized controlled trials. *J Pain Symptom Manage* 59:1304–19.
- Yangöz ST, Özer Z. 2019. The effect of music intervention on patients with cancer-related pain: A systematic review and meta-analysis of randomized controlled trials. *J Adv Nurs* 75:3362–73.

### *Art Therapy*

- Bozcuk H, Ozcan K, Erdogan C, et al. 2017. A comparative study of art therapy in cancer patients receiving chemotherapy and improvement in quality of life by watercolor painting. *Complement Ther Med* 30:67-72.
- Luzzatto P, Magill L. 2010. Art therapy and music therapy. In *Psycho-Oncology*, 2nd ed., Holland JC, Breitbart WS, Jacobsen PB, et al. (eds.). Oxford: Oxford University Press.

- Luzzatto P, Sereno V, Capps R. 2003. A communication tool for cancer patients with pain: The art therapy technique of the Body Outline. *Palliative and Supportive Care* 1:135–42.
- Reynolds MW, Nabors L, Quinlan A. 2000. The effectiveness of art therapy: Does it work? *Art Therapy: J Am Art Ther Assoc* 17:207–13.
- Wood MJM. 2015. The contribution of art therapy to palliative medicine. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC. (eds.). Oxford: Oxford University Press.

## Chapter 9. Psychological Considerations

### General References

- Breitbart W, Bruera E, Chochinov H, et al. 1995. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. *J Pain Symptom Manage* 10:131–41.
- Carver CS. 1997. You want to measure coping but your protocol's too long: Consider the Brief COPE. *Int J Behav Med* 4:92–100.
- Derogatis LR, Morrow GR, Feting J, et al. 1983. The prevalence of psychiatric disorders among cancer patients. *JAMA* 249:751–57.
- Institute of Medicine (US) Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting; Adler NE, Page AEK (eds.). 2008. *Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs*. Washington, DC: National Academies Press. doi: 10.17226/11993. PMID: 20669419. Bookshelf ID: NBK4015.
- Lang-Rollin I, Berberich G. 2018. Psycho-oncology. *Dialogues Clin Neurosci* 20:13–22.
- Masel EK, Berghoff AS, Mladen A, et al. 2016. Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit. *Palliat Support Care* 14:250–58.
- Miovic M, Block SD. 2007. Psychiatric disorders in advanced cancer. *Cancer* 110:1665–76.
- NCCN. 2021. Distress management guidelines, version 2. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431>.

## Psychological Support and Counseling

- Breitbart W, Poppito S, Rosenfeld B, et al. 2012. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. *J Clin Oncol*. 30:1304–9.
- Breitbart W, Rosenfeld B, Pessin H, et al. 2015. Meaning-centered group psychotherapy: An effective intervention for improving psychological well-being in patients with advanced cancer. *J Clin Oncol* 33:749–54.
- Cayley B. 2006. Comfort always. *FPM* 13:74.
- Druss RG. 2003. To comfort always. *American Journal of Psychiatry* 160:25–26.
- Faulkner A, Maguire P. 1994. *Talking to Cancer Patients and Their Relatives*. Oxford: Oxford Medical.
- Kim GM, Kim SJ, Song SK, et al. 2017. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. *BMC Cancer* 17:283.
- Nipp RD, El-Jawahri A, Fishbein JN, et al. 2016. The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. *Cancer* 122:2110–16.
- Nipp RD, Greer JA, El-Jawahri A, et al. 2017. Coping and prognostic awareness in patients with advanced cancer. *J Clin Oncol* 35:2551–57.
- Roberts N, Czajkowska Z, Radiotis G, et al. 2013. Distress and coping strategies among patients with skin cancer. *J Clin Psychol Med Settings* 20:209–14.
- Rosenfeld B, Saracino R, Tobias K, et al. 2017. Adapting meaning-centered psychotherapy for the palliative care setting: Results of a pilot study. *Palliat Med* 31:140–46.
- Ryan H, Schofield P, Cockburn J, et al. 2005. How to recognize and manage psychological distress in cancer patients. *Eur J Cancer Care (Engl)* 14:7–15.
- Saracino RM, Rosenfeld B, Breitbart W, et al. 2019. Psychotherapy at the end of life. *Am J Bioeth* 19:19–28.
- Thomas LP, Meier EA, Irwin SA. 2014. Meaning-centered psychotherapy: A form of psychotherapy for patients with cancer. *Curr Psychiatry Rep* 16:488.
- Walshe C, Roberts D, Appleton L, et al. 2017. Coping well with advanced cancer: A serial qualitative interview study with patients and family carers. *PLoS One* 12:e0169071



## Existential Distress

- Amonoo HL, Harris JH, Murphy WS, et al. 2020. The physician's role in responding to existential suffering: What does it mean to comfort always? *J Palliat Med* 35:8–12.
- Frankl VE. 1992. *Man's Search for Meaning: An Introduction to Logotherapy*. Boston: Beacon Press.
- LeMay K, Wilson KG. 2008. Treatment of existential distress in life threatening illness: A review of manualized interventions. *Clin Psychol Rev* 28:472–93.
- Levine C. 1984. When parents choose prayer over medicine, should courts step in? *Hastings Cent Rep* 14:3–4.

## Anxiety

- Ganzel BL. 2018. Trauma-informed hospice and palliative care. *Gerontologist* 58:409–19.
- Juurlink D. 2016. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. *BMJ* 354:i5309
- Noyes R Jr., Hoehn-Saric R. 1998. *The Anxiety Disorders*. Cambridge: Cambridge University Press.
- Richards S, Umbreit JN, Fanucchi MP, et al. 2003. Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. *South Med J* 96:1031.
- Stark D, Kiely M, Smith A, et al. 2002. Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. *J Clin Oncol* 20:3137–48.
- Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 67:361–70.

## *Post-traumatic Stress Reactions*

- Chan CMH, Ng CG, Taib NA, et al. 2018. Course and predictors of post-traumatic stress disorder in a cohort of psychologically distressed patients with cancer: A 4-year follow-up study. *Cancer* 124:406–16.

## Depression

- Beach SR, Celano CM, Noseworthy PA, et al. 2013. QTc prolongation, torsades de pointes, and psychotropic medications. *Psychosomatics* 54:1–13.
- Block SD. 2000. Assessing and managing depression in the terminally ill patient. *Ann Intern Med* 132:209–18.

- Breitbart W, Rosenfeld B, Pessin H, et al. 2000. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. *JAMA* 284:2907–11
- Chochinov HM, Wilson KG, Enns M, et al. 1997. Are you depressed? Screening for depression in the terminally ill. *Am J Psychiatry* 154:674–76.
- Goldman N, Frankenthaler M, Klepacz L. 2019. The efficacy of ketamine in the palliative care setting: A comprehensive review of the literature. *J Palliat Med* 22:1154–61.
- Grassi L, Nanni MG, Rodin G, et al. 2018. The use of antidepressants in oncology: A review and practical tips for oncologists. *Ann Oncol* 29:101–11.
- Griffiths RR, Johnson MW, Carducci MA, et al. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol* 30:1181–97.
- Howard P, Twycross R, Shuster J, et al. 2012. Antidepressant drugs. *J Pain Symptom Manage* 44:763–83.
- Juurlink D. 2016. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. *BMJ* 354:i5309.
- Kroenke K, Spitzer RL, Williams JB. 2001. The PHQ-9: Validity of a brief depression severity measure. *J Gen Intern Med* 16:606–13.
- Massie MJ. 2004. Prevalence of depression in patients with cancer. *J Natl Cancer Inst Monogr* 2004:57–71.
- Rozans M, Dreisbach A, Lertora JJJ, et al. 2002. Palliative uses of methylphenidate in patients with cancer: A review. *J Clin Oncol* 20:335–39.
- Turaga KK, Malafa MP, Jacobsen PB, et al. 2011. Suicide in patients with pancreatic cancer. *Cancer* 117:642–47.
- World Health Organization (WHO) and the International Society for Prevention of Child Abuse and Neglect (ISPCAN). 2006. Preventing Child Maltreatment: A Guide to Taking Action and Generating Evidence. Geneva: WHO Press.  
[https://apps.who.int/iris/bitstream/handle/10665/43499/9241594365\\_eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/43499/9241594365_eng.pdf?sequence=1&isAllowed=y).
- Wygant C, Hui D, Bruera E. 2011. Childhood sexual abuse in advanced cancer patients in the palliative care setting. *J Pain Sympt Manage* 42:290–95.
- Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 67:361–70.

## Personality Disorders

Groves JE. 1978. Taking care of the hateful patient. *N Engl J Med* 298:883–87.

Meyer F, Block S. 2011. Personality disorders in the oncology setting. *J Supportive Oncol* 9:44–51.

## Delirium / Neuroleptic therapy

Agar MR, Lawlor PG, Quinn S, et al. 2017. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: A randomized clinical trial. *JAMA Intern Med* 177:34–42.

Avital A, Gross-Isseroff R, Stryker R., et al. 2009. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. *European Neuropsychopharmacology* 19:476–82.

Beach SR, Celano CM, Noseworthy PA, et al. 2013. QTc prolongation, torsades de pointes, and psychotropic medications. *Psychosomatics* 54:1–13.

Boettger S, Friedlander M, Breitbart W, et al. 2011. Aripiprazole and haloperidol in the treatment of delirium. *Aust N Z J Psychiatry* 45:477–82.

Breitbart W, Marotta R, Platt MM, et al. 1996. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. *Am J Psychiatry* 153:231–37.

Caroff SN, Hurford I, Lybrand J, et al. 2011. Antipsychotic drugs: Implications of the CATIE schizophrenia trial. *Neurol Clin* 29:127–48.

de Stoutz ND, Bruera E, Suarez-Almazor M. 1995. Opioid rotation for toxicity reduction in terminal cancer patients. *J Pain Symptom Manage* 10:378–84.

de Stoutz ND, Tapper M, Fainsinger R. 1995. Reversible delirium in terminally ill patients. *J Pain Symptom Manage* 10:249–53.

Goodnick PJ, Jerry JM. 2002. Aripiprazole: Profile on efficacy and safety. *Expert Opin Pharmacother* 3:1773–81.

Hui D, Bush SH, Gallo LE, et al. 2010. Neuroleptic dose in the management of delirium in patients with advanced cancer. *J Pain Symptom Manage* 39:186–96.

Kang JH, Shin SH, Bruera E. 2013. Comprehensive approaches to managing delirium in patients with advanced cancer. *Cancer Treat Rev* 39:105–12.

- Kasper S, Lerman MN, McQuade RD, et al. 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. *Int J Neuropsychopharmacol* 6:325–37.
- Kestenbaum MG, Vilches AO, Messersmith S, et al. 2014. Alternative routes to oral opioid administration in palliative care: A review and clinical summary. *Pain Med* 15:1129–53.
- Lawlor PG, Gagnon B, Mancini IL, et al. 2000. Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. *Arch Intern Med* 160:786–94.
- Poyurovsky M, Pashinian A, Weizman R, et al. 2006. Low-dose mirtazapine: A new option in the treatment of anti-psychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. *Biol Psych* 59:1071–77.
- Sher Y, Miller Cramer AC, Ament A, et al. 2015. Valproic acid for treatment of hyperactive or mixed delirium: Rationale and literature review. *Psychosomatics* 56:615–25.
- Warren DE. 1996. Practical use of rectal medications in palliative care. *J Pain Symptom Manage* 11:378–87.
- Weissman DE. 1988. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: A review. *J Clin Oncol* 6:543–51.

### *Serotonin Syndrome*

- Ables AZ, Nagubilli R. 2010. Prevention, diagnosis, and management of serotonin syndrome. *Am Fam Physician* 81:1139–42.
- Boyer EW, Shannon M. 2005. The serotonin syndrome. *N Engl J Med* 352:1112–20.
- Kotlinska-Lemieszek A, Klepstad P, Faksvåg D. 2019. Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: A systematic review. *J Pain Symptom Manage* 57:989–98.
- Levin TT, Cortes-Ladino A, Weiss M, et al. 2008. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug-drug interaction: Case reports and discussion. *Gen Hosp Psychiatry* 30:372–77.
- Mahlberg R, Kunz D, Sasse J, et al. 2004. Serotonin syndrome with tramadol and citalopram. *Am J Psychiatry* 161:1129.
- Mastroianni A, Ravaglia G. 2017. Serotonin syndrome due to co-administration of linezolid and methadone. *Infez Med* 25:263–66.

## Chapter 10. Managing Other Distressing Problems

### General References

- Bruera E, Higginson IJ, von Gunten C, et al. 2016. Textbook of Palliative Medicine and Supportive Care. 2nd ed. Boca Raton, FL: CRC Press.
- Cherny NI, Fallon MT, Kaasa S, et al., eds. 2015. Oxford Textbook of Palliative Medicine: Principles and Practice of Supportive Care in Oncology. 5th ed. Oxford: Oxford University Press.
- Henson LA, Maddocks M, Evans C, et al. 2020. Palliative care and the management of common distressing symptoms in advanced cancer: Pain, breathlessness, nausea and vomiting, and fatigue. *J Clin Oncol* 38:905–14.
- Holland JC, Breitbart WS, Butow PN, et al., eds. 2015. Psycho-Oncology. 3rd ed. Oxford: Oxford University Press.
- Quill T, Periyakoil V, Denney-Koelsch E, et al. 2019. Primer of Palliative Care. 7th ed. Glenview, IL: American Academy of Hospice and Palliative Medicine.
- Waller A, Caroline NL. 2000. Handbook of Palliative Care in Cancer. 2nd ed. Boston: Butterworth-Heinemann.

### Oral Care

#### *Chemo- and Radiation Therapy–Induced Mucositis: Prevention and Treatment*

- Bauman B, Mick R, Martinez E, et al. 2019. Efficacy of oral cryotherapy during oxaliplatin infusion in preventing oral thermal hyperalgesia: A randomized trial. *J Natl Compr Cancer Netw* 17:358–64.
- Bowen J, Al-Dasooqi N, Bossi P, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2019. The pathogenesis of mucositis: Updated perspectives and emerging targets. *Support Care Cancer* 27:4023–33.
- Correa MEP, Cheng KKF, Chiang K, et al. 2020. Systemic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 28:2449–56.
- Elad S. Guest editor. 2019. Special section on the MASCC/ISOO clinical practice guidelines for the management of mucositis—2019 update. *Support Care Cancer* 27:3927–4033.

- Elad S. Guest editor. 2020. Special section on the MASCC/ISOO clinical practice guidelines for the management of mucositis—2019 update, part 2. *Support Care Cancer* 28:2443–98.
- Elad S, Yarom N. 2019. The search for an effective therapy and pain relief for oral mucositis. *JAMA* 321:1459–61.
- Elad S, Zadik Y, Hewson I, et al., for the Viral Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO). 2010. A systematic review of viral infections associated with oral involvement in cancer patients: A spotlight on Herpesviridea. *Support Care Cancer* 18:993–1006.
- Hong CHL, Gueiros LA, Fulton JS, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2019. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 27:3949–67.
- Logan RM, Al-Azri AR, Bossi P, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2020. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 28:2485–98.
- Paglioni MdP, Alves CGB, Fontes EK, et al. 2019. Is photobiomodulation therapy effective in reducing pain caused by toxicities related to head and neck cancer treatment? A systematic review. *Support Care Cancer* 27:4043–54.
- Saunders DP, Rouleau T, Cheng K, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2020. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 28:2473–84.
- Sio TT, Le-Rademacher JG, Leenstra JL, et al. 2019. Effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiation-related mucositis pain: The Alliance A221304 randomized clinical trial. *JAMA* 32:1481–90.
- Sonis S. 2020. Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity? *Support Care Cancer* 28:423–24.
- Zadik Y, Arany PR, Rodrigues Fregnani E, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2019. Systematic review of photobiomodulation for the

management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 27:3969–83.

### *Candida*

Bays DJ, Thompson GR. 2019. Fungal infections of the stem cell transplant recipient and hematologic malignancy patients. *Infect Dis Clin North Amer* 33:545–66.

### *Xerostomia*

Blom M, Lundeberg T. 2000. Long-term followup of patients treated with acupuncture for xerostomia and the influence of additional treatment. *Oral Dis* 6:15–24.

Ellershaw JE, Sutcliffe JM, Saunders CM. 1995. Dehydration and the dying patient. *J Pain Symptom Manage* 10:192–97.

Fleming M, Craigs CL, Bennett MI. 2020. Palliative care assessment of dry mouth: What matters most to patients with advanced disease. *Support Care Cancer* 28:1121–29.

Jensen SB, Pedersen AML, Vissink A, et al., Salivary Gland Hypofunction / Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO). 2010a. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact. *Support Care Cancer* 18:1061–79.

Jensen SB, Pedersen AML, Vissink A, et al., Salivary Gland Hypofunction / Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO). 2010b. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Prevalence, severity, and impact on quality of life. *Support Care Cancer* 18:1039–60.

Mercadante V, Jensen SB, Smith DK et al. 2021. Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO guideline. *J Clin Oncol* 39:2825–43.

## Gastrointestinal Problems

### *Ascites*

Rosemurgy AS, Zervos EE, Clark WC, et al. 2004. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: A prospective randomized trial. *Ann Surg* 239:883–91.

Yarmohammadi H, Getrajdman GI. 2017. Symptomatic fluid drainage: Peritoneovenous shunt placement. *Semin Intervent Radiol* 34:343–48.

### *Constipation/Diarrhea*

- Bowen JM, Gibson RJ, Collier JK, et al., for the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). 2019. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. *Support Care Cancer* 27:4011–22.
- Chauhan A, Patel RA, Luque L, et al. 2020. Amino acid mixture (enterade) as a new approach to reducing cancer therapy-induced gastrointestinal toxicity: A retrospective study. *J Clin Oncol* 38:e24107.
- Davies A, Leach C, Caponero R, et al. 2020. MASCC recommendations on the management of constipation in patients with advanced cancer. *Support Care Cancer* 28:23–33.
- Ginex PK, Hanson BJ, LeFebvre KB, et al. 2020. Management of opioid-induced and non-opioid-related constipation in patients with cancer: Systematic review and meta-analysis. *Oncol Nurs Forum* 47:E211–24.
- Ippoliti C, Champlin R, Bugozia N, et al. 1997. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. *J Clin Oncol* 15:3330–54.
- Kornblau S, Benson AB, Catalano R, et al. 2000. Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. *J Pain Symptom Manage* 19:118–29.
- Liu Z, Yan S, Wu J, et al. 2016. Acupuncture for severe functional constipation: A randomized trial. *Ann Intern Med* 165:761–69.
- National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.
- van der Meij BS, de Graaf P, Wierdsma NJ, et al. 2013. Nutritional support in patients with GVHD of the digestive tract: State of the art. *Bone Marrow Transplant* 48:474–82.
- Waller A, Caroline NL. 2000. Diarrhea and rectal discharge. In *Handbook of Palliative Care in Cancer*. 2nd ed. Boston: Butterworth-Heinemann.

### *Dysphagia / Nausea and Vomiting*

- Avital A, Gross-Isseroff R, Stryker R, et al. 2009. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. *European Neuropsychopharmacology* 19:476–82.
- Dana-Farber Cancer Institute. 2020. Pink Book. Last updated 2020. <https://pinkbook.dfci.org>.
- Davis MP, Hallerberg G. 2010. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. *J Pain Symptom Manage* 39:756–67.



- Frowen J, Hughes R, Skeat J. 2020. The prevalence of patient-reported dysphagia and oral complications in cancer patients. *Support Care Cancer* 28:1141–50.
- Fuccio L, Mandolesi D, Farioli A, et al. 2017. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies. *Radiother Oncol* 122:332–39.
- Hammond DC, ed. 1990. *Handbook of Hypnotic Suggestion and Metaphors*. New York: Norton.
- Harder S, Groenvold M, Isaksen J, et al. 2018. Antiemetic use of olanzapine in patients with advanced cancer: Results from an open-label multicenter study. *Support Care Cancer* 27:2849–56.
- Howard I. 2019. Cannabis hyperemesis syndrome in palliative care: A case study and narrative review. *J Palliat Med* 22:1227–31.
- Johnson AM, Spaete JP, Jowell PS, et al. 2018. Top ten tips palliative care clinicians should know about interventional symptom management options when caring for patients with gastrointestinal malignancies. *J Palliat Med* 21:1339–42.
- Katsanos K, Sabharwal T, Adam A. 2010. Stenting of the upper gastrointestinal tract: Current status. *Cardiovasc Intervent Radiol* 33:690–705.
- Kawamoto T, Nihei K, Sasai K, et al. 2018. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. *Int J Clin Oncol* 23:1076–83.
- LeGrand S, Walsh D. 2010. Scopolamine for cancer-related nausea. *J Pain Symptom Manage* 40:136–41.
- Monte AA, Shelton SK, Mills E, et al. 2019. Acute illness associated with cannabis use, by route of exposure: An observational study. *Ann Intern Med* 170:531–37.
- National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.
- National Institute for Health and Care Excellence (NIHCE). 2011. Colorectal Cancer: The Diagnosis and Full Management of Colorectal Cancer. Full guideline. <https://www.nice.org.uk/guidance/cg131>.
- Poyurovsky M, Pashinian A, Weizman R, et al. 2006. Low-dose mirtazapine in the treatment of antipsychotic-induced akathisia: A randomized, double-blind, placebo- and propranolol-controlled trial. *Biol Psych* 59:1071–77.
- Smith TJ, Ritter JK, Poklis JL, et al. 2012. ABH gel is not absorbed from the skin of normal volunteers. *J Pain Symptom Manage* 43:961–66.

Walsh D, Davis M, Ripamonti C, et al. 2017. 2016 updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer. *Support Care Cancer* 25:333–40.

Wickham RJ. 2020. Revisiting the physiology of nausea and vomiting—challenging the paradigm. *Support Care Cancer* 28:13–21.

### *Treatment-Induced Nausea and Vomiting*

Bhargava R, Chasen M, Elten M, et al. 2020. The effect of ginger (*Zingiber officinale* Roscoe) in patients with advanced cancer. *Support Care Cancer* 28:3279–86.

Cohen RE, Blanchard EB, Ruckdeschel JC, et al. 1986 Prevalence and correlates of posttreatment and anticipatory nausea and vomiting in cancer chemotherapy. *J Psychosom Res* 30:643–54.

Einhorn LH, Rapoport B, Navari RM, et al. 2017. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. *Support Care Cancer* 25:303–8.

Grunberg S, Chua D, Maru A, et al. 2011. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol. *J Clin Oncol* 29:1495–1501.

Hainsworth JD. Nausea and vomiting. In *Abeloff's Clinical Oncology*, 6th ed., Niederhuber JE, Armitage JO, Dporoshow JH, Kastan MB, Tepper JE (eds.). Philadelphia: Elsevier, pp. 598–606.

Hesketh PJ, Kris MG, Basch E, et al. 2020. Antiemetics: American Society of Clinical Oncology guideline update. *J Clin Oncol* 38:2782–97.

Johnson MH, Moroney CE, Gay CF. 1997. Relieving nausea and vomiting in patients with cancer: A treatment algorithm. *Oncol Nurs Forum* 24:51–57.

Laszlo J, Clark RA, Hanson DC, et al. 1985. Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects. *J Clin Oncol* 3:864–69.

Leventhal H, Easterling DV, Nerenz DR, et al. 1988. The role of motion sickness in predicting anticipatory nausea. *J Behav Med* 11:117–30.

Mahendraratnam N, Farley FJ, Basch E, et al. 2019. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. *Support Care Cancer* 27:4525–34.

Molassiotis A, Russell W, Hughes J, et al. 2013. The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed

- nausea: Assessment of nausea in chemotherapy research (ANCHoR), a randomized trial. *Health Technol Assess* 17:1–114.
- Morrow GR, Morrell BS. 1982. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. *N Engl J Med* 307:1476–80.
- Mosa ASM, Hossain AM, Lavoie BJ, et al. 2020. Patient-related risk factors for chemotherapy-induced nausea and vomiting: A systematic review. *Front Pharmacol* 11:329.
- National Academies of Science, Engineering and Medicine (NASEM). 2017. *Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: National Academies Press.
- National Comprehensive Cancer Network (NCCN). 2020a. NCCN antiemesis guidelines. Version 2. NCCN Clinical Practice Guidelines. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1415>.
- Razvi Y, Chan S, McFarlane T, et al. 2019. ASCO, NCCN, MASCC/ESMO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. *Support Care Cancer* 27:87–95.
- Roberts JT, Priestman TJ. 1993. A review of ondansetron in the management of radiotherapy-induced emesis. *Oncology* 50:173–79.
- Roeland EJ, Ruddy KJ, LeBlanc TW, et al. 2020. What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. *JNCCN* 18:676–81.
- Roila F, Donati D, Tamberi S, et al. 2002. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. *Support Care Cancer* 10:88–95.
- Roscoe JA, Heckler CE, Morrow GR, et al. 2012. Prevention of delayed nausea: A University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. *J Clin Oncol* 30:3389–95.
- Roscoe JA, Morrow GR, Aapro MS, et al. 2011. Anticipatory nausea and vomiting. *Support Care Cancer* 19:1533–38.
- Scarantino CW, Ornitz RD, Hoffman LG, et al. 1992. Radiation-induced emesis: Effects of ondansetron. *Semin Oncol* 6(suppl 15):38–43.
- Singh K, Paul SM, Kober KM, et al. 2020. Neuropsychological symptoms and intrusive thoughts are associated with worse trajectories of chemotherapy-induced nausea. *J Pain Symptom Manage* 59:668–78.

Sullivan JR, Leyden MJ, Bell R. 1983. Decreased cisplatin induced nausea and vomiting with chronic alcohol ingestion. *N Engl J Med* 309:796.

Uthaipaisanwong A, Oranratanaphan S, Musigavong N. 2020. Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: A randomized controlled study. *Support Care Cancer* 28:3831–38.

### *Malignant Bowel Obstruction*

Allievi N, Ceresoli M, Fugazzola P, et al. 2017. Endoscopic stenting as bridge to surgery versus emergency resection for left-sided malignant colorectal obstruction: An updated meta-analysis. *Int J Surg Oncol* epub. PMID: 28761765.

Bozzetti F. 2019. The role of parenteral nutrition in patients with malignant bowel obstruction. *Support Care Cancer* 27:4393–99.

Englert ZP, White MA, Fitzgerald TL, et al. 2012. Surgical management of malignant bowel obstruction: At what price palliation? *Am Surg* 78:647–52.

Johnson AM, Spaete JP, Jowell PS, et al. 2018. Top ten tips palliative care clinicians should know about interventional symptom management options when caring for patients with gastrointestinal malignancies. *J Palliat Med* 21:1339–42.

Kasi PM. 2018. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues. *Drugs of Today* 54:423–32.

Laval G, Arvieux C, Stefani L, et al. 2006. Protocol for the treatment of malignant inoperable bowel obstruction: A prospective study of 80 cases at Grenoble University Hospital Center. *J Pain Symptom Manage* 31:502–12.

Lee YC, Jivraj N, Wang L, et al. 2019. Optimizing the care of malignant bowel obstruction in patients with advanced gynecological cancer. *J Oncol Pract* 15:e1066–e1075.

Mariani P, Blumberg J, Landau A, et al. 2012. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: A randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 30:4337–43.

Mercadante S, Porzio G. 2012. Octreotide for malignant bowel obstruction: Twenty years after. *Critical Reviews in Oncology/Hematology* 83:388–92.

National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.

Prommer EE. 2008. Established and potential therapeutic applications of octreotide in palliative care. *Support Care Cancer* 16:1117–23.

Ripamonti CI, Easson AM, Gerdes H. 2008. Management of malignant bowel obstruction. *Eur J Cancer* 44:1105–15.

Soriano A, Davis MP. 2011. Malignant bowel obstruction: Individualized treatment near the end of life. *Cleveland Clinic J Med* 78:197–206.

## Respiratory Problems

### *Dyspnea*

Barnes H, McDonald J, Smallwood N, et al. 2016. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. *Cochrane Database Syst Rev* 3:CD011008.

Bausewein C, Booth S, Gysels M, et al. 2008. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *Cochrane Database Syst Rev* 2:CD005623

Benítez-Rosario MA, Rosa-González I, González-Dávila E, et al. 2019. Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. *Support Care Cancer* 27:157–64.

Cavalleri V, Burtin C, Formico VR, et al. 2019. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. *Cochrane Database Syst Rev* 6:CD009955.

Clemens KE, Klaschik E. 2011. Dyspnea associated with anxiety—symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in cancer patients. *Support Care Cancer* 19:2027–33.

Clemens KE, Quednau I, Klaschik E. 2009. Use of oxygen and opioids in the palliation of dyspnea in hypoxic and non-hypoxic palliative care patients: A prospective study. *Support Care Cancer* 17:367–77.

Ferreira DH, Louw S, McCloud P, et al., for the Australian National Palliative Care Clinical Studies Collaborative. 2020. Controlled-release oxycodone vs placebo in the treatment of chronic breathlessness—a multisite randomized placebo-controlled trial. *J Pain Symptom Manage* 59:581–89.

Hui D, Hernandez F, Larsson L, et al. 2019. Prophylactic fentanyl sublingual spray for episodic exertional dyspnea in cancer patients: A pilot double-blind randomized controlled trial. *J Pain Symptom Manage* 58:605–13.

Hui D, Hernandez F, Thomas S, et al. 2020. High flow oxygen for dyspnea in hospitalized patients with cancer: A 4x4 crossover randomized clinical trial. *J Clin Oncol* 38:12077.

- Hui D, Bohlke K, Bao T, et al. 2021. Management of dyspnea in advanced cancer: ASCO Guideline. *J Clin Oncol* 39:1389–1411.
- Kloke M, Cherny N, for the ESMO Guidelines Committee. 2015. Treatment of dyspnea in advanced cancer patients: ESMO Clinical Practice Guideline. *Ann Oncol suppl* 5:169–73.
- National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.
- Peddle-McIntyre CJ, Singh F, Thomas R, et al. 2019. Exercise training for advanced lung cancer. *Cochrane Database Syst Rev* 2:CD012685.
- Pilling JE, Dusmet ME, Ladas G, et al. 2010. Prognostic factors for survival after surgical palliation of malignant pleural effusion. *J Thorac Oncol* 5:1544–50.
- Qian Y, Wu Y, Rosman de Moraes A, et al. 2019. Fan therapy for the treatment of dyspnea in adults: A systematic review. *J Pain Symptom Manage* 58:481–86.
- Shah N, Mehta Z, Mehta Y. 2018. High-flow nasal cannula oxygen therapy in palliative care. *Fast Facts and Concepts* #330. *J Palliat Med* 20:679–80.
- Swan F, Newey A, Bland M, et al. 2019. Airflow relieves chronic breathlessness in people with advanced disease: An exploratory systematic review and meta-analyses. *Pall Med* 33:618–33.
- Thomas JR, von Gunten CF. 2003. Management of dyspnea. *Support Oncol* 1:23–34.
- Tiep B, Sun V, Koczywas M, et al. 2015. Pulmonary rehabilitation and palliative care for the lung cancer patients. *J Hosp Palliat Nurs* 17:462–68.
- Verberkt CA, van den Beuken-van Everdingen MH, Schols JMGA, et al. 2017. Respiratory adverse effects of opioids for breathlessness: A systematic review and meta-analysis. *Eur Respir J* 50:CD1701153
- Viola R, Kiteley C, Lloyd NS, et al., for the Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based Care. 2008. The management of dyspnea in cancer patients: A systematic review. *Supp Care Ca* 16:329–37.
- Waller A, Caroline NL. 2000. Dyspnea. In *Handbook of Palliative Care in Cancer*. 2nd ed. Boston: Butterworth-Heinemann.

### *Pleurodesis for Malignant Pleural Effusions*

- Barbetakis N, Vassiliadis M, Kaplanis K, et al. 2004. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. *BMC Palliat Care* 3:4.

Dresler CM, Olak J, Herndon JE, et al. 2005. Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. *Chest* 127:909–15.

Shaw P, Agrawal R. 2004. Pleurodesis for malignant pleural effusions. *Cochrane Database Syst Rev* 1:CD002916.

### *Cough*

Truesdale K, Jurdi A. 2013. Nebulized lidocaine in the treatment of intractable cough. *Am J Hosp Palliat Care* 30:587–89.

### *Hemoptysis*

Marcelin C, Soussan J, Desmots F, et al. 2018. Outcomes of pulmonary artery embolization and stent graft placement for the treatment of hemoptysis caused by lung tumors. *J Vasc Interv Radiol* 29:975–80.

Wand O, Guber E, Guber A, et al. 2018. Inhaled tranexamic acid for hemoptysis treatment: A randomized controlled trial. *Chest* 154:1379–84.

### *Hiccups*

Bilotta F, Rosa G. 2000. Nefopam for severe hiccups (Letter). *N Engl J Med* 343:1973–74.

Calsina-Berna A, Garcia-Gomez G, Gonzales-Barboteo J, et al. 2012. Treatment of chronic hiccups in cancer patients: A systematic review. *J Palliat Med* 15:1142–50.

Cunningham VL. 2002. Benztropine for the treatment of intractable hiccups: New indication for an old drug? *CJEM* 4:205–6.

Hernandez SL, Fasnacht KS, Sheyner I, et al. 2015. Treatment of refractory hiccups with amantadine. *J Pain Palliat Care Pharmacother* 29:374–77.

Howard P, Twycross R, Shuster J, et al. 2011. Antipsychotics. *J Pain Symptom Manage* 41:956–65.

Polito NB, Fellows SE. 2017. Pharmacologic interventions for intractable and persistent hiccups: A systematic review. *J Emerg Med* 53:540–49.

### *Immunotherapy Toxicity*

Choi J, Anderson R, Blidner A, et al. 2020. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. *Support Care Cancer* 28:6119–28.

Cooksley T, Girotra M, Ginex P, et al. 2020. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management immune



- checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. *Support Care Cancer* 28:6175–81.
- Dougan M, Blidner AG, Choi J, et al. 2020. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. *Support Care Cancer* 28:6129–43.
- Hansen ED, Wang X, Case AA, et al. 2018. Immune checkpoint inhibitor toxicity review for the palliative care clinician. *J Pain Symptom Manage* 56:460–72.
- Lacouture ME, Sibaud V, Gerber PA, et al. 2021. Prevention and management of dermatologic toxicities related to anticancer agents: ESMO clinical practice guidelines. *Ann Oncol* 32:157–70.
- Matts C, Beck A. 2019. Immunotherapy-related adverse effects when treating cancer #375. *J Palliat Med* 22:724–25.
- Neelapu SS. 2019. Managing the toxicities of CAR T-cell therapy. *Hematol Oncol* 37:48–52.
- Phillips GS, Wu J, Hellman MD, et al. 2019. Treatment outcomes of immune-related cutaneous adverse events. *J Clin Oncol* 37:2746–58.
- Rapoport BL, Anderson R, eds. 2020. Special section: The Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated adverse events from checkpoint inhibitors. *Support Care Cancer* 28:6015–6181.
- Shannon VR, Anderson R, Blidner A, et al. 2020. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: Pulmonary toxicity. *Support Care Cancer* 28:6145–57.
- Suarez-Almazor ME, Pundole X, Abdel-Wahab N, et al. 2020. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. *Support Care Cancer* 28:6159–73.
- Thompson JA, Schneider BJ, Brahmer J, et al. 2020. Management of immunotherapy-related toxicities, version 1. *JNCCN* 18:231–41.
- Wiesenthal AC, Patel SP, LeBlanc TW, et al. 2018. Top ten tips for palliative care clinicians caring for cancer patients receiving immunotherapies. *J Palliat Med* 21:694–98.



## Skin Problems

### *General*

Deutsch A, Leboeuf NR, Lacouture ME, et al. 2020. Dermatologic adverse events of systemic anticancer therapies: Cytotoxic chemotherapy, targeted therapy, and immunotherapy. 2020 ASCO Educational Book, pp. 485–500. <https://asco.org/edbook>.

Lacouture ME. 2012. Dr. Lacouture's Skin Care Guide for People Living with Cancer. Cold Spring Harbor, NY: Harborside Press.

Phillips GS, Wu J, Hellman MD, et al. 2019. Treatment outcomes of immune-related cutaneous adverse events. *J Clin Oncol* 37:2746–58.

### *Hand-Foot Syndrome*

Latifyan S, Genot MT, Fernez B, et al. 2020. Use of low-level laser therapy (LLST) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy. *Support Care Cancer* 28:3287–90.

Lacouture ME, Sibaud V, Gerber PA, et al. 2021. Prevention and management of dermatologic toxicities related to anticancer agents: ESMO clinical practice guidelines. *Ann Oncol* 32:157–70.

Manchen E, Robert C, Porta C. 2011. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: Viewpoints from the medical oncologist, dermatologist, and oncology nurse. *Support Oncology* 9:13–22.

Miller KK, Gorcey L, McLellan BN. 2014. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management capsule summary. *J Am Acad Dermatol* 71:787–94.

Wolf SL, Qin R, Menon SP, et al. 2010. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group study N05C5. *J Clin Oncol* 28:5182–87.

### *EGFR-Inhibitors*

Lacouture ME, Anadkat MJ, Jatoi A, et al. 2018. Dermatologic toxicity occurring during anti-EGFR-therapy in patients with metastatic colorectal cancer. *Clin Colorectal Cancer* 17:85–96.

Lacouture ME, Sibaud V, Gerber PA, et al. 2021. Prevention and management of dermatologic toxicities related to anticancer agents: ESMO clinical practice guidelines. *Ann Oncol* 32:157–70.

### *Fungating Skin Lesions and Pressure Ulcers*

- DeConno F, Ventafridda V, Saita L. 1991. Skin problems in advanced and terminal cancer patients. *J Pain Symptom Manage* 6:247–56.
- Gould L, Stuntz M, Giovannelli M, et al. 2015. Wound healing society 2016 update on guidelines for pressure ulcers. *Wound Repair Regen* 24:145–62.
- Grocott P, Gethin G, Probst S. 2015. Skin problems in palliative care. In *Oxford Textbook of Palliative Medicine*, 5th ed, Cherny NI, Fallon MT, Kaasa S, Portenoy RK, Currow DC (eds.). Oxford: Oxford University Press, pp. 715–23.
- Hayashida K, Ogino R, Yamakawa S, et al. 2020. Antiodor effects of rice bran sheets in patients with malodorous wounds. *J Palliat Med* 23:750–51.
- Landi F, Aloe L, Russo A, et al. 2003. Topical treatment of pressure ulcers with nerve growth factor: A randomized clinical trial. *Ann Intern Med* 139:635–41.
- Merims S, Lotem M. 2015. Skin problems in oncology. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon MT, Kaasa S, Portenoy RK, Currow DC (eds.). Oxford: Oxford University Press, pp. 930–39.
- Waller A, Caroline NL. 2000a. Pressure sores. In *Handbook of Palliative Care in Cancer*. 2nd ed. Boston: Butterworth-Heinemann.
- Waller A, Caroline NL. 2000b. Smelly tumors. In *Handbook of Palliative Care in Cancer*. 2nd ed. Boston: Butterworth-Heinemann.
- Zeppetella G, Ribeiro PJ. 2003. Analgesic efficacy of morphine applied topically to painful ulcers. *J Pain Symptom Manage* 25:555–58.

### *Pruritus*

- Bergasa NV, Alling DW, Talbot TL, et al. 1999. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. *J Am Acad Dermatol* 41:431–34.
- Davis MP, Frandsen JL, Walsh D, et al. 2003. Mirtazapine for pruritus. *J Pain Symptom Manage* 25:288–91.
- Dull MM, Kremer AE. 2019. Treatment of pruritus secondary to liver disease. *Curr Gastroenterol Rep* 21:48.
- Duval A, Dubertret L. 2009. Aprepitant as an antipruritic agent? *N Engl J Med* 361:1415–16.
- Dy SM, Harman SM, Braun UK, et al. 2012. To stent or not to stent: An evidence-based approach to palliative procedures at the end of life. *J Pain Symptom Manage* 43:795–801.

- Fawaz B, Chamseddin BH, Griffin JR. 2021. Defining the role of mirtazapine in refractory pruritus. *J Dermatolog Treat* 32:132–36.
- Jones EA, Zylicz Z. 2005. Treatment of pruritis caused by cholestasis with opioid antagonists. *J Palliat Med* 8:1290–93.
- Kouwenhoven TA, van de Kerkhof M, Kamsteeg M. 2017. Use of oral antidepressants in patients with chronic pruritus: A systematic review. *J Am Acad Dermatol* 77:1068–73.
- Kwatra SG, Ständer S, Kang H. 2018. PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist. *N Engl J Med* 379:1578–79.
- Mu D, Deng J, Liu K-F, et al. 2017. A central neural circuit for itch sensation. *Science* 357:695–99.
- Oaklander AL, Bowsher D, Galer B, et al. 2003. Herpes zoster itch: Preliminary epidemiological data. *Pain* 4:338–43.
- Phillips GS, Wu J, Hellman MD, et al. 2019. Treatment outcomes of immune-related cutaneous adverse events. *J Clin Oncol* 37:2746–58.
- Ragazzo J, Cesta A, Jassal SV, et al. 2020. Development and validation of a uremic pruritus treatment algorithm and patient information toolkit in patients with chronic kidney disease and end stage kidney disease. *J Pain Symptom Manage* 59:279–92.
- Singh R, Patel P, Thakker M, et al. 2019. Naloxone and maintenance naltrexone as novel and effective therapies for immunotherapy-induced pruritus: A case report and brief literature review. *J Onc Pract* 15:347–48.
- Song JS, Song H, Chau NF, et al. 2018. Resolution of refractory pruritus with aprepitant in a patient with microcytic adnexal carcinoma. *J Commun Support Oncol* March-April e100–e101.
- To THM, Clark K, Lam L, et al. 2012. The role of ondansetron in the management of cholestatic or uremic pruritus—a systematic review. *J Pain Symptom Manage* 44:725–30.
- Vallely JJ, Hudson KE, Locke SC, et al. 2019. Pruritus in patients with solid tumors: An overlooked supportive care need. *Support Care Cancer* 27:3897–3904.
- Vincenzi B, Tonini G, Santini D. 2010. Aprepitant for erlotinib-induced pruritus. *N Engl J Med* 363:397–98.
- Waller A, Caroline NL. 2000. Pruritus. In *Handbook of Palliative Care in Cancer*. 2nd ed. Boston: Butterworth-Heinemann.
- Wang W, Zhou L, Sun L. 2017. Ondansetron for neuraxial morphine-induced pruritus: A meta-analysis of randomized controlled trials. *J Clin Pharm Ther* 42:383–93.

Zylicz Z, Smits C, Krajnik M. 1998. Paroxetine for pruritus in advanced cancer. *J Pain Symptom Manage* 16:121–24.

## Insomnia

Berger AM, Matthews EE, Kenkel AM. 2017. Management of sleep-wake disturbances comorbid with cancer. *Oncology* 31:610–17;642.

Brasure M, Fuchs E, MacDonald R, et al. 2016. Psychological and behavioral interventions for managing insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. *Ann Intern Med* 165:113–24.

Denlinger CS, Sanft T, Moslehi JJ., et al. 2020. NCCN guidelines insights: Survivorship, version 2.2020. *J Natl Compr Canc Netw* 18:1016–23.

Early, CJ. 2003. Restless leg syndrome. *N Engl J Med* 348:2103–9.

Guzman-Marin R, Aidan AY. 2015. Sleep disorders in patients with cancer. *J Commun Support Oncol* 13:148–55.

Hajjar RR. 2008. Sleep disturbance in palliative care. *Clin Geriatr Med* 24:83–91.

Irwin MR, Olmstead R, Carrillo C, et al. 2017. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: A randomized, partially blinded, non-inferiority trial. *J Clin Oncol* 35:2656–65.

Muth CC. 2017. Restless legs syndrome. *JAMA* 317:780.

National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.

Phillips KM, Jim HS, Donovan KA. 2012. Characteristics and correlates of sleep disturbances in cancer patients. *Support Care Cancer* 20:357–65.

Qaseem A, Kansagara D, Forcica MA, et al. for the clinical guidelines committee of the American College of Physicians. 2016. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 165:125–33.

Savard J, Ivers H, Villa J. 2011. Natural course of insomnia comorbid with cancer: An 18-month longitudinal study. *J Clin Oncol* 29:3580–86.

Scholz H, Trenkwalder C, Kohnen R, et al. 2011. Dopamine agonists for restless legs syndrome. *Cochrane Database Syst Rev* CD006009.

- Schutte-Rodin S, Broch L, Buysse D, et al. 2008. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med* 4:487–504.
- Wilt TJ, MacDonald R, Brasure M, et al. 2016. Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. *Ann Intern Med* 165:103–12.

## Hot Flashes

- Bordeleau L, Pritchard KI, Loprinzi CL, et al. 2010. Multicenter randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. *J Clin Oncol* 28:5147–52.
- Buchanan DT, Landis CA, Hoheebsee C, et al. 2017. Effects of yoga and aerobic exercise on actigraphic sleep parameters in menopausal women with hot flashes. *J Clin Sleep Med* 13:11–18.
- Morrow PKH, Mattair DN, Hortobagyi GN. 2011. Hot flashes: A review of pathophysiology and treatment modalities. *Oncologist* 216:1658–64.
- Simon JA, Gaines T, LaGuadia KD, for VMS Study Group. 2016. Extended-release oxybutynin therapy for vasomotor symptoms in women: A randomized clinical trial. *J N Amer Menopause Soc* 23:1214–21.
- Smith TJ, Loprinzi CL, Deville C. 2018. Oxybutynin for hot flashes due to androgen deprivation in men. *N Engl J Med* 378:1745–46
- Tremblay A, Sheeran L, Aranda SK. 2008. Psychoeducational interventions to alleviate hot flashes: A systematic review. *Menopause* 15:193–202.

## Weakness and Fatigue

### *General References*

- Fleishman SB, Khan H, Homel P, et al. 2010. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. *J Clin Oncol* 28:5054–60.
- Kerr CW, Drake J, Milch RA, et al. 2012. Effects of methylphenidate on fatigue and depression: A randomized, double-blind, placebo-controlled trial. *J Pain Symptom Manage* 43:68–77.
- Millar MP, Walsh D. 2010. Mechanisms of fatigue. *J Support Oncol* 8:164–74.
- Moraska AR, Sood A, Dakhil SR, et al. 2010. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. *J Clin Oncol* 28:3673–79.

- National Comprehensive Cancer Network (NCCN). 2020b. Cancer-related fatigue, version 2. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1424>.
- National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.
- Pedersen L, Lund L, Petersen MA et al. 2020. Methylphenidate as needed for fatigue in patients with advanced cancer. A prospective, double-blind, and placebo-controlled study. *J Pain Symptom Manage* 60:992–1002.
- Porter AB, Liu H, Kohli S, et al. 2020. A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma. Abstract from 2020 ASCO Virtual Scientific Program. ASCO Meeting Library. <https://meetinglibrary.asco.org/record/186732/abstract>.
- Strasser F, Bruera ED. 2002. Update of anorexia and cachexia. *Hematol Oncol Clin N Am* 16:589–617.
- Strasser F, Palmer JL, Schover LR, et al. 2006. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: A pilot study. *Cancer* 107:2949–57.
- Temel JS, Abernathy AP, Currow DC, et al. 2016. Anamorelin in patients with non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. *Lancet Oncol* 17:519–31.
- Von Haehling S, Anker SD. 2015. Treatment of cachexia: an overview of recent developments. *Int J Cardiol* 184:736–742.
- Wang XS, Giralt SA, Mendoza TR, et al. 2002. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. *J Clin Oncol* 20:1319–28.
- Yennurajalingam S, Bruera E. 2007. Palliative management of fatigue at the close of life: “It feels like my body is just worn out.” *JAMA* 297:295–304.

### *Lambert-Eaton Syndrome*

- Kesner VG, Oh SJ, Dimachkle MM, et al. 2018. Lambert-Eaton myasthenic syndrome. *Neurol Clin* 36:379–94.
- Yoon CH, Owusu-Guha J, Smith A, et al. 2020. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: A new take on an old drug. *Ann Pharmacother* 54:56–63.

### *Myositis*

Ravishankar A, Park SS, Olivier KR, et al. 2018. Gemcitabine-induced radiation recall myositis: Case report and review of the literature. *Case Rep Oncol* 11:168–78.

### *Anemia*

Mitchell SA, Beck SL, Hood LE, et al. 2007. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. *Clin J Oncol Nurs* 11:99–113.

National Comprehensive Cancer Network. 2020c. Hematopoietic growth factors, version 2. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1493>.

### *Endocrine and Metabolic Abnormalities*

Gebauer J, Higham C, Langer T, et al. 2019. Endocrine and metabolic consequences of cancer treatment: A systematic review. *Endocrin Rev* 40:711–67.

### *Hypercalcemia*

Feldenzler KL, Sarno J. 2018. Hypercalcemia of malignancy. *J Adv Pract Oncol* 9:496–504.

Wright JD, Tergas AI, Ananth CV, et al. 2015. Quality and outcomes of treatment of hypercalcemia of malignancy. *Cancer Invest* 33:331–39.

### *Hyponatremia*

Gralla RJ, Ahmad F, Blais JD, et al. 2017. Tolvaptan use in cancer patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone: A post hoc analysis of the SALT-1 and SALT-2 trials. *Cancer Med* 6:723–29.

Schrier RW, Gross P, Gheorghiade M, for the SALT investigators. 2006. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 355:2099–2112.

### *Hypokalemia: Ectopic ACTH*

Raff H, Carroll T. 2015. Cushing's syndrome: From physiologic principles to diagnosis and clinical care. *J Physiol* 593:493–506.

### *Hypoglycemia*

Brown E, Watkin D, Evans J, et al. 2018. Multidisciplinary management of refractory insulinomas. *Clin Endocrinol* 88:615–24.

### *Unknown or Irreversible Causes*

Zhou ES, Hall KT, Michaud AL, et al. 2019. Open-label placebo reduces fatigue in cancer survivors: A randomized trial. *Support Care Cancer* 27:2179–87.

### *Anorexia and Cachexia*

Bouleuc C, Anota A, Cornet C, et al. 2020. Impact on health-related quality of life of parenteral nutrition for patients with advanced cancer cachexia: Results from a randomized controlled trial. *Oncologist* 25:e843–51.

Jozwiak R, Recka K. 2020. The anorexia-cachexia syndrome: Definitions, evaluation, and nonpharmacological management #386. *J Palliat Med* 23:287–89.

National Comprehensive Cancer Network (NCCN). 2020d. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <http://www.nccn.org>.

Roeland EJ, Bohlke K, Baracos VE, et al. 2020. Management of cancer cachexia: An ASCO Guideline. *J Clin Oncol* 38:2438–53.

### *DYSGEUSIA*

Campagna S, Gonella S, Sperlinga R, et al. 2018. Prevalence, severity, and self-reported characteristics of taste alterations in patients receiving chemotherapy. *Onc Nurs Forum* 45:342–53.

Epstein JB, de Andrade e Silva SM, Epstein GL, et al. 2019. Taste disorders following cancer treatment: Report of a case series. *Support Care Ca* 27:4587–95.

Hovan AJ, Williams PM, Stevenson-Moore P, et al., Dysgeusia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO). 2010. A systematic review of dysgeusia induced by cancer therapies. *Support Care Cancer* 18:1081–87.

Ijpma I, Renhen RJ, Ter Horst FJ, et al. 2015. Metallic taste in cancer patient treated with chemotherapy. *Cancer Treat Rev* 41:179–86.

### *MEGESTROL ACETATE (MEGACE) AND ANDROGENS*

Earthman CP, Reid PM, Harper IT, et al. 2002. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. *J Parenter Enteral Nutr* 26:357–65.

Leinung MC, Liporace R, Miller CH. 1995. Induction of adrenal suppression by megestrol acetate in patients with AIDS. *Ann Intern Med* 122:843–45.

### *CORTICOSTEROIDS*

Bruera E, Roca E, Cedaro L, et al. 1985. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. *Cancer Treat Rep* 69:751–54.

Cardenas-Mori J, Lewis-Ramos V. 2020. Corticosteroids for common palliative care symptoms #395. *J Palliat Med* 23:987–89.



Yavuzsen T, Davis MP, Walsh D, et al. 2005. Systematic review of the treatment of cancer-associated anorexia and weight loss. *J Clin Oncol* 23:8500–8511.

#### *DRONABINOL ( $\Delta$ -9-TETRAHYDROCANNABINOL)*

Beal JE, Olson R, Laubenstein L, et al. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage* 10:89–97.

#### *ENTERAL OR PARENTERAL FEEDING AND HYDRATION*

Ahronheim JC. 1996. Nutrition and hydration in the terminal patient. *Clin Geriatr Med* 12:379–91.

Bozzetti F, Gavazzi C, Miceli R, et al. 2000. Perioperative total parenteral nutrition in malnourished gastrointestinal cancer patients: A randomized, clinical trial. *JPEN* 24:7–14.

Casarett D, Kapo J, Caplan A. 2005. Appropriate use of artificial nutrition and hydration—fundamental principles and recommendations. *N Engl J Med* 353:2607–12.

Ellershaw JE, Sutcliffe JM, Saunders CM. 1995. Dehydration and the dying patient. *J Pain Symptom Manage* 10:192–97.

McCann RM, Hall WJ, Groth-Junker A. 1994. Comfort care for terminally ill patients: The appropriate use of nutrition and hydration. *JAMA* 272:1263–66.

National Comprehensive Cancer Network (NCCN). 2020b. Cancer-related fatigue, version 2. NCCN Clinical Practice Guidelines in Oncology.  
<https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1424>.

## Chapter 11. Approaching the End

Agin-Liebes G, Malone T, Yalch MM, et al. 2020. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *J Psychopharmacol* 34:155–66.

Ando M, Morita T, Akechi T, et al. 2008. One-week short-term life review interview can improve spiritual well-being of terminally ill cancer patients. *Psychooncology* 17:885–90.

Back AL. 2019. What psilocybin taught me about dying. *J Palliat Med* 22:861–62.

Billings JA. 1985. *Outpatient Management of Advanced Cancer: Symptom Control, Support, and Hospice-in-the-Home*. Philadelphia: Lippincott.

Block SD. 2001. Psychological considerations, growth, and transcendence at the end of life: The art of the possible. *JAMA* 285:2898–2905.

- Byock I. 1997. *Dying Well: Peace and Possibilities at the End of Life*. New York: Riverhead Books.
- Byock I. 2004. *The Four Things that Matter Most: A Book about Living*. New York: Atria Books / Simon and Schuster.
- Cain CL, McCleskey S. 2019. Expanded definitions of the “good death”? Race, ethnicity, and medical aid in dying. *Sociol Health Illn* 41:1175–91.
- Cassell EJ. 2004. *The Nature of Suffering and the Goals of Medicine*. 2nd ed. New York: Oxford University Press.
- Davies N, Barado-Martin Y, Vickerstaff V, et al. 2021. Enteral tube feeding for patients with severe dementia. *Cochrane Database Syst Rev* 8:CD013503.
- Institute of Medicine (IOM). 1997. *Approaching Death: Improving Care at the End of Life*. Washington, DC: National Academy Press.
- Jackson VJ, Ryan D (with Michelle D. Seaton). 2017. *Living with Cancer: A Step-by-Step Guide for Coping Medically and Emotionally with a Serious Diagnosis*. Baltimore, MD: Johns Hopkins University Press.
- Ko E, Cho S, Perez R, et al. 2013. Good and bad death: Exploring the perspectives of older Mexican Americans. *J Gerontol Soc Work* 56:6–25.
- LeBaron VT, Cooke A, Resmini J, et al. 2015. Clergy views on a good versus a poor death: Ministry to the terminally ill. *J Palliat Med* 18:1000–1007.
- Lynn J, Harrold J, Schuster JL. 2011. *Handbook for Mortals*. 2nd ed. New York: Oxford University Press.
- Miller BJ, Berger S. 2019. *A Beginner’s Guide to the End: Practical Advice for Living Life and Facing Death*. New York: Simon and Schuster.
- Mori M, Kuwama YU, Ashikaga T, et al. 2018. Acculturation and perceptions of a good death among Japanese Americans and Japanese living in the U.S. *J Pain Symptom Manage* 55:31–38.
- Saracino RM, Rosenfeld B, Breitbart W, et al. 2019. Psychotherapy at the end of life. *Am J Bioethics* 19:19–28.
- Teno JM, Gozalo P, Mitchell S, et al. 2012. Feeding tubes and the prevention or healing of pressure ulcers. *Arch Intern Med* 172:697–701.
- Tong E, McGraw SA, Dobihal E, et al. 2003. What is a good death? Minority and non-minority perspectives. *J Pall Care* 19:168–75.

Valenti KG, Jen S, Parajuli J, et al. 2020. Experiences of palliative and end-of-life care among older LGBTQ women: A review of current literature. *J Palliat Med* 23:1532–39.

Webb M. 1997. *The Good Death: The New American Search to Reshape the End of Life*. New York: Bantam.

## Hospice

Cherny NI, Coyle N, Foley KM. 1996. Guidelines in the care of the dying cancer patient. *Hematol Oncol Clin North Am* 10:261–86.

Cicoello K, Anandarajah G. 2019. Multiple stakeholders' perspectives regarding barriers to hospice enrollment in diverse patient populations: A qualitative study. *J Pain Symptom Manage* 57:869–79.

Fishman J, O'Dwyer P, Lu HL, et al. 2009. Race, treatment preferences, and hospice enrollment: Eligibility criteria may exclude patients with the greatest needs for care. *Cancer* 115:689–97.

Harris NJ, Dunmore R, Tsheu MJ. 1996. The Medicare hospice benefit: Fiscal implications for hospice program management. *Cancer Manage* 3:6–11.

Henckel C, Revette A, Huntington SF, et al. 2020. Perspectives regarding hospice services and transfusion access: Focus groups with blood cancer patients and bereaved caregivers. *J Pain Symptom Manage* 59:1195–1203.

Higginson IJ, Daveson BA, Morrison RS, et al., for BuildCARE. 2017. Social and clinical determinants of preferences and their achievement at the end of life: Prospective cohort study of older adults receiving palliative care in three countries. *BMC Geriatr* 17:271. doi: 10.1186/s12877-017-0648-4.

Kreling B, Seisky C, Perret-Gentil M, et al., for the Latin American Cancer Research Coalition. 2010. “The worst thing about hospice is that they talk about death”: Contrasting hospice decisions and experience among immigrant Central and South American Latinos to US-born white, non-Latino cancer caregivers. *Palliat Med* 24:427–34.

Leiter R. 2019. “Is Dying at Home Overrated?” *New York Times*, September 3, 2019. <https://www.nytimes.com/2019/09/03/well/live/is-dying-at-home-overrated.html>.

National Hospice and Palliative Care Organization. 2020. “About NHPCO.” Accessed August 15, 2020. <https://www.NHPCO.org/about-nhpco/>.

Pan CX, Abraham O, Giron F, et al. 2015. Just ask: Hospice familiarity in Asian and Hispanic Adults. *J Pain Symptom Manage* 49:928–33.

## Palliative Care Team: Role and Integration with Oncology

- Abernathy AP, Currow DC. 2011. Time for better integration of oncology and palliative care. *J Onc Practice* 7:346–48.
- Abraham JL. 2000. The palliative care consultation team as a model for palliative care education. In *Topics in Palliative Care*, vol. 4, Portenoy RK, Bruera E (eds.). Oxford: Oxford University Press.
- Abraham JL. 2012. Integrating palliative care into comprehensive cancer care. *JNCCN* 10:1192–98.
- Back A, Friedman T, Abraham J. 2020. Palliative care skills and new resources for oncology practices: Meeting the palliative care needs of patients with cancer and their families. *ASCO Oncol Educ Book* 40:1–9.
- Bakitas M, Tosteson T, Li Z, et al. 2015. Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *J Clin Oncol* 33:1438–45.
- Bellhouse S, Galvin L, Turner L, et al. 2020. Phase I cancer trials: A qualitative study of specialist palliative care. *BMJ Support Palliat Care* 10:234–41.
- Beninghof A, Singer A. 1992. Transdisciplinary teaming: An inservice training activity. *Teaching Exceptional Children* 24:58–61.
- Billings JA, Block S. 1997. Palliative care in undergraduate medical education. *JAMA* 278:733–43.
- Block SD. 2002. Medical education in end-of-life care: The status of reform. *J Palliat Med* 5:243–48.
- Boaden N, Leaviss J. 2000. Putting teamwork in context. *Med Educ* 34:921–27.
- Bruera E, Hui D. 2012. Conceptual models for integrating palliative care at cancer centers. *J Palliat Med* 15:1261–69.
- Bubis LD, Davis L, Mahar A, et al. 2018. Symptom burden in the first year after cancer diagnosis: An analysis of patient-reported outcomes. *J Clin Oncol* 36:1103–11.
- Cassel JB, Del Fabbro E, Arkenau T, et al. 2016. Phase I cancer trials and palliative care: Antagonism, irrelevance, or synergy? *J Pain Symptom Manage* 52:437–45.
- Center to Advance Palliative Care (CAPC). 2021. About palliative care. CAPC. Accessed November 1, 2021. <https://www.capc.org/about/palliative-care/>.

- Cloyes KG, Hull W, Davis A. 2018. Palliative and end-of-life care for lesbian, gay, bisexual, and transgender (LGBT) cancer patients and their caregivers. *Semin Oncol Nurs* 34:60–71.
- El-Jawahri A, LeBlanc TW, Kavanaugh A et al. 2021. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: A randomized clinical trial. *JAMA Oncol* 7:238–45.
- El-Jawahri A, LeBlanc TW, VanDusen H, et al. 2016. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: A randomized clinical trial. *JAMA* 316:2094–2103.
- El-Jawahri A, Traegre L, Greer JA, et al. 2017. Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: Results of a randomized clinical trial. *J Clin Oncol* 35:3714–21.
- Elsayem A, Swint K, Fisch MJ, et al. 2004. Palliative care inpatient service in a comprehensive cancer center: Clinical and financial outcomes. *J Clin Oncol* 22:2008–14.
- Ferrell BR, Chung V, Koczywas M, et al. 2020. Dissemination and implementation of palliative care in oncology. *J Clin Oncol* 38:995–1001.
- Ferrell BR, Temel JS, Temin S, et al. 2017. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 35:96–112.
- Finlay E, Newport K, Sivendran S, et al. 2019. Models of outpatient palliative care clinics for patients with cancer. *J Oncol Pract* 15:187–93.
- Finlay E, Rabow MW, Buss MK. 2018. Filling the gap: Creating an outpatient palliative care program in your institution. *ASCO Educ Book* 38:111–21.
- Gilligan T. 2003. When do we stop talking about curative care? *J Palliat Med* 6:657–60.
- Gilligan T. 2018. Personalizing medicine. *J Clin Oncol* 37:165–66.
- Gilligan T, Coyle N, Frankel RM, et al. 2017. Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618–32.
- Gilligan T, Salmi L, Enzinger A. 2018. Patient-clinician communication is a joint creation: Working together toward well-being. *ASCO Educ Book* 38:532–39.
- Greer JA, Jacobs JM, El-Jawahri A, et al. 2018. Role of patient coping strategies in understanding the effects of early palliative care on quality of life and mood. *J Clin Oncol* 36:53–60.

- Hoerger M, Greer JA, Jackson VA, et al. 2018. Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. *J Clin Oncol* 36:1096–1102.
- Hui D, Hannon BL, Zimmermann C, et al. 2018. Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care. *CA Cancer J Clin* 68:356–76.
- LeBlanc TW, El-Jawahri A. 2015. When and why should patients with hematologic malignancies see a palliative care specialist. *Palliative Care in Hematologic Malignancies. Hematology Am Soc Hematol Educ Program* 2015:471–78.
- LeBlanc TW, Marron JM, Ganai S, et al. 2019. Prognostication and communication in oncology. *J Onc Pract* 15:208–15.
- Loggers ET, LeBlanc TW, El-Jawahri A, et al. 2016. Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. *Biol Blood Marrow Transplant* 22:1299–1305.
- National Comprehensive Cancer Network. 2020. Palliative care, version 1. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454>.
- Oncology (special issue on palliative care). 2011. 25(13).
- Oneschuk D, Fainsinger R, Hanson J, et al. 1997. Assessment and knowledge in palliative care in second year family medicine residents. *J Pain Symptom Manage* 14:265–73.
- Quill TE, Abernethy AP. 2013. Generalist plus specialist palliative care—creating a more sustainable model. *N Engl J Med* 368:1173–75.
- Rabow MW, Hardie GE, Fair JM, et al. 2000. End-of-life care content in 50 textbooks from multiple specialties. *JAMA* 283:771–78.
- Rodenbach RA, Brandes K, Fiscella K, et al. 2017. Promoting end-of-life discussions in advanced cancer: Effects of patient coaching and question prompt lists. *J Clin Oncol* 35:842–51.
- Schneiter MK, Karlekar MB, Crispens MA, et al. 2019. The earlier the better: The role of palliative care consultation on aggressive end of life care, hospice utilization, and advance care planning documentation among gynecologic oncology patients. *Supp Care Cancer* 27:1927–34.
- Sedhom R, Gupta A, Kamal AH. 2020. Case for dual training in medical oncology and palliative care. *JCO Oncol Pract* 16:537–39.

- Smith TJ and Cassel JB. 2009. Cost and non-clinical outcomes of palliative care. *J Pain Symptom Manage* 38:32–44.
- Smith TJ, Chung V, Hughes MT, et al. 2020. A randomized trial of a palliative care intervention for patients on phase 1 studies. *J Clin Oncol* 38:120001.
- Stein GL, Berkman C, O’Mahony S, et al. 2020. Experiences of lesbian, gay, bisexual, and transgender patients and families in hospice and palliative care: Perspectives of the palliative care team. *J Palliat Med* 23:817–24.
- Stevens EE, Abrahm JL. 2019. Adding silver to the rainbow: Palliative and end-of-life care for the geriatric LGBTQ patient. *J Palliat Med* 22:602–6.
- Temel JS, Greer JA, El-Jawahri A, et al. 2017. Effects of early integrated palliative care in patients with lung and GI cancer: A randomized clinical trial. *J Clin Oncol* 35:834–41.
- Temel JS, Greer JA, Muzikansky A, et al. 2010. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 363:733–42.
- Thomas TH, Jackson VA, Carlson H, et al. 2019. Communication differences between oncologists and palliative care clinicians: A qualitative analysis of early, integrated palliative care in patients with advanced cancer. *J Palliat Med* 22:41–49.
- Tseng YD, Krishnan MS, Jones JA, et al. 2014. Supportive and palliative radiation oncology service: Impact of a dedicated service on palliative cancer care. *Pract Radiat Oncol* 4:247–53.
- von Gunten CF. 2002. Secondary and tertiary palliative care in US hospitals. *JAMA* 287:875–81.
- von Gunten CF, von Roenn JH, Gradishar W, et al. 1995. A hospice / palliative medicine rotation for fellows training in hematology-oncology. *J Cancer Educ* 10:200–202.
- Zimmermann C, Swami N, Krzyzanowska M, et al. 2014. Early palliative care for patients with advanced cancer: A cluster-randomised controlled trial. *Lancet* 383:1721–30.

## Medical Aid in Dying / Physician-Assisted Death

- AAHPM. 2020. Guidance on responding to requests for physician-assisted dying. AAHPM Advisory Brief. Accessed August 15, 2020. <http://aahpm.org/positions/padbrieff>.
- Block SD, Billings JA. 1994. Patient requests to hasten death: Evaluation and management in terminal care. *Arch Intern Med* 154:2039–47.
- Byock I. 1997. *Dying Well: Peace and Possibilities at the End of Life*. New York: Riverhead Books.

- Cassell EJ. 1991. Recognizing suffering. *Hastings Cent Rep* 21:24–31.
- Foley KM. 1991. The relationship of pain and symptom management to patient requests for physician-assisted suicide. *J Pain Symptom Manage* 6:289–97.
- Foley KM. 1995. Pain, physician-assisted suicide, and euthanasia. *Pain Forum* 4:163–78.
- Foley KM. 1997. Competent care for the dying instead of physician-assisted suicide. *N Engl J Med* 336:54–58.
- Foley KM, Hendin H, eds. 2004. *The Case against Assisted Suicide: For the Right to End-of-Life Care*. Baltimore, MD: Johns Hopkins University Press.
- Fujioka JK, Mirza RM, McDonald PL, et al. 2018. Implementation of medical assistance in dying: A scoping review of health care provider perspectives. *J Pain Symptom Manage* 55:1564–76.
- Isenberg-Grzeda E, Bean S, Cohen C, et al. 2020. Suicide attempts after determination of ineligibility for assisted death: A case series. *J Pain Symptom Manage* 60:158–63.
- Loggers ET, Starks H, Shannon-Dudley M, et al. 2013. Implementing a death with dignity program at a comprehensive cancer center. *N Engl J Med* 368:1417–24.
- Oregon Public Health Division. 2019. *Death with Dignity Act Annual Report: Year 22*. Salem: Oregon Public Health Division.
- Sulmasy DP, Finlay I, Fitzgerald F, et al. 2018. Physician-assisted suicide: Why neutrality by organized medicine is neither neutral nor appropriate. *J Gen Intern Med* 33:1394–99.
- Quill TE. 1993. *Death and Dignity*. New York: Norton.
- Quill TE. 2004. Dying and decision-making: Evaluation of end of life options. *N Engl J Med* 350:2029–32.
- Quill TE, Back AL, Block SD. 2016. Responding to patients requesting physician-assisted death: Physician involvement at the very end of life. *JAMA* 315:245–46.
- Quill TE, Lo B, Brock DW. 1997. Palliative options of last resort: A comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. *JAMA* 278:2099–2104.
- Quill TE, Truog RD, Pope TM. 2018. Voluntarily stopping eating and drinking: Clinical, ethical, and legal aspects. *JAMA Intern Med* 178:123–27.



## Chapter 12. The Last Days

- Abraham JL. 2012. Integrating palliative care into comprehensive cancer care. *JNCCN* 10:1192–98.
- American Academy of Hospice and Palliative Medicine. 2007. AAHPM position statements. *J Palliat Med* 10:851–57.
- American Medical Association. 2013. Opinion 2.201—Sedation to unconsciousness in end-of-life care. *AMA Code of Medical Ethics’ Opinions on Sedation at the End of Life*. May 2013. <https://journalofethics.ama-assn.org/article/ama-code-medical-ethics-opinions-sedation-end-life/2013-05>.
- American Nurses Association. 2001. *Code of Ethics for Nurses with Interpretive Statements*. Silver Springs, MD: ANA.
- American Society of Health-System Pharmacists. 2002. ASHP statement on the pharmacist’s role in hospice and palliative care. *Am J Health Syst Pharm* 59:1770–73.
- Bailey FA, Williams BR. 2005. Preparation of residents for death pronouncement: A sensitive and supportive method. *Palliat Support Care* 3:107–14.
- Beller EM, van Driel ML, McGregor L, et al. 2015. Palliative pharmacological sedation for terminally ill adults. *Cochrane Database Syst Rev* 1:CD010206.
- Berger JT. 2010. Rethinking guidelines for the use of palliative sedation. *Hastings Center Report* 40:32–38.
- Bernacki R, Paladino J, Neville VBVA, et al. 2019. Effect of the Serious Illness Care Program in outpatient oncology: A cluster randomized clinical trial. *JAMA Intern Med* 179:751–59.
- Block SD. 2001. Psychological considerations, growth, and transcendence at the end of life: The art of the possible. *JAMA* 285:2898–2905.
- Bradley CT. 2009. Roman Catholic doctrine guiding end-of-life care: A summary of the recent discourse. *J Palliat Med* 12:373–77.
- Bradley EH, Prigerson H, Carlson MDA, et al. 2004. Depression among surviving caregivers: Does length of hospice enrollment matter? *Am J Psychiatry* 161:2257–62.
- Byock I. 1997. *Dying Well: Peace and Possibilities at the End of Life*. New York: Riverhead Books.
- Cassell EJ, Rich BA. 2010. Intractable end-of-life suffering and the ethics of palliative sedation. *Pain Medicine* 11:435–38.

- Cassem NH. 1991. The dying patient. In Massachusetts General Hospital Handbook of General Hospital Psychiatry, Cassem NH (ed.). St Louis: Mosby Year Book.
- Cavanaugh TA. 1996. The ethics of death-hastening or death-causing palliative analgesic administration to the terminally ill. *J Pain Symptom Manage* 12:248–54.
- Chakraborty R, El-Jawahri AR, Litzow MR, et al. 2017. A systematic review of religious beliefs about end-of-life issues in the five major world religions. *Palliat Support Care* 15:609–22.
- Cherny NI. 2006. Sedation for the care of patient with advanced cancer. *Nat Clin Pract Oncol* 3:492–500.
- Cherny NI, Radbruch L; Board of the European Association for Palliative Care. 2009. European Association of Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. *Palliat Med* 23:581–93.
- Christakis NA, Iwashyna TJ. 2003. The health impact of health care on families: A matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. *Soc Sci Med* 57:465–75.
- Claessens P, Menten J, Schotsmans P, et al. 2008. Palliative sedation: A review of the research literature. *J Pain Symptom Manage* 36:310–33.
- Doyle-Brown M. 2000. The transitional phase: The closing journey for patients and family caregivers. *Am J Hospice Palliat Care* 17:354–57.
- Ellershaw JE, Sutcliffe JM, Saunders CM. 1995. Dehydration and the dying patient. *J Pain Symptom Manage* 10:192–97.
- Ferris TGG, Hallward JA, Ronan L, et al. 1998. When a patient dies: A survey of medical housestaff about care after death. *J Palliat Med* 1:231–40.
- Fromme E, Billings JA. 2003. Care of the dying doctor: On the other end of the stethoscope. *JAMA* 290:2048–55.
- Ganzini L, Goy ER, Miller LL, et al. 2003. Nurses' experiences with hospice patients who refuse food and fluids to hasten death. *N Engl J Med* 349:359–65.
- Golf M, Paice JA, Feulner E, et al. 2004. Refractory status epilepticus. *J Palliat Med* 7:85–88.
- Good P, Richard R, Syrmiss W, et al. 2014. Medically assisted hydration for palliative care patients. *Cochrane Database Sys Rev* 4:CD006273. doi: 10.1002/14651858.CD006273.pub3.
- Granek L, Mazzotta P, Tozer R, et al. 2012. What do oncologists want? Suggestions from oncologists on how their institutions can support them in dealing with patient loss. *Support Care Cancer* 20:2627–32.

- Grond S, Zech D, Schug SA, et al. 1991. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. *J Pain Symptom Manage* 6:411–22.
- Hofherr ML, Abrahm JL, Rickerson E. 2020. Dexmedetomidine: A novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. *J Palliat Med* 23:1515–17.
- Hospice and Palliative Nursing Association. 2003. Position statement: Palliative sedation at end of life. June 2003.  
[http://www.hpna.org/pdf/Palliative\\_Sedation\\_Position\\_Statement\\_PDF.pdf](http://www.hpna.org/pdf/Palliative_Sedation_Position_Statement_PDF.pdf).
- Hui D, De La Rosa A, Wilson A, et al. 2020. Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: A single-centre, double-blind, parallel-group, randomized trial. *Lancet Oncol* 21:989–98.
- Imai K, Morita T, Akechi T, et al. 2020. The principles of revised clinical guidelines about palliative sedation therapy of the Japanese Society for Palliative Medicine. *J Palliat Med* 23:1184–90.
- Jackson VA, Mack J, Matsumaya R, et al. 2008. A qualitative study of oncologists' approaches to end-of-life care. *J Palliat Med* 11:893–906.
- Kelly BJ, Varghese FT, Pelusi D. 2003. Countertransference and ethics: A perspective on clinical dilemmas in end-of-life decisions. *Pall Supp Care* 1:367–75.
- Kelly SA, Kabir R, Keshvani N. 2020. Implantable cardioverter defibrillator management at the end of life: A teachable moment. *JAMA Intern Med* 180:1691–92. doi: 10.1001/jamainternmed.2020.5041.
- Kintzel PE, Chase SL, Thomas W, et al. 2009. Anticholinergic medications for managing noisy respirations in adult hospice patients. *Am J Health Syst Pharm* 66:458–64.
- Kirk TW, Mahon MM, for the Palliative Sedation Task Force of the National Hospice and Palliative Care Organization Ethics Committee. 2010. National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients. *J Pain Symptom Manage* 39:914–22.
- Lawlor PG, Gagnon B, Mancini IL, et al. 2000. Occurrence, causes and outcome of delirium in patients with advanced cancer: A prospective study. *Arch Intern Med* 160:786–94.
- Lynn J, Teno JM, Phillips RS, et al., for the SUPPORT Investigators. 1997. Perceptions by family members of the dying experience of older and seriously ill patients. *Ann Intern Med* 126:97–106.
- Maltoni M, Scarpi E, Rosati M, et al. 2012. Palliative sedation in end-of-life care and survival: A systematic review. *J Clin Oncol* 30:1378–83.

- McIver B, Walsh D, Nelson K. 1994. The use of chlorpromazine for symptom control in dying cancer patients. *J Pain Symptom Manage* 9:341–45.
- McPherson ML, Kim M, Walker KA. 2012. 50 practical medication tips at end of life. *J Support Oncol* 10:222–29.
- Moyle J. 1995. The use of propofol in palliative medicine. *J Pain Symptom Manage* 10:643–46.
- National Ethics Committee, Veterans Health Administration. 2006. The ethics of palliative sedation as a therapy of last resort. *Am J Hospice Palliat Care* 23:483–49.
- Pan CX, Costa BM, Yushuvayev EK, et al. 2020. Can Orthodox Jewish patients undergo palliative extubation? A challenging ethics case study. *J Pain Symptom Manage* 60:1260–65.
- Payne SA, Hasselaar J. 2020. European palliative sedation project. *J Palliat Med* 23:154–55.
- Pitorak EF. 2003. Care at the time of death: How nurses can make the last hours of life a richer, more comfortable experience. *Am J Nurs* 103:42–52.
- Quill TE. 1996. *A Midwife through the Dying Process: Stories of Healing and Hard Choices at the End of Life*. Baltimore, MD: Johns Hopkins University Press.
- Quill TE, Lo B, Brock D. 2009. Last resort options for palliative sedation. *Ann Intern Med* 151:421–24.
- Raijmakers NJH, van Zuylen L, Constantini M, et al., for OPCARE9. 2011. Artificial nutrition and hydration in the last week of life in cancer patients: A systematic literature review of practices and effects. *Ann Oncol* 22:1478–86.
- Redinbaugh EM, Sullivan AM, Block SD, et al. 2003. Doctors' emotional reactions to recent death of a patient: Cross-sectional study of hospital doctors. *BMJ* 327:185.
- Samala RV, Davis MP. 2012. Palliative care per rectum. *Fast Facts and Concepts #257. J Palliat Med* 15:1038–39.
- Schuman ZD, Abrahm JL. 2005. Implementing institutional change: An institutional case study of palliative sedation. *J Palliat Med* 8:666–76.
- Schuman-Olivier Z, Brendel DH, Forstein M, et al. 2008. The use of palliative sedation for existential distress: A psychiatric perspective. *Harv Rev Psychiatry* 16:339–51.
- Slavin SD, Allen LA, McIlvennan, et al. 2020. Left ventricular assist device withdrawal: Ethical, psychological, and logistical challenges. *J Palliat Med* 23:456–58.
- Smith TH, Ritter JK, Poklis JL, et al. 2012. ABH gel is not absorbed from the skin of normal volunteers. *J Pain Symptom Manage* 43:961–66.

- Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT). 1995. A controlled trial to improve care for seriously ill hospitalized patients. *JAMA* 274:1591–98.
- Truog RD, Berde CB, Mitchell C, et al. 1992. Barbiturates in the care of the terminally ill. *N Engl J Med* 327:1678–82.
- von Gunten C, Weissman DE. 2003a. Information for patients and families about ventilator withdrawal. *J Palliat Med* 6:775–76.
- von Gunten C, Weissman DE. 2003b. Symptom control for ventilator withdrawal in the dying patient. *J Palliat Med* 6:774–75.
- von Gunten C, Weissman DE. 2003c. Ventilator withdrawal protocol. *J Palliat Med* 6:773–74.
- Waller A, Caroline NL. 1996. Terminal care. In *Handbook of Palliative Care in Cancer*. Boston: Butterworth-Heinemann.
- Wee B, Hiller R. 2008. Interventions for noisy breathing in patients near to death. *Cochrane Database Sys Rev* 1:CD005177
- Whippen DA, Canellos GP. 1991. Burnout syndrome in the practice of oncology: Result of a random survey of 1000 oncologists. *J Clin Oncol* 9:1916–20.
- Wilcock A, Twycross R. 1996. Midazolam for intractable hiccup. *J Pain Symptom Manage* 12:59–61.
- Wright AA, Keating NL, Balboni TA, et al. 2010. Place of death: Correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. *J Clin Oncol* 28:4457–64.
- Yachter C. *Kol Torah*. Vol. 17, Halacha. Teaneck, NJ: Torah Academy.
- Yuen JK, Reid C, Feters MD. 2011. Hospital do-not-resuscitate orders: Why they have failed and how to fix them. *J Gen Intern Med* 26:791–97.
- Zimmerman CA. 2020. The origins of thirst: Sensory signals arise throughout the body and converge in the brain to regulate drinking. *Science* 370:45–46.

## Chapter 13. Bereavement

### The Bereaved

- Abraham JL, Cooley ME, Ricacho L. 1995. Efficacy of an educational bereavement program for families of veterans with cancer. *J Cancer Educ* 10:207–12.
- Barry LC, Kasl SV, Prigerson HG. 2002. Psychiatric disorders among bereaved persons: The role of perceived circumstances of death and preparedness for death. *Am J Geriatr Psychiatry* 10:447–57.
- Block SD. 1985. Coping with loss. In *Outpatient Management of Advanced Cancer: Symptom Control, Support, and Hospice-in-the-Home*, Billings JA (ed.). Philadelphia, PA: Lippincott.
- Block SD. 2001. Psychological considerations, growth, and transcendence at the end of life: The art of the possible. *JAMA* 285:2898–2905.
- Boelan PA, de Keijser J, van den Hout MA, et al. 2007. Treatment of complicated grief: A comparison between cognitive-behavioral therapy and supportive counseling. *J Consult Clin Psychol* 75:271–84.
- Bradley EH, Prigerson H, Carlson MDA, et al. 2004. Depression among surviving caregivers: Does length of hospice enrollment matter? *Am J Psych* 161:2257–62.
- Chochinov H, Holland JC, Katz LY. 1998. Bereavement: A special issue in oncology. In *Psycho-Oncology*, Holland JC (ed.). New York: Oxford University Press.
- Christakis NA, Iwashyna TJ. 2003. The health impact of health care on families: A matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. *Soc Sci and Medicine* 57:465–75.
- Doka KJ, Martin TL. 2010. *Grieving beyond Gender: Understanding the Ways Men and Women Mourn*. Rev. ed., Death, Dying, and Bereavement series, Neimeyer R (ed.). New York: Routledge.
- Greer S. 2010. Bereavement care: Some clinical observations. *Psychooncology* 19:1156–60.
- ICD. 2021. Prolonged grief disorder. ICD-11, version 05/2021. <https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1183832314>.
- Kissane DW, Zaider TI. 2015. Bereavement. In *Oxford Textbook of Palliative Medicine*, 5th ed., Cherny NI, Fallon MT, Kassa S, et al. (eds.). Oxford: Oxford University Press.

- Kristensen P, Dyregrov K, Dyregrov A. 2017. What distinguishes prolonged grief disorder from depression? *Tidsskr Nor Laegeforen* 137:538–39. English, Norwegian. doi: 10.4045/tidsskr.16.0629. PMID: 28383227.
- Lobb EA, Kristjanson LJ, Aoun SM, et al. 2010. Predictors of complicated grief: A systematic review of empirical studies. *Death Stud* 34:673–98. doi: 10.1080/07481187.2010.496686. PMID: 24482845.
- Lundorff M, Holmgren H, Zachariae R, et al. 2017. Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. *J Affect Disord* 212:138–49.
- Maciejewski PK, Zhang B, Block SD, et al. 2007. An empirical examination of the stage theory of grief. *JAMA* 297:716–23.
- Morris S. 2018. *Overcoming Grief: A Self-Help Guide Using Cognitive Behavioral Techniques*. London: Robinson.
- Morris S, Block S. 2012. Grief and bereavement. In *Clinical Psycho-Oncology: An International Perspective*, Grassi L, Riba M (ed.). Hoboken, NJ: Wiley.
- Morris SE, Block SD. 2015. Adding value to palliative care services: The development of an institutional bereavement program. *J Palliat Med* 18:915–22.
- Morris SE, Dole OR, Joselow M, et al. 2017. The development of a hospital-wide bereavement program: Ensuring bereavement care for all families of pediatric patients. *J Pediatr Health Care* 31:88–95.
- Nouwen H. 1979. *The Wounded Healer*. Garden City, NY: Doubleday.
- Parkes CM. 1987. *Bereavement: Studies of Grief in Adult Life*. 2nd ed. Madison, CT: International Universities Press.
- Parkes CM. 1998. Bereavement in adult life. *BMJ* 316:856–59.
- Prigerson HG, Bierhals AJ, Kasl SV, et al. 1996. Complicated grief as a disorder distinct from bereavement-related depression and anxiety: A replication study. *Am J Psychiatry* 153:1484–86.
- Prigerson HG, Horowitz MJ, Jacobs SC, et al. 2009. Prolonged grief disorder: Psychometric validation of criteria proposed for DSM-V and ICD-11. *PLoS Med* 6:e1000121, doi: 10.1371/journal.pmed.1000121.
- Prigerson HG, Jacobs SC. 2001. Caring for bereaved patients: “All the doctors just suddenly go.” *JAMA* 286:1369–76.
- Rando TA. 1984. *Grief, Dying, and Death: Clinical Interventions for Caregivers*. Champaign, IL: Research Press.

- Rando TA. 1993. *Treatment of Complicated Mourning*. Champaign, IL: Research Press.
- Shear MK. 2010. Complicated grief treatment: The theory, practice and outcomes. *Bereave Care* 29:10–14. doi: 10.1080/02682621.2010.522373.
- Shear K, Frank E, Houck PR, et al. 2005. Treatment of complicated grief: A randomized controlled trial. *JAMA* 293:2601–8.
- Shear MK, Reynolds CF 3rd, Simon NM, et al. 2016. Optimizing treatment of complicated grief: A randomized clinical trial. *JAMA Psychiatry* 73:685–94. doi: 10.1001/jamapsychiatry.2016.0892. PMID: 27276373; PMCID: PMC5735848.
- Stroebe M, Schut H, Stroebe W. 2007. Health outcomes of bereavement. *Lancet* 370:1960–73.
- Worden JW. 1985. Bereavement. *Semin Oncol* 12:472–75.
- Wright AA, Keating NL, Balboni TA, et al. 2010. Place of death: Correlation with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. *J Clin Oncol* 28:4457–64.
- Zhang B, El-Jawahri A, Prigerson HG. 2006. Update on bereavement research: Evidence-based guidelines for the diagnosis and treatment of complicated bereavement. *J Palliat Med* 9:1188–1203.
- Zisook S, Shuchter SR, Pedrelli P, et al. 2001. Bupropion sustained-release treatment for bereavement: Results of an open trial. *J Clin Psychiatry* 62:227–30.

## Wounded Healers

- Dyrbye LN, Thomas MR, Massie S, et al. 2008. Burnout and suicidal ideation among US medical students. *Ann Intern Med* 149:334–41.
- Figley CR, ed. 1995. *Compassion Fatigue: Coping with Secondary Traumatic Stress in Those Who Treat the Traumatized*. London: Brunner-Routledge.
- Gilligan T. 2003. When do we stop talking about curative care? *J Palliat Med* 6:657–60.
- Kearney MK, Weininger RB, Vachon MLS, et al. 2009. Self-care for physicians caring for patients at the end of life: “Being connected . . . a key to my survival.” *JAMA* 301:1155–64.
- McFarland DC, Hlubocky F, Susaimanickam B, et al. 2019. Addressing depression, burnout, and suicide in oncology physicians. *Am Soc Clin Oncol Educ Book*. 39:590–98. doi: 10.1200/EDBK\_239087.
- Meier DE, Back AL, Morrison RS. 2001. The inner life of physicians and care of the seriously ill (the patient-physician relationship). *JAMA* 286:3007–14.



- Morris SE, Kearns JP, Moment A, et al. 2019. “Remembrance”: A self-care tool for clinicians. *J Palliat Med* 22:316–18.
- Murali K, Makker V, Lynch J, et al. 2018. From burnout to resilience: An update for oncologists. 2018 ASCO Educ Book 38:862–72.
- Nouwen H. 1979. *The Wounded Healer*. Garden City, NY: Doubleday.
- Novak DH, Suchman AL, Clark W, et al. 1997. Calibrating the physician: Personal awareness and effective palliative care. *JAMA* 278:502–9.
- Penberthy JK, Chhabra D, Ducar DM, et al. 2018. Impact of coping and communication skills program on physician burnout, quality of life, and emotional flooding. *Saf Health Work* 9:381–87.
- Raphael MJ, Fundytus A, Hopman WM, et al. 2019. Medical oncology job satisfaction: Results of a global survey. *Semin Oncol* 46:73–82.
- Remen RN. 1996. *Kitchen Table Wisdom: Stories That Heal*. New York: Riverhead Books.
- Remen RN. n.d. *The Healer’s Art*. Syllabus available from the Institute for the Study of Health and Illness at Commonweal: FHC curriculum. [www.rishiprograms.org](http://www.rishiprograms.org).
- Shanafelt T, Dyrbye L. 2012. Oncologist burnout: Causes, consequences, and responses. *J Clin Oncol* 30:1235–41.
- Stahl B, Goldstein E. 2010. *A Mindfulness-Based Stress Reduction Workbook*. Oakland, CA: New Harbinger.
- Thomas JD. 2019. Breaching the professional-personal boundary—An unrecognized risk for burnout. *N Engl J Med* 381:998–99.
- Thomas NK. 2004. Resident burnout. *JAMA* 292:2880–89.
- Vachon MLS. 2010. Oncology staff stress and related interventions. In *Psycho-Oncology*, 2nd ed., Holland JC, Breitbart WS, Jacobsen PB, et al. (eds.). Oxford: Oxford University Press.
- Von Roenn JH, Temel J. 2011. The integration of palliative care and oncology: The evidence. *Oncology* 25:1258–66.
- West CP, Dyrbye LN, Shanafelt TD. 2018. Physician burnout: Contributors, consequences and solutions. *J Intern Med* 283:516–29. <https://doi.org/10.1111/joim.12752>.
- Wright B. 2004. Compassion fatigue: How to avoid it. *J Palliat Med* 18:4–5.